US3948254A
(en)
*
|
1971-11-08 |
1976-04-06 |
Alza Corporation |
Novel drug delivery device
|
US3996933A
(en)
*
|
1972-10-02 |
1976-12-14 |
Morton Gutnick |
Intrauterine contraceptive devices and processes
|
US4325388A
(en)
*
|
1973-02-05 |
1982-04-20 |
Louis Bucalo |
Apparatus for collecting and processing body fluids
|
US3971376A
(en)
*
|
1973-02-26 |
1976-07-27 |
Ceskoslovenska Akademie Ved |
Method and apparatus for introducing fluids into the body
|
US4177256A
(en)
*
|
1973-04-25 |
1979-12-04 |
Alza Corporation |
Osmotic bursting drug delivery device
|
GB1465684A
(en)
*
|
1973-07-27 |
1977-02-23 |
Emmett L |
Contraceptive device
|
US4111196A
(en)
*
|
1973-07-27 |
1978-09-05 |
Lionel C. R. Emmett |
Intrauterine contraceptive device of c or omega form with tubular inserter and method of placement
|
US4018220A
(en)
*
|
1974-07-19 |
1977-04-19 |
Lionel C. R. Emmett |
Method of insertion for intrauterine device of C or omega form with tubular inserter
|
US4172446A
(en)
*
|
1974-12-20 |
1979-10-30 |
Louis Bucalo |
Apparatus for collecting body fluids
|
US4093708A
(en)
*
|
1974-12-23 |
1978-06-06 |
Alza Corporation |
Osmotic releasing device having a plurality of release rate patterns
|
US3946734A
(en)
*
|
1975-02-19 |
1976-03-30 |
The United States Of America As Represented By The Secretary Of State |
Apparatus for controlling the release of a drug
|
ZA761193B
(en)
*
|
1975-03-19 |
1977-02-23 |
Procter & Gamble |
Controlled release articles
|
US3977404A
(en)
*
|
1975-09-08 |
1976-08-31 |
Alza Corporation |
Osmotic device having microporous reservoir
|
US4034758A
(en)
*
|
1975-09-08 |
1977-07-12 |
Alza Corporation |
Osmotic therapeutic system for administering medicament
|
US4036228A
(en)
*
|
1975-09-11 |
1977-07-19 |
Alza Corporation |
Osmotic dispenser with gas generating means
|
US3987790A
(en)
*
|
1975-10-01 |
1976-10-26 |
Alza Corporation |
Osmotically driven fluid dispenser
|
US4077407A
(en)
*
|
1975-11-24 |
1978-03-07 |
Alza Corporation |
Osmotic devices having composite walls
|
US4073833A
(en)
*
|
1975-12-08 |
1978-02-14 |
The Procter & Gamble Company |
Encapsulation process
|
US4031202A
(en)
*
|
1975-12-08 |
1977-06-21 |
The Procter & Gamble Company |
Controlled release contraceptive article
|
US4014334A
(en)
*
|
1976-02-02 |
1977-03-29 |
Alza Corporation |
Laminated osmotic system for dispensing beneficial agent
|
US4058122A
(en)
*
|
1976-02-02 |
1977-11-15 |
Alza Corporation |
Osmotic system with laminated wall formed of different materials
|
US4008719A
(en)
*
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4203439A
(en)
*
|
1976-11-22 |
1980-05-20 |
Alza Corporation |
Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
|
US4207890A
(en)
*
|
1977-01-04 |
1980-06-17 |
Mcneilab, Inc. |
Drug-dispensing device and method
|
US4218433A
(en)
*
|
1977-03-03 |
1980-08-19 |
Nippon Kayaku Kabushiki Kaisha |
Constant-rate eluting tablet and method of producing same
|
US4160452A
(en)
*
|
1977-04-07 |
1979-07-10 |
Alza Corporation |
Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
|
US4182330A
(en)
*
|
1977-07-25 |
1980-01-08 |
Alza Corporation |
Means for administering amphipathic medicament
|
US4190642A
(en)
*
|
1978-04-17 |
1980-02-26 |
Alza Corporation |
Ocular therapeutic system for dispensing a medication formulation
|
US4344929A
(en)
*
|
1980-04-25 |
1982-08-17 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
US4265874A
(en)
*
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
SE448203B
(sv)
*
|
1980-09-10 |
1987-02-02 |
Johan Alfred Olof Johansson |
formkropp framstelld av agar och/eller agaros och/eller ett derivat derav innehallande farmakologiskt verksamt emne
|
US4439195A
(en)
*
|
1980-10-14 |
1984-03-27 |
Alza Corporation |
Theophylline therapy
|
US4455145A
(en)
*
|
1981-07-10 |
1984-06-19 |
Alza Corporation |
Dispensing device with internal drive
|
US4973307A
(en)
*
|
1981-07-13 |
1990-11-27 |
Alza Corporation |
Method for administering drugs to a patient
|
US4740198A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Method of administering intravenous drug using rate-controlled dosage form
|
USRE34365E
(en)
*
|
1981-07-13 |
1993-08-31 |
|
Intravenous system for delivering a beneficial agent
|
US4511353A
(en)
*
|
1981-07-13 |
1985-04-16 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4432756A
(en)
*
|
1981-11-27 |
1984-02-21 |
Alza Corporation |
Parenteral controlled therapy
|
US4994031A
(en)
*
|
1981-07-13 |
1991-02-19 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4552555A
(en)
*
|
1981-07-31 |
1985-11-12 |
Alza Corporation |
System for intravenous delivery of a beneficial agent
|
US4857052A
(en)
*
|
1981-07-13 |
1989-08-15 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4740201A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4790820A
(en)
*
|
1981-07-13 |
1988-12-13 |
Alza Corporation |
Parenteral agent dispensing equipment with drug releasing member
|
US5069671A
(en)
*
|
1981-07-13 |
1991-12-03 |
Alza Corporation |
Intravenous medication
|
US4985017A
(en)
*
|
1981-07-13 |
1991-01-15 |
Alza Corporation |
Parenteral therapeutical system comprising drug cell
|
US4525162A
(en)
*
|
1981-07-31 |
1985-06-25 |
Alza Corporation |
Parenteral controlled delivery
|
GR76223B
(hr)
*
|
1981-07-31 |
1984-08-04 |
Alza Corp |
|
US4871360A
(en)
*
|
1981-07-31 |
1989-10-03 |
Alza Corporation |
System for intravenous delivery of a beneficial drug at a regulated rates
|
US4439194A
(en)
*
|
1981-09-08 |
1984-03-27 |
Merck & Co., Inc. |
Water and drug delivery system for suppository use
|
US4586922A
(en)
*
|
1981-10-09 |
1986-05-06 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4740199A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4741734A
(en)
*
|
1981-10-09 |
1988-05-03 |
Alza Corporation |
Releasing means for adding agent using releasing means to IV fluid
|
US4740200A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4741735A
(en)
*
|
1981-10-09 |
1988-05-03 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4740103A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4740197A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent via polymer delivery
|
US4416659A
(en)
*
|
1981-11-09 |
1983-11-22 |
Eli Lilly And Company |
Sustained release capsule for ruminants
|
US4493702A
(en)
*
|
1981-11-27 |
1985-01-15 |
Alza Corporation |
Parenteral administration using osmotically motivated delivery system
|
US4579553A
(en)
*
|
1981-11-27 |
1986-04-01 |
Alza Corporation |
Parenteral controlled therapy
|
US4484909A
(en)
*
|
1981-11-27 |
1984-11-27 |
Alza Corporation |
Parenteral therapy using solid drug
|
US4552556A
(en)
*
|
1981-11-27 |
1985-11-12 |
Alza Corporation |
Parenteral controlled therapy
|
US4479794A
(en)
*
|
1981-11-27 |
1984-10-30 |
Alza Corporation |
System for intravenous therapy
|
US4479793A
(en)
*
|
1981-11-27 |
1984-10-30 |
Alza Corporation |
Parenteral administration using drug delivery device
|
US4583981A
(en)
*
|
1981-11-27 |
1986-04-22 |
Alza Corporation |
Parenteral controlled therapy, using a porous matrix with parenteral agent
|
US4548599A
(en)
*
|
1981-11-27 |
1985-10-22 |
Alza Corporation |
Parenteral controlled therapy
|
US4484921A
(en)
*
|
1982-02-01 |
1984-11-27 |
Alza Corporation |
Theophylline therapy utilizing osmotic delivery
|
US4475916A
(en)
*
|
1982-03-18 |
1984-10-09 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4439196A
(en)
*
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4449983A
(en)
*
|
1982-03-22 |
1984-05-22 |
Alza Corporation |
Simultaneous delivery of two drugs from unit delivery device
|
US4455143A
(en)
*
|
1982-03-22 |
1984-06-19 |
Alza Corporation |
Osmotic device for dispensing two different medications
|
US4664650A
(en)
*
|
1982-05-24 |
1987-05-12 |
Alza Corporation |
Apparatus for parenteral infusion of fluid containing beneficial agent
|
US4515585A
(en)
*
|
1982-05-24 |
1985-05-07 |
Alza Corporation |
System for parenteral administration of agent
|
US4908019A
(en)
*
|
1982-05-24 |
1990-03-13 |
Alza Corporation |
Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
|
US4519801A
(en)
*
|
1982-07-12 |
1985-05-28 |
Alza Corporation |
Osmotic device with wall comprising cellulose ether and permeability enhancer
|
US4553973A
(en)
*
|
1982-07-12 |
1985-11-19 |
Alza Corporation |
Process for preparing osmotic device
|
US4539004A
(en)
*
|
1982-09-22 |
1985-09-03 |
Alza Corporation |
Self-driven pump assembly and method of operation
|
US4522625A
(en)
*
|
1982-09-29 |
1985-06-11 |
Alza Corporation |
Drug dispenser comprising wall formed of semipermeable member and enteric member
|
US4552561A
(en)
*
|
1982-12-23 |
1985-11-12 |
Alza Corporation |
Body mounted pump housing and pump assembly employing the same
|
US4859667A
(en)
*
|
1983-01-21 |
1989-08-22 |
Merck Frosst Canada, Inc. |
Pharmaceutical compositions of phenothiazone derivatives and analogs
|
US4667032A
(en)
*
|
1983-01-21 |
1987-05-19 |
Merck Frosst Canada, Inc. |
Phenothiazone derivatives and analogs
|
US4576604A
(en)
*
|
1983-03-04 |
1986-03-18 |
Alza Corporation |
Osmotic system with instant drug availability
|
US4690682A
(en)
*
|
1983-04-15 |
1987-09-01 |
Damon Biotech, Inc. |
Sustained release
|
US4789516A
(en)
*
|
1983-04-15 |
1988-12-06 |
Damon Biotech, Inc |
Production of sustained released system
|
US4503030A
(en)
*
|
1983-06-06 |
1985-03-05 |
Alza Corporation |
Device for delivering drug to certain pH environments
|
US4610686A
(en)
*
|
1983-11-02 |
1986-09-09 |
Alza Corporation |
Controlled delivery of haloperidol by an osmotic delivery system
|
GB2150830B
(en)
*
|
1983-12-05 |
1987-08-19 |
Alza Corp |
Drug dispenser
|
US4692336A
(en)
*
|
1984-03-19 |
1987-09-08 |
Alza Corporation |
Self controlled release device for administering beneficial agent to recipient
|
US4729793A
(en)
*
|
1985-08-09 |
1988-03-08 |
Alza Corporation |
Composition for manufacturing wall of dispensing device
|
US4844984A
(en)
*
|
1984-03-19 |
1989-07-04 |
Alza Corporation |
Dispensing system with means for increasing delivery of beneficial agent from the system
|
US4612186A
(en)
*
|
1984-03-19 |
1986-09-16 |
Alza Corporation |
Method for establishing blood levels of biocide in animals
|
US4624945A
(en)
*
|
1984-03-19 |
1986-11-25 |
Alza Corporation |
Dispensing system with means for increasing delivery of beneficial agent from the system
|
US4717566A
(en)
*
|
1984-03-19 |
1988-01-05 |
Alza Corporation |
Dosage system and method of using same
|
US4927633A
(en)
*
|
1984-03-19 |
1990-05-22 |
Alza Corporation |
Dispenser for delivering drug to livestock
|
US4684524A
(en)
*
|
1984-03-19 |
1987-08-04 |
Alza Corporation |
Rate controlled dispenser for administering beneficial agent
|
US5000957A
(en)
*
|
1984-03-19 |
1991-03-19 |
Alza Corporation |
Dispenser comprising hydrophilic osmopolymer
|
US4814180A
(en)
*
|
1984-03-21 |
1989-03-21 |
Alza Corporation |
Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
|
US4716031A
(en)
*
|
1984-03-21 |
1987-12-29 |
Alza Corporation |
Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
|
US4663149A
(en)
*
|
1984-03-21 |
1987-05-05 |
Alza Corporation |
Dispenser comprising inner and outer walls functioning as cooperative unit
|
US4678467A
(en)
*
|
1984-03-21 |
1987-07-07 |
Alza Corporation |
Dispenser comprising capsule with volume displacing member
|
GB2155889B
(en)
*
|
1984-03-21 |
1988-03-02 |
Alza Corp |
Dispenser-capsule
|
US4663148A
(en)
*
|
1984-03-21 |
1987-05-05 |
Alza Corporation |
Dispenser comprising telescopically engaging members
|
US4692326A
(en)
*
|
1984-03-21 |
1987-09-08 |
Alza Corporation |
Dispenser comprising inner positioned soft or hard capsule
|
US4615698A
(en)
*
|
1984-03-23 |
1986-10-07 |
Alza Corporation |
Total agent osmotic delivery system
|
US4511351A
(en)
*
|
1984-05-14 |
1985-04-16 |
Alza Corporation |
Parenteral delivery system utilizing a hollow fiber cellular unit
|
US4596555A
(en)
*
|
1984-05-14 |
1986-06-24 |
Alza Corporation |
Parenteral delivery system utilizing a hollow fiber cellular unit
|
US4511352A
(en)
*
|
1984-05-14 |
1985-04-16 |
Alza Corporation |
Parenteral delivery system with in-line container
|
US4968507A
(en)
*
|
1984-06-20 |
1990-11-06 |
Merck & Co., Inc. |
Controlled porosity osmotic pump
|
US4769027A
(en)
*
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
EP0203186B1
(en)
*
|
1984-12-03 |
1992-03-04 |
BAXTER INTERNATIONAL INC. (a Delaware corporation) |
Drug delivery apparatus preventing local and systemic toxicity
|
US4765985A
(en)
*
|
1985-03-05 |
1988-08-23 |
Ciba-Geigy Corporation |
Devices and methods for treating memory impairment
|
US4680172A
(en)
*
|
1985-03-05 |
1987-07-14 |
Ciba-Geigy Corporation |
Devices and methods for treating memory impairment
|
JPS61153350U
(hr)
*
|
1985-03-13 |
1986-09-22 |
|
|
US4693886A
(en)
*
|
1985-04-22 |
1987-09-15 |
Alza Corporation |
Osmotic device with inert core
|
CA1309557C
(en)
|
1985-06-18 |
1992-10-27 |
Robert N. Young |
Leukotriene antagonists
|
US4717718A
(en)
*
|
1985-08-09 |
1988-01-05 |
Alza Corporation |
Device for the controlled delivery of a beneficial agent
|
US4717568A
(en)
*
|
1985-08-09 |
1988-01-05 |
Alza Corporation |
Laminar arrangement for increasing delivery of beneficial agent from dispenser
|
US4963141A
(en)
*
|
1985-08-16 |
1990-10-16 |
Alza Corporation |
Dispensing system for administering beneficial agent formulation to ruminants
|
US4865598A
(en)
*
|
1985-08-16 |
1989-09-12 |
Alza Corporation |
Dispensing system for administering beneficial agent
|
US4643731A
(en)
*
|
1985-08-16 |
1987-02-17 |
Alza Corporation |
Means for providing instant agent from agent dispensing system
|
US4966767A
(en)
*
|
1985-08-16 |
1990-10-30 |
Alza Corporation |
Ruminant dispensing device comprising agent displacement member
|
US5098425A
(en)
*
|
1985-08-16 |
1992-03-24 |
Alza Corporation |
Method of administering a ruminant dispensing device comprising density member dispersed in hydrogel member
|
US4883667A
(en)
*
|
1985-08-16 |
1989-11-28 |
Alza Corporation |
Process for forming dispensing device
|
US4675174A
(en)
*
|
1985-08-16 |
1987-06-23 |
Alza Corporation |
Veterinary dispenser delivering beneficial agent by gas power generated in situ
|
US4955881A
(en)
*
|
1985-08-16 |
1990-09-11 |
Alza Corporation |
Ruminant dispensing device
|
US4871544A
(en)
*
|
1985-08-16 |
1989-10-03 |
Alza Corporation |
Ruminant dispensing device
|
US4704118A
(en)
*
|
1985-08-16 |
1987-11-03 |
Alza Corporation |
Ruminant dispensing device with thermo-activated memory
|
US4756314A
(en)
*
|
1985-10-28 |
1988-07-12 |
Alza Corporation |
Sweat collection patch
|
US4680266A
(en)
*
|
1985-11-21 |
1987-07-14 |
Contraves Ag |
Cell culture chamber with means for automatic replenishment of nutrient
|
US5008112A
(en)
*
|
1985-12-16 |
1991-04-16 |
International Minerals & Chem. Corporation |
Device for the extended delivery of diffusible agents
|
US4867969A
(en)
*
|
1986-02-07 |
1989-09-19 |
Alza Corporation |
Hydrogel formulation for administering non-steroidal drugs
|
US4971790A
(en)
*
|
1986-02-07 |
1990-11-20 |
Alza Corporation |
Dosage form for lessening irritation of mocusa
|
US4865845A
(en)
*
|
1986-03-21 |
1989-09-12 |
Alza Corporation |
Release rate adjustment of osmotic or diffusional delivery devices
|
DE3786030T2
(de)
|
1986-03-27 |
1993-12-02 |
Merck Frosst Canada Inc |
Tetrahydrocarbazole Ester.
|
US4755180A
(en)
*
|
1986-06-16 |
1988-07-05 |
Alza Corporation |
Dosage form comprising solubility regulating member
|
US4847093A
(en)
*
|
1986-06-19 |
1989-07-11 |
Alza Corporation |
Dosage form with means for governing rate of gas formation
|
US4838862A
(en)
|
1986-08-04 |
1989-06-13 |
Pharmetrix Corp. |
Portable controlled release osmotic infusion device
|
USRE34990E
(en)
*
|
1986-08-07 |
1995-07-04 |
Ciba-Geigy Corporation |
Oral therapeutic system having systemic action
|
CH668187A5
(de)
*
|
1986-08-07 |
1988-12-15 |
Ciba Geigy Ag |
Therapeutisches system mit systemischer wirkung.
|
EP0277092B1
(de)
*
|
1987-01-14 |
1992-01-29 |
Ciba-Geigy Ag |
Therapeutisches System für schwerlösliche Wirkstoffe
|
US4801461A
(en)
*
|
1987-01-28 |
1989-01-31 |
Alza Corporation |
Pseudoephedrine dosage form
|
US5023076A
(en)
*
|
1987-02-27 |
1991-06-11 |
Alza Corporation |
Lamina comprising carboxyvinyl polymer
|
US4915952A
(en)
*
|
1987-02-27 |
1990-04-10 |
Alza Corporation |
Composition comprising drug, HPC, HPMC and PEO
|
US4888416A
(en)
*
|
1987-03-30 |
1989-12-19 |
International Minerals & Chemical Corp. |
Method for stabilizing somatotropins
|
US5391381A
(en)
*
|
1987-06-25 |
1995-02-21 |
Alza Corporation |
Dispenser capable of delivering plurality of drug units
|
US5938654A
(en)
*
|
1987-06-25 |
1999-08-17 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
US4957494A
(en)
*
|
1987-06-25 |
1990-09-18 |
Alza Corporation |
Multi-layer delivery system
|
US5499979A
(en)
*
|
1987-06-25 |
1996-03-19 |
Alza Corporation |
Delivery system comprising kinetic forces
|
US5340590A
(en)
*
|
1987-06-25 |
1994-08-23 |
Alza Corporation |
Delivery system with bilayer osmotic engine
|
US5110597A
(en)
*
|
1987-06-25 |
1992-05-05 |
Alza Corporation |
Multi-unit delivery system
|
US4874388A
(en)
*
|
1987-06-25 |
1989-10-17 |
Alza Corporation |
Multi-layer delivery system
|
US5023088A
(en)
*
|
1987-06-25 |
1991-06-11 |
Alza Corporation |
Multi-unit delivery system
|
US5236689A
(en)
*
|
1987-06-25 |
1993-08-17 |
Alza Corporation |
Multi-unit delivery system
|
US4891223A
(en)
*
|
1987-09-03 |
1990-01-02 |
Air Products And Chemicals, Inc. |
Controlled release delivery coating formulation for bioactive substances
|
US4886668A
(en)
*
|
1987-09-24 |
1989-12-12 |
Merck & Co., Inc. |
Multiparticulate controlled porosity osmotic pump
|
US4880631A
(en)
*
|
1987-09-24 |
1989-11-14 |
Merck & Co., Inc. |
Controlled porosity osmotic pump
|
US4950486A
(en)
*
|
1987-10-02 |
1990-08-21 |
Alza Corporation |
Dosage form for treating cardiovascular diseases
|
US4946687A
(en)
*
|
1987-10-02 |
1990-08-07 |
Alza Corporation |
Dosage form for treating cardiovascular diseases
|
US4816263A
(en)
*
|
1987-10-02 |
1989-03-28 |
Alza Corporation |
Dosage form for treating cardiovascular diseases comprising isradipine
|
US4994273A
(en)
*
|
1987-11-02 |
1991-02-19 |
Merck & Co., Inc. |
Solubility modulated drug delivery device
|
US5030203A
(en)
*
|
1987-11-16 |
1991-07-09 |
Baxter International Inc. |
Ampule for controlled administration of beneficial agent
|
JP2590358B2
(ja)
*
|
1988-03-01 |
1997-03-12 |
正雄 五十嵐 |
子宮内膜症治療用の子宮内又は膣内投与製剤
|
US4837111A
(en)
*
|
1988-03-21 |
1989-06-06 |
Alza Corporation |
Dosage form for dispensing drug for human therapy
|
US4996060A
(en)
*
|
1988-03-25 |
1991-02-26 |
Alza Corporation |
Device comprising liner for protecting fluid sensitive medicament
|
US4855141A
(en)
*
|
1988-03-25 |
1989-08-08 |
Alza Corporation |
Device comprising means for protecting and dispensing fluid sensitive medicament
|
US4959218A
(en)
*
|
1988-03-25 |
1990-09-25 |
Alza Corporation |
Method for delivering somatotropin to an animal
|
US5019397A
(en)
*
|
1988-04-21 |
1991-05-28 |
Alza Corporation |
Aqueous emulsion for pharmaceutical dosage form
|
US4892739A
(en)
*
|
1988-04-25 |
1990-01-09 |
Ciba-Geigy Corporation |
Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
|
US4931285A
(en)
*
|
1988-04-28 |
1990-06-05 |
Alza Corporation |
Aqueous based pharmaceutical coating composition for dosage forms
|
US5006346A
(en)
*
|
1988-04-28 |
1991-04-09 |
Alza Corporation |
Delivery system
|
US5160743A
(en)
*
|
1988-04-28 |
1992-11-03 |
Alza Corporation |
Annealed composition for pharmaceutically acceptable drug
|
US5024842A
(en)
*
|
1988-04-28 |
1991-06-18 |
Alza Corporation |
Annealed coats
|
US4859470A
(en)
*
|
1988-06-02 |
1989-08-22 |
Alza Corporation |
Dosage form for delivering diltiazem
|
US4966769A
(en)
*
|
1988-06-02 |
1990-10-30 |
Alza Corporation |
Method for delivering dosage form for diltiazem
|
US5028434A
(en)
*
|
1988-07-21 |
1991-07-02 |
Alza Corporation |
Method for administering nilvadipine for treating cardiovascular symptoms
|
GB8820353D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Staniforth J N |
Controlled release tablet
|
US5612059A
(en)
*
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
US5096716A
(en)
*
|
1988-09-01 |
1992-03-17 |
Alza Corporation |
Dosage form for administering calcium antagonist nicardipine
|
US5236714A
(en)
*
|
1988-11-01 |
1993-08-17 |
Alza Corporation |
Abusable substance dosage form having reduced abuse potential
|
US5030456A
(en)
*
|
1988-11-07 |
1991-07-09 |
Alza Corporation |
Dosage form for treating cardiovascular diseases
|
US4997658A
(en)
*
|
1988-11-21 |
1991-03-05 |
Merck & Co., Inc. |
Method for enhancing the lowering of plasma cholesterol levels
|
US5376383A
(en)
*
|
1988-11-21 |
1994-12-27 |
Merck & Co., Inc. |
Method for enhancing the lowering of plasma-cholesterol levels
|
US5728088A
(en)
*
|
1988-12-13 |
1998-03-17 |
Alza Corporation |
Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
|
US5174999A
(en)
*
|
1988-12-13 |
1992-12-29 |
Alza Corporation |
Delivery system comprising fluid ingress and drug egress
|
US5110596A
(en)
*
|
1988-12-13 |
1992-05-05 |
Alza Corporation |
Delivery system comprising means for delivering agent to livestock
|
US5037420A
(en)
*
|
1988-12-13 |
1991-08-06 |
Alza Corporation |
Delivery system comprising two sections for delivering somatotropin
|
US5057318A
(en)
*
|
1988-12-13 |
1991-10-15 |
Alza Corporation |
Delivery system for beneficial agent over a broad range of rates
|
US5059423A
(en)
*
|
1988-12-13 |
1991-10-22 |
Alza Corporation |
Delivery system comprising biocompatible beneficial agent formulation
|
US5034229A
(en)
*
|
1988-12-13 |
1991-07-23 |
Alza Corporation |
Dispenser for increasing feed conversion of hog
|
US5135523A
(en)
*
|
1988-12-13 |
1992-08-04 |
Alza Corporation |
Delivery system for administering agent to ruminants and swine
|
US5108756A
(en)
*
|
1989-01-12 |
1992-04-28 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
US5030452A
(en)
*
|
1989-01-12 |
1991-07-09 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
IL92966A
(en)
*
|
1989-01-12 |
1995-07-31 |
Pfizer |
Hydrogel-operated release devices
|
US5186942A
(en)
*
|
1989-01-30 |
1993-02-16 |
Alza Corporation |
Nicardipine therapy
|
DD295760A5
(de)
*
|
1989-01-31 |
1991-11-14 |
Martin-Luther-Universitaet Halle Wittenberg,De |
Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
|
US4969872A
(en)
*
|
1989-03-08 |
1990-11-13 |
Alza Corporation |
Intravenous system for delivering a beneficial agent with delivery rate control via permeable surface area variance
|
US5019396A
(en)
*
|
1989-05-12 |
1991-05-28 |
Alza Corporation |
Delivery dispenser for treating cardiac arrhythmias
|
US5021053A
(en)
*
|
1989-07-14 |
1991-06-04 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
US5776493A
(en)
*
|
1989-07-14 |
1998-07-07 |
Alza Corporation |
Oral osmotic device for delivery of nystatin with hydrogel driving member
|
US5273752A
(en)
*
|
1989-07-18 |
1993-12-28 |
Alza Corporation |
Controlled release dispenser comprising beneficial agent
|
US5126142A
(en)
*
|
1989-07-18 |
1992-06-30 |
Alza Corporation |
Dispenser comprising ionophore
|
US5591454A
(en)
*
|
1989-09-05 |
1997-01-07 |
Alza Corporation |
Method for lowering blood glucose
|
US6361795B1
(en)
|
1989-09-05 |
2002-03-26 |
Alza Corporation |
Method for lowering blood glucose
|
US5091190A
(en)
*
|
1989-09-05 |
1992-02-25 |
Alza Corporation |
Delivery system for administration blood-glucose lowering drug
|
US5024843A
(en)
*
|
1989-09-05 |
1991-06-18 |
Alza Corporation |
Oral hypoglycemic glipizide granulation
|
US20020197309A1
(en)
*
|
1989-09-05 |
2002-12-26 |
Kuczynski Anthony L. |
Method for lowering blood glucose
|
US5035897A
(en)
*
|
1989-09-05 |
1991-07-30 |
Alza Corporation |
Dosage form for delivering soluble or insoluble drugs
|
US5112614A
(en)
*
|
1989-09-14 |
1992-05-12 |
Alza Corporation |
Implantable delivery dispenser
|
US5098714A
(en)
*
|
1989-11-16 |
1992-03-24 |
Alza Corporation |
Osmotic, oral dosage form for fertility control
|
US5200197A
(en)
*
|
1989-11-16 |
1993-04-06 |
Alza Corporation |
Contraceptive pill
|
US5474785A
(en)
*
|
1990-01-24 |
1995-12-12 |
Alza Corporation |
Delivery system comprising means for controlling internal pressure
|
US5071607A
(en)
*
|
1990-01-31 |
1991-12-10 |
Alza Corporatino |
Method and apparatus for forming a hole in a drug dispensing device
|
US5024663A
(en)
*
|
1990-02-21 |
1991-06-18 |
Alza Corporation |
Self-contained suction pump
|
US5178866A
(en)
*
|
1990-03-23 |
1993-01-12 |
Alza Corporation |
Dosage form for delivering drug to the intestine
|
US5242391A
(en)
*
|
1990-04-25 |
1993-09-07 |
Alza Corporation |
Urethral insert for treatment of erectile dysfunction
|
US5017381A
(en)
*
|
1990-05-02 |
1991-05-21 |
Alza Corporation |
Multi-unit pulsatile delivery system
|
US5192550A
(en)
*
|
1990-05-07 |
1993-03-09 |
Alza Corporation |
Dosage form for treating central nervous system disorders
|
US5190763A
(en)
*
|
1990-05-07 |
1993-03-02 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5221536A
(en)
|
1990-05-07 |
1993-06-22 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5057321A
(en)
*
|
1990-06-13 |
1991-10-15 |
Alza Corporation |
Dosage form comprising drug and maltodextrin
|
US5128145A
(en)
*
|
1990-06-13 |
1992-07-07 |
Alza Corporation |
Dosage form for Parkinson's disease, spasticity and muscle spasms
|
US5180591A
(en)
*
|
1990-07-11 |
1993-01-19 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5238687A
(en)
*
|
1990-07-11 |
1993-08-24 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5234694A
(en)
*
|
1990-07-11 |
1993-08-10 |
Alza Corporation |
Method for increasing feed efficiency in animals
|
US5234692A
(en)
*
|
1990-07-11 |
1993-08-10 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5234693A
(en)
*
|
1990-07-11 |
1993-08-10 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5147654A
(en)
*
|
1990-07-23 |
1992-09-15 |
Alza Corporation |
Oral osmotic device for delivering nicotine
|
DE69107461T2
(de)
*
|
1990-08-07 |
1995-06-22 |
Pfizer |
Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
|
US5104899A
(en)
*
|
1990-08-13 |
1992-04-14 |
Sepracor, Inc. |
Methods and compositions for treating depression using optically pure fluoxetine
|
US5589511A
(en)
*
|
1990-08-13 |
1996-12-31 |
Sepracor Inc. |
Method for treating migraine headaches using optically pure S(+) fluoxetine
|
US5156850A
(en)
*
|
1990-08-31 |
1992-10-20 |
Alza Corporation |
Dosage form for time-varying patterns of drug delivery
|
US5232705A
(en)
*
|
1990-08-31 |
1993-08-03 |
Alza Corporation |
Dosage form for time-varying patterns of drug delivery
|
US5246709A
(en)
*
|
1990-09-10 |
1993-09-21 |
Alza Corporation |
Antiemetic therapy
|
US5166145A
(en)
*
|
1990-09-10 |
1992-11-24 |
Alza Corporation |
Antiemetic therapy
|
ES2053339T3
(es)
*
|
1990-09-28 |
1994-07-16 |
Pfizer |
Dispositivo dispensador conteniendo un medio hidrofobo.
|
US5151093A
(en)
*
|
1990-10-29 |
1992-09-29 |
Alza Corporation |
Osmotically driven syringe with programmable agent delivery
|
US5443459A
(en)
*
|
1991-01-30 |
1995-08-22 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
US5708035A
(en)
*
|
1991-02-04 |
1998-01-13 |
Sepracor Inc. |
Methods of use and compositions of R(-) fluoxetine
|
US5861166A
(en)
*
|
1991-03-12 |
1999-01-19 |
Alza Corporation |
Delivery device providing beneficial agent stability
|
US5208037A
(en)
*
|
1991-04-22 |
1993-05-04 |
Alza Corporation |
Dosage forms comprising polymers comprising different molecular weights
|
US5198229A
(en)
*
|
1991-06-05 |
1993-03-30 |
Alza Corporation |
Self-retaining gastrointestinal delivery device
|
US5227167A
(en)
*
|
1991-06-11 |
1993-07-13 |
Alza Corporation |
Long-term delivery device including hydrophobic loading dose
|
US5137727A
(en)
*
|
1991-06-12 |
1992-08-11 |
Alza Corporation |
Delivery device providing beneficial agent stability
|
US5801141A
(en)
*
|
1991-06-24 |
1998-09-01 |
American Cyanamid Company |
Implant compositions containing a biologically active protein, peptide or polypeptide
|
US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5252338A
(en)
*
|
1991-06-27 |
1993-10-12 |
Alza Corporation |
Therapy delayed
|
US5160744A
(en)
*
|
1991-06-27 |
1992-11-03 |
Alza Corporation |
Verapmil therapy
|
US5190765A
(en)
*
|
1991-06-27 |
1993-03-02 |
Alza Corporation |
Therapy delayed
|
US5178867A
(en)
*
|
1991-08-19 |
1993-01-12 |
Alza Corporation |
Dosage form for delivering drug in short-time period
|
US5240713A
(en)
*
|
1991-09-27 |
1993-08-31 |
Alza Corporation |
Dual rate agent delivery device
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5254349A
(en)
*
|
1991-12-06 |
1993-10-19 |
Alza Corporation |
Process for lessening irritation caused by drug
|
US5200195A
(en)
*
|
1991-12-06 |
1993-04-06 |
Alza Corporation |
Process for improving dosage form delivery kinetics
|
US5266332A
(en)
*
|
1991-12-06 |
1993-11-30 |
Alza Corporation |
Method for administering anti-Parkinson drug
|
US5200194A
(en)
*
|
1991-12-18 |
1993-04-06 |
Alza Corporation |
Oral osmotic device
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5223265A
(en)
*
|
1992-01-10 |
1993-06-29 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery
|
US5246711A
(en)
*
|
1992-02-27 |
1993-09-21 |
Alza Corporation |
Dosage form for treating dysthymia
|
US5185158A
(en)
*
|
1992-02-27 |
1993-02-09 |
Alza Corporation |
Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
|
US5330762A
(en)
*
|
1992-02-27 |
1994-07-19 |
Alza Corporation |
Tandospiaine antidepressive therapy
|
US5688518A
(en)
*
|
1992-02-27 |
1997-11-18 |
Alza Corporation |
Antidepressive therapy
|
US5246710A
(en)
*
|
1992-02-27 |
1993-09-21 |
Alza Corporation |
Dosage form for treating cyclothymia
|
US5858407A
(en)
*
|
1992-02-27 |
1999-01-12 |
Alza Corporation |
Method for administering tandospirone
|
US5248310A
(en)
*
|
1992-03-27 |
1993-09-28 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
US5512299A
(en)
*
|
1992-03-30 |
1996-04-30 |
Alza Corporation |
Method of treating oral inflammatory disease
|
US5869097A
(en)
|
1992-11-02 |
1999-02-09 |
Alza Corporation |
Method of therapy comprising an osmotic caplet
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
US5573776A
(en)
*
|
1992-12-02 |
1996-11-12 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
US5358721A
(en)
*
|
1992-12-04 |
1994-10-25 |
Alza Corporation |
Antiviral therapy
|
CA2151742C
(en)
*
|
1993-02-22 |
1999-05-25 |
Alfred A. Amkraut |
Compositions for oral delivery of active agents
|
ATE195252T1
(de)
*
|
1993-04-23 |
2000-08-15 |
Novartis Erfind Verwalt Gmbh |
Wirkstoffabgabevorrichtung mit gesteuerter freigabe
|
IL109460A
(en)
|
1993-05-10 |
1998-03-10 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US6287598B1
(en)
|
1993-05-28 |
2001-09-11 |
Alza Corporation |
Method for providing sustained antiepileptic therapy
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
US5410054A
(en)
*
|
1993-07-20 |
1995-04-25 |
Merck Frosst Canada, Inc. |
Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US5498255A
(en)
*
|
1993-08-17 |
1996-03-12 |
Alza Corporation |
Osmotic device for protracted pulsatile delivery of agent
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
DE4342173A1
(de)
*
|
1993-12-10 |
1995-06-14 |
Lohmann Therapie Syst Lts |
Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
|
US5532003A
(en)
*
|
1994-01-18 |
1996-07-02 |
Alza Corporation |
Pentoxifylline therapy
|
US5540665A
(en)
*
|
1994-01-31 |
1996-07-30 |
Alza Corporation |
Gas driven dispensing device and gas generating engine therefor
|
US5985328A
(en)
*
|
1994-03-07 |
1999-11-16 |
Regents Of The University Of California |
Micromachined porous membranes with bulk support
|
US5770076A
(en)
*
|
1994-03-07 |
1998-06-23 |
The Regents Of The University Of California |
Micromachined capsules having porous membranes and bulk supports
|
US5985164A
(en)
*
|
1994-03-07 |
1999-11-16 |
Regents Of The University Of California |
Method for forming a filter
|
US5798042A
(en)
*
|
1994-03-07 |
1998-08-25 |
Regents Of The University Of California |
Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
US20040191314A1
(en)
*
|
1994-04-28 |
2004-09-30 |
Frank Jao |
Antiepileptic dosage form and process for protecting antiepileptic drug
|
ZA953078B
(en)
*
|
1994-04-28 |
1996-01-05 |
Alza Corp |
Effective therapy for epilepsies
|
US5411745A
(en)
*
|
1994-05-25 |
1995-05-02 |
Euro-Celtique, S.A. |
Powder-layered morphine sulfate formulations
|
US6077533A
(en)
*
|
1994-05-25 |
2000-06-20 |
Purdue Pharma L.P. |
Powder-layered oral dosage forms
|
US5460826A
(en)
*
|
1994-06-27 |
1995-10-24 |
Alza Corporation |
Morphine therapy
|
US5698224A
(en)
*
|
1994-06-27 |
1997-12-16 |
Alza Corporation |
Tacrine therapy
|
US5529787A
(en)
*
|
1994-07-07 |
1996-06-25 |
Alza Corporation |
Hydromorphone therapy
|
US5914131A
(en)
*
|
1994-07-07 |
1999-06-22 |
Alza Corporation |
Hydromorphone therapy
|
US5633011A
(en)
*
|
1994-08-04 |
1997-05-27 |
Alza Corporation |
Progesterone replacement therapy
|
DE4431653C2
(de)
*
|
1994-09-06 |
2000-01-20 |
Lohmann Therapie Syst Lts |
Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
|
US6491945B1
(en)
|
1994-09-16 |
2002-12-10 |
Alza Corporation |
Hydrocodone therapy
|
US5718700A
(en)
*
|
1994-09-20 |
1998-02-17 |
Alza Corporation |
Exit means in dosage form
|
US5614578A
(en)
*
|
1994-10-28 |
1997-03-25 |
Alza Corporation |
Injection-molded dosage form
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US5595759A
(en)
*
|
1994-11-10 |
1997-01-21 |
Alza Corporation |
Process for providing therapeutic composition
|
US5582838A
(en)
*
|
1994-12-22 |
1996-12-10 |
Merck & Co., Inc. |
Controlled release drug suspension delivery device
|
US5595997A
(en)
|
1994-12-30 |
1997-01-21 |
Sepracor Inc. |
Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US5651979A
(en)
*
|
1995-03-30 |
1997-07-29 |
Gel Sciences, Inc. |
Apparatus and method for delivering a biologically active compound into a biological environment
|
US5736159A
(en)
*
|
1995-04-28 |
1998-04-07 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
|
US5558879A
(en)
*
|
1995-04-28 |
1996-09-24 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water soluble drugs in which a passageway is formed in situ
|
US5912268A
(en)
*
|
1995-05-22 |
1999-06-15 |
Alza Corporation |
Dosage form and method for treating incontinence
|
US6262115B1
(en)
*
|
1995-05-22 |
2001-07-17 |
Alza Coporation |
Method for the management of incontinence
|
US5674895A
(en)
*
|
1995-05-22 |
1997-10-07 |
Alza Corporation |
Dosage form comprising oxybutynin
|
US6124355A
(en)
*
|
1995-05-22 |
2000-09-26 |
Guittard; George V. |
Oxybutynin therapy
|
US5817335A
(en)
*
|
1995-05-26 |
1998-10-06 |
Alza Corporation |
Osmotic device with high drug loading and delayed activation of drug delivery
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US5800422A
(en)
*
|
1995-06-02 |
1998-09-01 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery and complete drug release
|
US5690952A
(en)
*
|
1995-06-07 |
1997-11-25 |
Judy A. Magruder et al. |
Implantable system for delivery of fluid-sensitive agents to animals
|
US5713852A
(en)
*
|
1995-06-07 |
1998-02-03 |
Alza Corporation |
Oral dosage and method for treating painful conditions of the oral cavity
|
US5798119A
(en)
*
|
1995-06-13 |
1998-08-25 |
S. C. Johnson & Son, Inc. |
Osmotic-delivery devices having vapor-permeable coatings
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
US5780058A
(en)
|
1995-07-21 |
1998-07-14 |
Alza Corporation |
Oral delivery of discrete units
|
US5840332A
(en)
*
|
1996-01-18 |
1998-11-24 |
Perio Products Ltd. |
Gastrointestinal drug delivery system
|
US6858589B2
(en)
|
1996-01-25 |
2005-02-22 |
Pharmacy And Therapeutic Advisory Consultancy Pty Ltd |
Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
|
PT914097E
(pt)
*
|
1996-03-12 |
2002-06-28 |
Alza Corp |
Composicao e forma de dosagem compreendendo antagonista de opioide
|
US6096339A
(en)
*
|
1997-04-04 |
2000-08-01 |
Alza Corporation |
Dosage form, process of making and using same
|
US5902605A
(en)
*
|
1996-04-18 |
1999-05-11 |
Alza Corporation |
Drug delivery device with minimal residual drug retention
|
CA2253549C
(en)
|
1996-06-18 |
2005-10-25 |
Alza Corporation |
Device for enhancing transdermal agent delivery or sampling
|
DE69720735T9
(de)
*
|
1996-08-12 |
2005-08-25 |
Celgene Corp. |
Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
|
ATE205381T1
(de)
*
|
1996-10-18 |
2001-09-15 |
Alza Corp |
Austragevorrichtung für aktive wirkstoffe
|
AU729905B2
(en)
*
|
1996-10-18 |
2001-02-15 |
Alza Corporation |
Multiple flow path device for oral delivery of discrete units
|
US6024721A
(en)
|
1996-10-18 |
2000-02-15 |
Alza Corporation |
Mixing system for an active agent delivery device
|
US6361796B1
(en)
|
1996-10-25 |
2002-03-26 |
Shire Laboratories, Inc. |
Soluble form osmotic dose delivery system
|
ES2255103T3
(es)
*
|
1996-10-25 |
2006-06-16 |
Shire Laboratories Inc. |
Sistema osmotico de administracion de dosis en forma soluble.
|
US6919373B1
(en)
*
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
US5900421A
(en)
*
|
1997-02-11 |
1999-05-04 |
Sepracor Inc. |
Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
|
US5948787A
(en)
*
|
1997-02-28 |
1999-09-07 |
Alza Corporation |
Compositions containing opiate analgesics
|
US5939426A
(en)
*
|
1997-02-28 |
1999-08-17 |
Sepracor Inc. |
Methods for treating urinary incontinence using descarboethoxyloratadine
|
JP4380800B2
(ja)
|
1997-03-07 |
2009-12-09 |
バーナリス リサーチ リミテッド |
マラリアの処置のための(+)メフロキンの使用
|
DK1304105T3
(da)
*
|
1997-03-31 |
2006-11-20 |
Alza Corp |
Implanterbart diffusionsafleveringssystem
|
IL159636A0
(en)
*
|
1997-03-31 |
2004-06-01 |
Alza Corp |
Method for preparing a sustained release delivery system
|
ATE221762T1
(de)
*
|
1997-05-16 |
2002-08-15 |
Alza Corp |
Durchflussreglerkonfigurationen für ein wirkstoff abgebendes gerät
|
US5994148A
(en)
*
|
1997-06-23 |
1999-11-30 |
The Regents Of University Of California |
Method of predicting and enhancing success of IVF/ET pregnancy
|
US6110499A
(en)
*
|
1997-07-24 |
2000-08-29 |
Alza Corporation |
Phenytoin therapy
|
US6245042B1
(en)
|
1997-08-27 |
2001-06-12 |
Science Incorporated |
Fluid delivery device with temperature controlled energy source
|
US7060734B1
(en)
|
1997-09-09 |
2006-06-13 |
Alza Corporation |
Pharmaceutical coating composition and method of use
|
PT1014951E
(pt)
*
|
1997-09-09 |
2005-03-31 |
Alza Corp |
Composicao de revestimento farmaceutica e metodo para a sua utilizacao
|
US6514530B2
(en)
|
1997-09-09 |
2003-02-04 |
Alza Corporation |
Dosage form comprising means for changing drug delivery shape
|
SI1017392T1
(en)
|
1997-09-25 |
2002-12-31 |
Bayer Aktiengesellschaft |
Medicament formulation with a controlled release of an active agent
|
US20040062799A1
(en)
*
|
1997-09-29 |
2004-04-01 |
Ayer Atul D. |
Therapeutic composition and delivery system for administering drug
|
US6607751B1
(en)
|
1997-10-10 |
2003-08-19 |
Intellipharamaceutics Corp. |
Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
WO1999026627A1
(en)
|
1997-11-26 |
1999-06-03 |
Cerebrus Limited |
(-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
|
AU1534699A
(en)
|
1997-12-05 |
1999-06-28 |
Alza Corporation |
Osmotic dosage form comprising first and second coats
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
US7323179B2
(en)
*
|
1997-12-19 |
2008-01-29 |
Naomi Balaban |
Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
|
US20080219976A1
(en)
*
|
1997-12-19 |
2008-09-11 |
Naomi Balaban |
Methods and compositions for treatment and prevention of staphylococcal infections
|
PT1041975E
(pt)
|
1997-12-22 |
2003-01-31 |
Alza Corp |
Membranas de controlo de taxa para dispositivos de fornecimento controlado de drogas
|
AU773642C
(en)
|
1997-12-22 |
2006-04-06 |
Mundipharma Pty Limited |
Opioid agonist/antagonist combinations
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
ATE260640T1
(de)
|
1997-12-29 |
2004-03-15 |
Alza Corp |
Osmotisches verabreichungssystem mit stöpselrückhaltemechanismus
|
DE69834213T2
(de)
|
1997-12-31 |
2007-01-25 |
Alza Corp., Mountain View |
Osmotisches Abgabesystem für ein nützliches Mittel
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
JP2002501892A
(ja)
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な(−)−ビュープロピオンの薬学的使用
|
AU2349999A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmacological uses of pure (+) -bupropion
|
US6245357B1
(en)
|
1998-03-06 |
2001-06-12 |
Alza Corporation |
Extended release dosage form
|
US8524277B2
(en)
*
|
1998-03-06 |
2013-09-03 |
Alza Corporation |
Extended release dosage form
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
AR018321A1
(es)
*
|
1998-03-26 |
2001-11-14 |
Alza Corp |
Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
|
US6462034B1
(en)
|
1998-04-03 |
2002-10-08 |
Theravance, Inc. |
Local anesthetic compounds and uses
|
AR014809A1
(es)
|
1998-04-03 |
2001-03-28 |
Advanced Medicine Inc |
Compuestos multiligazon, composicion farmaceutica, metodo para prepara dichos compuestos y uso de dichos compuestos para preparar medicamentos
|
US6196993B1
(en)
|
1998-04-20 |
2001-03-06 |
Eyelab Group, Llc |
Ophthalmic insert and method for sustained release of medication to the eye
|
US20010038855A1
(en)
*
|
1998-06-05 |
2001-11-08 |
Desjardin Michael A. |
Dosage form for administering prescribed dose
|
US6897305B2
(en)
|
1998-06-08 |
2005-05-24 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US6420354B1
(en)
|
1998-06-08 |
2002-07-16 |
Advanced Medicine, Inc. |
Sodium channel drugs and uses
|
TR200103760T2
(tr)
|
1998-06-15 |
2002-06-21 |
Sepracor Inc. |
Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
|
CA2333666A1
(en)
|
1998-06-15 |
1999-12-23 |
Sepracor Inc. |
Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
|
US6369039B1
(en)
*
|
1998-06-30 |
2002-04-09 |
Scimed Life Sytems, Inc. |
High efficiency local drug delivery
|
US7890176B2
(en)
*
|
1998-07-06 |
2011-02-15 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating chronic pelvic pain
|
TW407058B
(en)
|
1998-07-17 |
2000-10-01 |
Dev Center Biotechnology |
Oral cisapride dosage forms with an extended duration
|
US7772220B2
(en)
*
|
2004-10-15 |
2010-08-10 |
Seo Hong Yoo |
Methods and compositions for reducing toxicity of a pharmaceutical compound
|
CN1205922C
(zh)
|
1998-07-24 |
2005-06-15 |
柳署弘 |
制备含有胆汁酸的澄清水溶液剂型
|
US7303768B2
(en)
|
1998-07-24 |
2007-12-04 |
Seo Hong Yoo |
Preparation of aqueous clear solution dosage forms with bile acids
|
US20050158408A1
(en)
*
|
1998-07-24 |
2005-07-21 |
Yoo Seo H. |
Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
|
US6974838B2
(en)
*
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
US6476078B2
(en)
*
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
US6331571B1
(en)
*
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
US6099862A
(en)
*
|
1998-08-31 |
2000-08-08 |
Andrx Corporation |
Oral dosage form for the controlled release of a biguanide and sulfonylurea
|
US6703050B1
(en)
*
|
1998-09-04 |
2004-03-09 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
US6551613B1
(en)
*
|
1998-09-08 |
2003-04-22 |
Alza Corporation |
Dosage form comprising therapeutic formulation
|
US6174547B1
(en)
*
|
1999-07-14 |
2001-01-16 |
Alza Corporation |
Dosage form comprising liquid formulation
|
EP1112060B1
(en)
*
|
1998-09-09 |
2005-12-07 |
ALZA Corporation |
Dosage form comprising liquid formulation
|
US7906143B1
(en)
|
1998-10-05 |
2011-03-15 |
Intellipharmaceutics Corp |
Controlled release pharmaceutical delivery device and process for preparation thereof
|
US7101909B2
(en)
*
|
1998-10-12 |
2006-09-05 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
GB9822854D0
(en)
|
1998-10-21 |
1998-12-16 |
Reckitt & Colmann Prod Ltd |
Improvements in or relating to organic compositions
|
US6706282B1
(en)
|
1998-11-02 |
2004-03-16 |
Evangeline Cruz |
Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
|
HUP0104993A3
(en)
|
1998-11-02 |
2003-02-28 |
Alza Corp Mountain View |
Method and device for controlled delivery of active agents
|
US6342533B1
(en)
*
|
1998-12-01 |
2002-01-29 |
Sepracor, Inc. |
Derivatives of (−)-venlafaxine and methods of preparing and using the same
|
US6342249B1
(en)
|
1998-12-23 |
2002-01-29 |
Alza Corporation |
Controlled release liquid active agent formulation dosage forms
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6855820B2
(en)
*
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6638727B1
(en)
*
|
1999-01-26 |
2003-10-28 |
Cytyc Health Corporation |
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
|
DE19906974C2
(de)
*
|
1999-02-19 |
2003-10-09 |
Lohmann Therapie Syst Lts |
Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
|
WO2000051582A2
(en)
|
1999-03-01 |
2000-09-08 |
Sepracor Inc. |
Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6353005B1
(en)
|
1999-03-02 |
2002-03-05 |
Sepracor, Inc. |
Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
|
US6362202B1
(en)
|
1999-03-02 |
2002-03-26 |
Sepracor Inc. |
Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
|
US6541021B1
(en)
*
|
1999-03-18 |
2003-04-01 |
Durect Corporation |
Devices and methods for pain management
|
US6835194B2
(en)
*
|
1999-03-18 |
2004-12-28 |
Durect Corporation |
Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
|
US6428818B1
(en)
|
1999-03-30 |
2002-08-06 |
Purdue Research Foundation |
Tea catechin formulations and processes for making same
|
US6410052B1
(en)
|
1999-03-30 |
2002-06-25 |
Purdue Research Foundation |
Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
|
PL350924A1
(en)
*
|
1999-04-06 |
2003-02-10 |
Sepracor Inc |
Derivatives of venlafaxine and methods of preparing and using the same
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
DE60040979D1
(de)
|
1999-05-07 |
2009-01-15 |
Wockhardt Ltd |
(s)-benzochinolizincarbonsäuren und ihre verwendung als antibakterielle mittel
|
US6479498B1
(en)
|
1999-06-04 |
2002-11-12 |
Theravance, Inc. |
Sodium channel drugs and uses
|
USRE47351E1
(en)
|
1999-06-22 |
2019-04-16 |
Gilead Sciences, Inc. |
2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
|
US6403567B1
(en)
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
US6214807B1
(en)
*
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
US6100274A
(en)
*
|
1999-07-07 |
2000-08-08 |
Schering Corporation |
8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
DK1225881T3
(da)
|
1999-09-03 |
2006-06-12 |
Apbi Holdings Llc |
Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion
|
US6491683B1
(en)
|
1999-09-07 |
2002-12-10 |
Alza Corporation |
Osmotic dosage form composed of an extruded polymer tube form
|
CO5210862A1
(es)
|
1999-09-15 |
2002-10-30 |
Alza Corp |
Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
CO5200844A1
(es)
|
1999-09-17 |
2002-09-27 |
Novartis Ag |
Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
|
US6878749B2
(en)
*
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
US6638263B1
(en)
|
1999-10-12 |
2003-10-28 |
Durect Corporation |
Regulation of drug delivery through flow diversion
|
US6114346A
(en)
|
1999-10-22 |
2000-09-05 |
Schering Corporation |
Treating sleep disorders using desloratadine
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
BRPI0015284B8
(pt)
|
1999-10-29 |
2021-05-25 |
Euro Celtique S/A |
formulações de hidrocodona de liberação controlada
|
KR100738276B1
(ko)
*
|
1999-12-09 |
2007-07-12 |
알자 코포레이션 |
항바이러스성 약제
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
WO2001045668A2
(en)
*
|
1999-12-20 |
2001-06-28 |
Schering Corporation |
Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
|
AU2276801A
(en)
|
1999-12-20 |
2001-07-03 |
Schering Corporation |
Extended release oral dosage composition
|
US6491949B2
(en)
|
2000-01-14 |
2002-12-10 |
Osmotica Corp. |
Osmotic device within an osmotic device
|
US6432446B2
(en)
|
2000-02-03 |
2002-08-13 |
Bridge Pharma, Inc. |
Non-arrhythmogenic metabolite of oxybutynin
|
US7405223B2
(en)
|
2000-02-03 |
2008-07-29 |
Schering Corporation |
Treating allergic and inflammatory conditions
|
US7700341B2
(en)
*
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
JP2004500378A
(ja)
*
|
2000-02-04 |
2004-01-08 |
ヨー、セオ、ホン |
胆汁酸を含有する清浄水溶液製型の製造
|
DE60135441D1
(de)
|
2000-02-08 |
2008-10-02 |
Euro Celtique Sa |
Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten
|
JP2003522144A
(ja)
|
2000-02-08 |
2003-07-22 |
ユーロ−セルティーク,エス.エイ. |
オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
|
US6616652B1
(en)
|
2000-02-15 |
2003-09-09 |
Microsolutions, Inc. |
Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter
|
US6471688B1
(en)
|
2000-02-15 |
2002-10-29 |
Microsolutions, Inc. |
Osmotic pump drug delivery systems and methods
|
US6464688B1
(en)
|
2000-02-15 |
2002-10-15 |
Microsolutions, Inc. |
Osmotic pump delivery system with flexible drug compartment
|
BR0108452A
(pt)
|
2000-02-18 |
2003-04-01 |
Cv Therapeutics Inc |
Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
|
AU2001238665A1
(en)
|
2000-02-23 |
2001-09-03 |
Cv Therapeutics, Inc. |
Method of identifying partial agonists of the a2a receptor
|
US6582441B1
(en)
|
2000-02-24 |
2003-06-24 |
Advanced Bionics Corporation |
Surgical insertion tool
|
US7074803B2
(en)
*
|
2001-03-02 |
2006-07-11 |
Durect Corporation |
Opioid formulations
|
US6569152B2
(en)
*
|
2000-03-21 |
2003-05-27 |
Farrington Pharmaceuticals, Llc |
Sustained release delivery systems for solutes
|
MXPA02009665A
(es)
*
|
2000-03-31 |
2005-09-08 |
Celgene Corp |
Inhibicion de actividad de ciclooxigenasa-2.
|
CA2407154A1
(en)
|
2000-04-27 |
2001-11-01 |
Verion, Inc |
Zero order release and temperature-controlled microcapsules and process for the preparation thereof
|
US7259152B2
(en)
|
2000-06-07 |
2007-08-21 |
Alfa Wasserman, Inc. |
Methods and compositions using sulodexide for the treatment of diabetic nephropathy
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
US6638924B2
(en)
|
2000-08-30 |
2003-10-28 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
US7449454B2
(en)
*
|
2000-08-30 |
2008-11-11 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
AU2001296770A1
(en)
*
|
2000-10-06 |
2002-04-15 |
Durect Corporation |
Devices and methods for management of inflammation
|
KR101045144B1
(ko)
|
2000-10-30 |
2011-06-30 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US20060034922A1
(en)
*
|
2000-11-03 |
2006-02-16 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
US6790459B1
(en)
*
|
2000-11-03 |
2004-09-14 |
Andrx Labs, Llc |
Methods for treating diabetes via administration of controlled release metformin
|
EP1723948A1
(en)
|
2000-11-03 |
2006-11-22 |
Andrx Labs, LLC |
Controlled release compositions of biguanide with less side effects and treatment regimen thereof
|
US6866866B1
(en)
*
|
2000-11-03 |
2005-03-15 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
US20070208087A1
(en)
*
|
2001-11-02 |
2007-09-06 |
Sanders Virginia J |
Compounds, compositions and methods for the treatment of inflammatory diseases
|
CA2429411A1
(en)
*
|
2000-11-17 |
2002-05-23 |
Pharmacyclics, Inc. |
Texaphyrin coordination compounds and uses thereof
|
US20030195706A1
(en)
*
|
2000-11-20 |
2003-10-16 |
Michael Korenberg |
Method for classifying genetic data
|
JP4248236B2
(ja)
*
|
2000-11-29 |
2009-04-02 |
デュレクト コーポレイション |
薬物送達装置からの送達を制御するための装置および方法
|
ES2250504T3
(es)
|
2000-11-29 |
2006-04-16 |
Allergan Inc. |
Prevencion del rechazo de injerto en el ojo.
|
ATE374609T1
(de)
*
|
2000-11-30 |
2007-10-15 |
Childrens Medical Center |
Synthese von 4-aminothalidomid enantiomeren
|
AU2002221412B2
(en)
|
2000-12-05 |
2006-04-13 |
Alexander Macgregor |
Hydrostatic delivery system for controlled delivery of agent
|
EP1341773A2
(en)
|
2000-12-07 |
2003-09-10 |
Cv Therapeutics, Inc. |
Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
|
US20030167524A1
(en)
*
|
2000-12-19 |
2003-09-04 |
Rooijen Gijs Van |
Methods for the production of multimeric protein complexes, and related compositions
|
US20060064140A1
(en)
*
|
2001-01-30 |
2006-03-23 |
Whitehurst Todd K |
Methods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder
|
US20050143789A1
(en)
*
|
2001-01-30 |
2005-06-30 |
Whitehurst Todd K. |
Methods and systems for stimulating a peripheral nerve to treat chronic pain
|
US7493172B2
(en)
*
|
2001-01-30 |
2009-02-17 |
Boston Scientific Neuromodulation Corp. |
Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
|
IN190699B
(hr)
|
2001-02-02 |
2003-08-16 |
Sun Pharmaceutical Ind Ltd |
|
ES2290281T5
(es)
*
|
2001-02-12 |
2017-09-11 |
Wyeth Llc |
Sal de succinato de O-desmetil-venlafaxina
|
US7125703B2
(en)
|
2001-03-13 |
2006-10-24 |
Dendreon Corporation |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
KR20040011480A
(ko)
|
2001-03-22 |
2004-02-05 |
덴드레온 샌 디에고 엘엘씨 |
세린 프로테아제 cvsp14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
|
EP1379637A4
(en)
|
2001-03-27 |
2005-04-06 |
Dendreon Corp |
TRANSMEMBRANE SERINE PROTEASE 9 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED, AND METHODS FORMING THEREOF
|
WO2002083631A1
(en)
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
US6632217B2
(en)
*
|
2001-04-19 |
2003-10-14 |
Microsolutions, Inc. |
Implantable osmotic pump
|
US6964966B2
(en)
*
|
2001-04-25 |
2005-11-15 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
US6878713B2
(en)
*
|
2001-04-25 |
2005-04-12 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
EP1387673B1
(en)
|
2001-05-11 |
2010-12-29 |
Endo Pharmaceuticals Inc. |
Abuse-resistant controlled-release opioid dosage form
|
EP1539942A4
(en)
|
2001-05-14 |
2005-10-19 |
Dendreon Corp |
A TRANSMEMBRANE SERINE PROTEASE 10 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED AND METHOD THEREOF
|
EP1404324B2
(en)
*
|
2001-06-11 |
2011-04-06 |
XenoPort, Inc. |
Prodrugs of gaba analogs, compositions and uses thereof
|
JP2005501013A
(ja)
*
|
2001-06-11 |
2005-01-13 |
ゼノポート,インコーポレイテッド |
Gaba類似体の全身濃度が持続するアミノ酸コンジュゲート
|
US7186855B2
(en)
*
|
2001-06-11 |
2007-03-06 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US7232924B2
(en)
*
|
2001-06-11 |
2007-06-19 |
Xenoport, Inc. |
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
|
US8048917B2
(en)
*
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US20040180087A1
(en)
*
|
2001-06-21 |
2004-09-16 |
Boyong Li |
Stable controlled release pharmaceutical compositions containing pravastatin
|
AUPR602401A0
(en)
*
|
2001-06-29 |
2001-07-26 |
Smart Drug Systems Inc |
Sustained release delivery system
|
US7034059B2
(en)
*
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
US20040247696A1
(en)
*
|
2001-07-05 |
2004-12-09 |
Antelman Marvin S. |
Methods of using electron active compounds for managing conditions afflicting mammals
|
WO2003004030A1
(en)
|
2001-07-06 |
2003-01-16 |
Endo Pharmaceuticals, Inc. |
Oxymorphone controlled release formulations
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
ES2292775T3
(es)
|
2001-07-06 |
2008-03-16 |
Penwest Pharmaceuticals Co. |
Formulaciones de liberacion prolongada de oximorfona.
|
US7713946B2
(en)
*
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
US7157440B2
(en)
*
|
2001-07-13 |
2007-01-02 |
Cv Therapeutics, Inc. |
Partial and full agonists of A1 adenosine receptors
|
SI1414451T1
(sl)
|
2001-08-06 |
2009-10-31 |
Euro Celtique Sa |
Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
EP1283025A1
(de)
*
|
2001-08-10 |
2003-02-12 |
Stöckert Instrumente GmbH |
Ballonokklusionsvorrichtung
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
BR0212951A
(pt)
*
|
2001-09-28 |
2004-10-26 |
Mcneil Ppc Inc |
Formas de dosagens compósitas
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
IL161867A0
(en)
|
2001-11-09 |
2005-11-20 |
Cv Therapeutics Inc |
A2b adenosine receptor antagonists
|
US20030134794A1
(en)
*
|
2001-11-20 |
2003-07-17 |
Madison Edwin L. |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
US7157493B2
(en)
*
|
2001-11-28 |
2007-01-02 |
Nashai Biotech, Llc |
Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof
|
WO2003049673A2
(en)
|
2001-12-05 |
2003-06-19 |
Baylor College Of Medicine |
Methods and compositions for control of bone formation via modulation of sympathetic tone
|
AU2002357935A1
(en)
*
|
2001-12-18 |
2003-06-30 |
Alza Corporation |
Dosage form for providing time-varying patterns of drug delivery
|
US20030198619A1
(en)
*
|
2001-12-19 |
2003-10-23 |
Dong Liang C. |
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
|
US20030232078A1
(en)
*
|
2001-12-19 |
2003-12-18 |
Dong Liang C. |
Formulation & dosage form for the controlled delivery of therapeutic agents
|
US20040009953A1
(en)
*
|
2002-01-10 |
2004-01-15 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
US20030181416A1
(en)
*
|
2002-01-10 |
2003-09-25 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
ES2309294T3
(es)
|
2002-02-01 |
2008-12-16 |
Pfizer Products Inc. |
Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo.
|
US20030161882A1
(en)
*
|
2002-02-01 |
2003-08-28 |
Waterman Kenneth C. |
Osmotic delivery system
|
AU2003212882A1
(en)
|
2002-02-01 |
2003-09-02 |
Euro-Celtique S.A. |
2 - piperazine - pyridines useful for treating pain
|
TW200302748A
(en)
*
|
2002-02-01 |
2003-08-16 |
Pfizer Prod Inc |
Osmotic delivery system
|
US8685427B2
(en)
|
2002-07-31 |
2014-04-01 |
Boston Scientific Scimed, Inc. |
Controlled drug delivery
|
US8133501B2
(en)
|
2002-02-08 |
2012-03-13 |
Boston Scientific Scimed, Inc. |
Implantable or insertable medical devices for controlled drug delivery
|
US7446107B2
(en)
*
|
2002-02-15 |
2008-11-04 |
Transform Pharmaceuticals, Inc. |
Crystalline forms of conazoles and methods of making and using the same
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
US20040260076A1
(en)
*
|
2002-10-11 |
2004-12-23 |
Castillo Gerardo M. |
Isolation, purification and synthesis of procyanidin B2 and uses thereof
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
AU2003223237C1
(en)
|
2002-02-19 |
2009-03-26 |
Gilead Palo Alto, Inc. |
Partial and full agonists of A1 adenosine receptors
|
AU2002316231A1
(en)
|
2002-02-19 |
2003-09-29 |
Xenoport, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
EP1494998A2
(en)
|
2002-03-01 |
2005-01-12 |
University Of South Florida |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
KR101173497B1
(ko)
*
|
2002-03-11 |
2012-08-14 |
알콘, 인코퍼레이티드 |
이식 가능한 약물 전달 시스템
|
EP1496838B1
(en)
|
2002-03-12 |
2010-11-03 |
Merck Sharp & Dohme Corp. |
Substituted amides
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
JP2005521706A
(ja)
*
|
2002-03-29 |
2005-07-21 |
アルザ・コーポレーシヨン |
体積効果的放出制御製剤
|
US20080109040A1
(en)
*
|
2002-04-04 |
2008-05-08 |
Luiz Belardinelli |
Method of treating arrhythmias
|
US20030220344A1
(en)
*
|
2002-04-04 |
2003-11-27 |
Luiz Belardinelli |
Method of treating arrhythmias
|
ES2733044T1
(es)
*
|
2002-04-05 |
2019-11-27 |
Mundipharma Pharmaceuticals S L |
Composición farmacéutica que contiene oxicodona y naloxona
|
WO2003090723A1
(en)
*
|
2002-04-23 |
2003-11-06 |
Bristol-Myers Squibb Company |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
US20040010000A1
(en)
*
|
2002-04-29 |
2004-01-15 |
Ayer Atul D. |
Methods and dosage forms for controlled delivery of oxycodone
|
US20050106249A1
(en)
*
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
US20060116663A1
(en)
*
|
2002-05-01 |
2006-06-01 |
Joshi Ashok V |
Electro-osmotic fluid delivery device and method
|
US7470267B2
(en)
*
|
2002-05-01 |
2008-12-30 |
Microlin, Llc |
Fluid delivery device having an electrochemical pump with an anionic exchange membrane and associated method
|
US7896867B2
(en)
*
|
2002-05-01 |
2011-03-01 |
Microlin, Llc |
Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
|
US7458965B2
(en)
*
|
2002-05-01 |
2008-12-02 |
Microlin, Llc |
Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
|
US7205413B2
(en)
*
|
2002-05-03 |
2007-04-17 |
Transform Pharmaceuticals, Inc. |
Solvates and polymorphs of ritonavir and methods of making and using the same
|
CN1697655B
(zh)
|
2002-05-17 |
2013-09-18 |
细胞基因公司 |
使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
WO2003099338A2
(en)
*
|
2002-05-17 |
2003-12-04 |
Xenoport, Inc. |
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
|
US7393862B2
(en)
*
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
NZ536908A
(en)
*
|
2002-05-17 |
2008-09-26 |
Celgene Corp |
Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
|
EP1505977B1
(en)
|
2002-05-21 |
2014-09-10 |
Gilead Sciences, Inc. |
Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
|
US8822473B2
(en)
*
|
2002-05-21 |
2014-09-02 |
Gilead Sciences, Inc. |
Method of treating diabetes
|
WO2003099214A2
(en)
*
|
2002-05-23 |
2003-12-04 |
Andrx Corporation |
Biguanide formulations
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
US7151961B1
(en)
*
|
2002-05-24 |
2006-12-19 |
Advanced Bionics Corporation |
Treatment of movement disorders by brain stimulation
|
US6995168B2
(en)
|
2002-05-31 |
2006-02-07 |
Euro-Celtique S.A. |
Triazaspiro compounds useful for treating or preventing pain
|
SI2527315T1
(sl)
|
2002-05-31 |
2014-06-30 |
Proteotech Inc., |
Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
|
US8829198B2
(en)
*
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
CN1671358A
(zh)
*
|
2002-05-31 |
2005-09-21 |
阿尔扎公司 |
用于渗透传递可变剂量的羟考酮的剂型和组合物
|
AU2003243354A1
(en)
*
|
2002-05-31 |
2003-12-19 |
Transform Pharmaceuticals, Inc. |
Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
|
US6900203B2
(en)
|
2002-06-19 |
2005-05-31 |
Polium Technologies, Inc. |
Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
|
CA2489984A1
(en)
|
2002-06-21 |
2003-12-31 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical compositions with improved dissolution
|
AR039744A1
(es)
*
|
2002-06-26 |
2005-03-09 |
Alza Corp |
Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
|
JP2005533084A
(ja)
*
|
2002-06-28 |
2005-11-04 |
アルザ・コーポレーシヨン |
液体の有効成分の製剤を含んでなりかつ膨張可能な浸透圧組成物によりその放出を制御する経口の投薬形態
|
TWI326214B
(en)
|
2002-07-17 |
2010-06-21 |
Avanir Pharmaceuticals Inc |
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
|
US7189865B2
(en)
*
|
2002-07-23 |
2007-03-13 |
Attenuon, Llc |
Thiomolybdate analogues and uses thereof
|
CN1688303A
(zh)
|
2002-07-23 |
2005-10-26 |
密歇根大学董事会 |
用于抗血管发生疗法的四硫代钼酸四丙铵及相关化合物
|
ATE548354T1
(de)
|
2002-07-24 |
2012-03-15 |
Ptc Therapeutics Inc |
Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
|
PA8578501A1
(es)
*
|
2002-07-25 |
2005-02-04 |
Pharmacia Corp |
Forma de dosificacion una vez al dia de pramipexol
|
US20050226926A1
(en)
|
2002-07-25 |
2005-10-13 |
Pfizer Inc |
Sustained-release tablet composition of pramipexole
|
US20050020915A1
(en)
*
|
2002-07-29 |
2005-01-27 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging methods and compositions
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
US7683037B2
(en)
*
|
2002-07-29 |
2010-03-23 |
Gilead Palo Alto, Inc. |
Myocardial perfusion imaging method
|
US8470801B2
(en)
|
2002-07-29 |
2013-06-25 |
Gilead Sciences, Inc. |
Myocardial perfusion imaging methods and compositions
|
EP1534238A1
(en)
*
|
2002-07-29 |
2005-06-01 |
ALZA Corporation |
Formulations and dosage forms for controlled delivery of topiramate
|
US8920826B2
(en)
|
2002-07-31 |
2014-12-30 |
Boston Scientific Scimed, Inc. |
Medical imaging reference devices
|
US7254449B2
(en)
*
|
2002-07-31 |
2007-08-07 |
Advanced Bionics Corp |
Systems and methods for providing power to one or more implantable devices
|
ES2358896T3
(es)
|
2002-08-15 |
2011-05-16 |
Euro-Celtique S.A. |
Composiciones farmacéuticas que comprenden un analgésico opioide.
|
US20040132806A1
(en)
|
2002-09-03 |
2004-07-08 |
Jackie Butler |
Pravastatin pharmaceutical formulations and methods of their use
|
US20060009739A1
(en)
*
|
2002-09-06 |
2006-01-12 |
Durect Corporation |
Implantable flow regulator with failsafe mode and reserve drug supply
|
EP1545551A4
(en)
|
2002-09-06 |
2008-10-22 |
Durect Corp |
DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
|
EP2422775A3
(en)
*
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US20050051922A1
(en)
*
|
2002-09-20 |
2005-03-10 |
Avinash Nangia |
Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
|
KR20120034211A
(ko)
|
2002-09-20 |
2012-04-10 |
안드렉스 랩스 엘엘씨 |
약제학적 정제
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US20050048119A1
(en)
*
|
2002-09-20 |
2005-03-03 |
Avinash Nangia |
Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
|
US7785627B2
(en)
*
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
WO2004029059A1
(en)
|
2002-09-25 |
2004-04-08 |
Euro-Celtique S.A. |
N-substituted hydromorphones and the use thereof
|
WO2004029025A2
(en)
*
|
2002-09-27 |
2004-04-08 |
Bioenvision, Inc. |
Methods and compositions for the treatment of autoimmune disorders using clofarabine
|
GB0222522D0
(en)
|
2002-09-27 |
2002-11-06 |
Controlled Therapeutics Sct |
Water-swellable polymers
|
CA2500091A1
(en)
*
|
2002-09-27 |
2004-04-08 |
Bioenvision, Inc. |
Methods and compositions for the treatment of lupus using clofarabine
|
CA2501625A1
(en)
*
|
2002-10-07 |
2004-04-22 |
Radiorx, Inc. |
X-nitro compounds, pharmaceutical compositions thereof and uses therof
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
EP1551385A4
(en)
*
|
2002-10-15 |
2008-10-22 |
Celgene Corp |
SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
UY28056A1
(es)
*
|
2002-10-31 |
2003-12-31 |
Alza Corp |
Formas de dosificacion que proporcionan la liberacion ascendente de una formulacion liquida.
|
EP1556000A1
(en)
*
|
2002-10-31 |
2005-07-27 |
Alza Corporation |
Pharmaceutical formulation providing an increased biovailability of hydrophobic drugs
|
EP1567169A4
(en)
*
|
2002-11-04 |
2009-10-21 |
Xenoport Inc |
GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
MXPA05004780A
(es)
|
2002-11-06 |
2005-10-05 |
Celgene Corp |
Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos.
|
NZ540384A
(en)
*
|
2002-11-06 |
2008-06-30 |
Celgene Corp |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
|
JP2006510617A
(ja)
*
|
2002-11-18 |
2006-03-30 |
セルジーン・コーポレーション |
(+)−3−(3,4−ジメトキシ−フェニル)−3−(1−オキソ−1,3−ジヒドロ−イソインドール−2−イル)−プロピオンアミドの使用方法およびそれを含む組成物
|
BR0316256A
(pt)
*
|
2002-11-18 |
2005-10-04 |
Celgene Corp |
Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
|
US7202259B2
(en)
*
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
US20040102476A1
(en)
*
|
2002-11-25 |
2004-05-27 |
Chan Tai Wah |
High concentration formulations of opioids and opioid derivatives
|
EA200500871A1
(ru)
*
|
2002-11-25 |
2006-04-28 |
Атеньюон, Ллк |
Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение
|
AU2003293423A1
(en)
|
2002-12-06 |
2004-06-30 |
Xenoport, Inc. |
Carbidopa prodrugs and uses thereof
|
US20040111071A1
(en)
*
|
2002-12-09 |
2004-06-10 |
Jeffrey Lewis Powers |
Portable device for dispensing hand treatments
|
US8286834B2
(en)
*
|
2002-12-09 |
2012-10-16 |
Jeffrey Lewis Powers |
Skin treatment dispenser and method of manufacture
|
WO2004052360A1
(en)
*
|
2002-12-11 |
2004-06-24 |
Xenoport, Inc. |
Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
|
WO2004053192A1
(en)
*
|
2002-12-11 |
2004-06-24 |
Xenoport, Inc. |
Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
|
SI2218448T1
(sl)
|
2002-12-13 |
2016-01-29 |
Durect Corporation |
Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo
|
WO2004058147A2
(en)
|
2002-12-16 |
2004-07-15 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
|
US20080051411A1
(en)
*
|
2002-12-17 |
2008-02-28 |
Cink Russell D |
Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
|
RU2356549C2
(ru)
*
|
2002-12-17 |
2009-05-27 |
Эббетт ГмбХ унд Ко.КГ |
Композиция, включающая фенофибриновую кислоту, ее физиологически приемлемую соль или производное
|
US7259186B2
(en)
*
|
2002-12-17 |
2007-08-21 |
Abbott Laboratories |
Salts of fenofibric acid and pharmaceutical formulations thereof
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
US7582635B2
(en)
*
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
EP2339328A3
(en)
|
2002-12-30 |
2011-07-13 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of celecoxib
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
JP2006522016A
(ja)
*
|
2003-01-14 |
2006-09-28 |
アルザ・コーポレーシヨン |
改変された粘度の層を用いる方法および投薬形態物
|
JP2006515891A
(ja)
|
2003-01-17 |
2006-06-08 |
シーブイ・セラピューティクス・インコーポレイテッド |
循環器疾患の処置に有効な置換ヘテロ環化合物
|
ZA200504940B
(en)
*
|
2003-01-28 |
2006-09-27 |
Xenoport Inc |
Amino acid derived prodrugs of propofol, compositions and uses thereof
|
JP2006517593A
(ja)
*
|
2003-02-11 |
2006-07-27 |
アルザ・コーポレーシヨン |
投薬形態物の層形状修飾方法およびそのような修飾を受けさせた投薬形態物
|
AR045414A1
(es)
|
2003-02-13 |
2005-10-26 |
Banyu Pharma Co Ltd |
Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
|
EP1608339B8
(en)
|
2003-02-28 |
2012-04-25 |
McNeill-PPC, Inc. |
Pharmaceutical co-crystal of celecoxib-nicotinamide
|
DK2163643T3
(en)
|
2003-03-05 |
2015-03-23 |
Halozyme Inc |
Soluble hyaluronidaseglycoprotein (sHASEGP), process for preparing the same, pharmaceutical compositions and uses thereof covered
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
EP1608357A4
(en)
*
|
2003-03-31 |
2008-03-26 |
Xenoport Inc |
TREATMENT OR PREVENTION OF HITZEWALLUNGEN USING PRODRUGS OF GABA ANALOGUE
|
SI3549936T1
(sl)
|
2003-04-11 |
2021-09-30 |
Ptc Therapeutics, Inc. |
Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
US20070083240A1
(en)
*
|
2003-05-08 |
2007-04-12 |
Peterson David K L |
Methods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator
|
JP2007525188A
(ja)
|
2003-05-16 |
2007-09-06 |
インターミューン インコーポレイテッド |
合成ケモカイン受容体リガンドおよびその使用方法
|
US8029822B2
(en)
*
|
2003-05-22 |
2011-10-04 |
Osmotica Kereskedelmi és Seolgáltató KFT |
Rupturing controlled release device having a preformed passageway
|
JP2007502865A
(ja)
*
|
2003-05-23 |
2007-02-15 |
ブリッジ ファーマ、インコーポレイテッド |
平滑筋鎮痙剤
|
US7186863B2
(en)
*
|
2003-05-23 |
2007-03-06 |
Transform Pharmaceuticals, Inc. |
Sertraline compositions
|
CA2527236A1
(en)
*
|
2003-05-27 |
2004-12-23 |
Attenuon Llc |
Thiotungstate analogues and uses thereof
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
US7438903B2
(en)
*
|
2003-06-06 |
2008-10-21 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
AR044688A1
(es)
*
|
2003-06-12 |
2005-09-21 |
Euro Celtique Sa |
Agentes terapeuticos utiles para el tratamiento del dolor
|
EP1643946A2
(en)
*
|
2003-06-20 |
2006-04-12 |
Viral Genomix, Inc. |
Compositions for and methods for treating hiv
|
US7145125B2
(en)
|
2003-06-23 |
2006-12-05 |
Advanced Optical Technologies, Llc |
Integrating chamber cone light using LED sources
|
CA2529984C
(en)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
DK1641775T3
(da)
*
|
2003-07-03 |
2009-04-20 |
Euro Celtique Sa |
2-pyridinalkynderivater, der er anvendelige til behandling af smerter
|
WO2005004882A1
(en)
*
|
2003-07-09 |
2005-01-20 |
Monash University |
Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
|
AU2004259024B2
(en)
*
|
2003-07-23 |
2011-06-23 |
Synta Pharmaceuticals, Corp. |
Compounds for inflammation and immune-related uses
|
US20050020692A1
(en)
*
|
2003-07-24 |
2005-01-27 |
Ciofalo Vincent B. |
Treatment of heaves
|
UA84710C2
(ru)
*
|
2003-07-24 |
2008-11-25 |
Евро-Селтик С.А. |
Пиперидиновые производные, фармацевтическая композиция, которая их содержит, и способ лечения
|
EP1867644B1
(en)
|
2003-07-24 |
2009-05-20 |
Euro-Celtique S.A. |
Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
|
MXPA06000940A
(es)
*
|
2003-07-24 |
2006-03-30 |
Euro Celtique Sa |
Agentes terapeuticos utiles para el tratamiento de dolor.
|
WO2005011630A2
(en)
*
|
2003-07-31 |
2005-02-10 |
Alza Corporation |
Permeation-resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation
|
US20090317476A1
(en)
*
|
2003-07-31 |
2009-12-24 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026882A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
|
PL1648880T3
(pl)
*
|
2003-08-01 |
2010-06-30 |
Euro Celtique Sa |
Środki lecznicze użyteczne do leczenia bólu
|
MXPA06001548A
(es)
*
|
2003-08-06 |
2006-09-04 |
Johnson & Johnson |
Suministro uniforme de topiramato durante un periodo prolongado con formulaciones de dispersion.
|
GB0318824D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Glaxo Group Ltd |
Novel composition
|
EP2354120A1
(en)
|
2003-08-20 |
2011-08-10 |
XenoPort, Inc. |
Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
|
PT1660440E
(pt)
*
|
2003-08-20 |
2012-05-15 |
Xenoport Inc |
Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização
|
WO2005020957A2
(en)
*
|
2003-08-22 |
2005-03-10 |
Alza Corporation |
Stepwise delivery of topiramate over prolonged period of time
|
WO2005023181A2
(en)
*
|
2003-08-22 |
2005-03-17 |
Vista Scientific |
Polymeric systems for controlled drug therapy
|
GB0320020D0
(en)
*
|
2003-08-27 |
2003-10-01 |
Mw Encap Ltd |
Improved formulation for providing an enteric coating material
|
WO2005020959A2
(en)
*
|
2003-09-02 |
2005-03-10 |
Alza Corporation |
Novel drug compositions and dosage forms of topiramate
|
JP2007504261A
(ja)
*
|
2003-09-03 |
2007-03-01 |
エイジーアイ・セラピューティクス・リサーチ・リミテッド |
プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
DE60314920T2
(de)
*
|
2003-09-04 |
2008-03-13 |
Wockhardt Ltd. |
Benzochinolizin-2-carbonsäureargininsalz- tetrahydrat
|
WO2005023204A2
(en)
*
|
2003-09-09 |
2005-03-17 |
Xenoport, Inc. |
Aromatic prodrugs of propofol, compositions and uses thereof
|
US7700652B2
(en)
|
2003-09-11 |
2010-04-20 |
Xenoport, Inc. |
Treating urinary incontinence using prodrugs of GABA analogs
|
EP1677812A4
(en)
*
|
2003-09-17 |
2010-03-24 |
Xenoport Inc |
TREATMENT OR PREVENTION OF NON-REST LEG SYNDROME USING GABA ANALOGUE-BASED PRODRUGS
|
WO2005027853A2
(en)
*
|
2003-09-19 |
2005-03-31 |
University Of Louisville Research Foundation Inc |
Method for treating snoring and sleep apnea with leukotriene antagonists
|
SI1664041T1
(sl)
*
|
2003-09-22 |
2008-12-31 |
Euro Celtique Sa |
Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
|
ATE412646T1
(de)
*
|
2003-09-22 |
2008-11-15 |
Euro Celtique Sa |
Zur behandlung von schmerzen geeignete therapeutische mittel
|
EP1663229B1
(en)
|
2003-09-25 |
2010-04-14 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
AU2004275813A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Osmotic dosage forms for controlled delivery of alprazolam
|
WO2005030181A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Controlled release formulations of opioid and nonopioid analgesics
|
US20070259033A1
(en)
|
2003-09-26 |
2007-11-08 |
Evangeline Cruz |
Controlled release formulations exhibiting an ascending rate of release
|
WO2005030166A1
(en)
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Oros push-stick for controlled delivery of active agents
|
NZ546148A
(en)
|
2003-09-26 |
2009-05-31 |
Alza Corp |
Drug coating providing high drug loading and methods for providing the same
|
CA2540045A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Dosage form for controlled release of an active agent formulation
|
DE602004006763T2
(de)
*
|
2003-09-26 |
2008-02-07 |
Alza Corp., Mountain View |
Darreichungsform zur kontrollierten Freisetzung einer Formulierung mit aktivem Mittel und Verfahren zur Herstellung der Darreichungsform
|
BRPI0415288B8
(pt)
*
|
2003-10-14 |
2021-05-25 |
Xenoport Inc |
composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US7407973B2
(en)
*
|
2003-10-24 |
2008-08-05 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
KR20060109922A
(ko)
*
|
2003-10-31 |
2006-10-23 |
알자 코포레이션 |
가바펜틴 및 프리가발린의 개선된 흡수를 위한 조성물 및제형
|
US20050118246A1
(en)
*
|
2003-10-31 |
2005-06-02 |
Wong Patrick S. |
Dosage forms and layered deposition processes for fabricating dosage forms
|
US20050113410A1
(en)
*
|
2003-11-03 |
2005-05-26 |
Mark Tawa |
Pharmaceutical salts of zafirlukast
|
US20050095288A1
(en)
*
|
2003-11-03 |
2005-05-05 |
Andrx Labs, Llc |
Decongestant and expectorant tablets
|
US8987322B2
(en)
*
|
2003-11-04 |
2015-03-24 |
Circ Pharma Research And Development Limited |
Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
|
EA200600921A1
(ru)
*
|
2003-11-06 |
2006-10-27 |
Селджин Корпорейшн |
Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
TW200528144A
(en)
*
|
2003-11-14 |
2005-09-01 |
Alza Corp |
Controlled release of topiramate in liquid dosage forms
|
US7470435B2
(en)
*
|
2003-11-17 |
2008-12-30 |
Andrx Pharmaceuticals, Llc |
Extended release venlafaxine formulation
|
EP2065383A1
(en)
|
2003-11-19 |
2009-06-03 |
Signal Pharmaceuticals, Inc. |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
WO2005051298A2
(en)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
US20050169994A1
(en)
*
|
2003-11-25 |
2005-08-04 |
Burke Matthew D. |
Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
|
US8734850B2
(en)
*
|
2003-11-25 |
2014-05-27 |
Flamel Technologies |
Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
|
EP1689787A2
(en)
|
2003-11-28 |
2006-08-16 |
Eastman Chemical Company |
Cellulose interpolymers and method of oxidation
|
US20050129764A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Vergez Juan A. |
Osmotic device containing licofelone
|
PL1691811T3
(pl)
|
2003-12-11 |
2014-12-31 |
Sunovion Pharmaceuticals Inc |
Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
|
WO2005062829A2
(en)
*
|
2003-12-19 |
2005-07-14 |
Advanced Bionics Corporation |
Skull-mounted electrical stimulation system and method for treating patients
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
AU2004308973A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Alza Corporation |
Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
|
CA2551815A1
(en)
*
|
2003-12-29 |
2005-07-21 |
Alza Corporation |
Novel drug compositions and dosage forms
|
AU2004312084A1
(en)
*
|
2003-12-29 |
2005-07-21 |
Alza Corporation, Inc. |
Novel drug compositions and dosage forms of topiramate
|
EP1702919B1
(en)
*
|
2003-12-29 |
2012-05-30 |
Msd K.K. |
Novel 2-heteroaryl-substituted benzimidazole derivative
|
US20050175696A1
(en)
*
|
2003-12-29 |
2005-08-11 |
David Edgren |
Drug granule coatings that impart smear resistance during mechanical compression
|
KR100867188B1
(ko)
*
|
2003-12-30 |
2008-11-06 |
유로-셀띠끄 소시에떼 아노님 |
통증 치료에 유용한 피페라진
|
US8138204B2
(en)
*
|
2004-01-07 |
2012-03-20 |
Aryx Therapeutics, Inc. |
Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
EP2194053B1
(en)
|
2004-01-07 |
2013-03-27 |
Armetheon, Inc. |
Methoxy piperidine derivatives for use inr the treatment of gastrointestinal and central nervous system disorders
|
US8524736B2
(en)
|
2004-01-07 |
2013-09-03 |
Armetheon, Inc. |
Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
US7976520B2
(en)
*
|
2004-01-12 |
2011-07-12 |
Nulens Ltd. |
Eye wall anchored fixtures
|
AU2005209201B2
(en)
|
2004-01-20 |
2010-06-03 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
EP2292213A1
(en)
|
2004-02-06 |
2011-03-09 |
Cephalon, Inc. |
Compositions comprising a polymorphic form of armodafinil
|
AU2005212005A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Athpharma Limited |
Chronotherapeutic compositions and methods of their use
|
ES2308451T3
(es)
|
2004-02-18 |
2008-12-01 |
Gpc Biotech Ag |
Satraplatino para el tratamiento de tumores resistentes o refractarios.
|
EP1729784A1
(en)
*
|
2004-02-23 |
2006-12-13 |
Attenuon, LLC |
Formulations of thiomolybdate or thiotungstate compounds and uses thereof
|
US20050196448A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Hai Yong Huang |
Polymeric compositions and dosage forms comprising the same
|
US20050196447A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196446A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196442A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US7612071B2
(en)
|
2004-03-12 |
2009-11-03 |
Syntrix Biosystems, Inc. |
Compositions and methods employing aminopterin
|
US20100004304A1
(en)
*
|
2004-03-16 |
2010-01-07 |
Kohn Leonard D |
Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
|
US20060211752A1
(en)
*
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050209295A1
(en)
*
|
2004-03-16 |
2005-09-22 |
Kohn Leonard D |
Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
|
US7928132B2
(en)
*
|
2004-08-06 |
2011-04-19 |
Ohio University |
Methods for the amelioration of episodes of acute or chronic ulcerative colitis
|
NZ550026A
(en)
|
2004-03-22 |
2009-10-30 |
Celgene Corp |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
WO2005092065A2
(en)
*
|
2004-03-25 |
2005-10-06 |
Transform Pharmaceuticals, Inc. |
Novel tricyclic compounds and related methods of treatment
|
TWI483944B
(zh)
|
2004-03-30 |
2015-05-11 |
Euro Celtique Sa |
含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
|
WO2005100346A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Wyeth |
Thioamide derivatives as progesterone receptor modulators
|
JP2007532642A
(ja)
*
|
2004-04-14 |
2007-11-15 |
セルジーン・コーポレーション |
脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
|
BRPI0418742A
(pt)
*
|
2004-04-14 |
2007-09-11 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
ZA200609228B
(en)
*
|
2004-04-23 |
2008-05-28 |
Celgene Corp |
Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
|
AU2005237520B2
(en)
*
|
2004-04-27 |
2012-01-19 |
Wyeth |
Purification of progesterone receptor modulators
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US8512738B2
(en)
|
2004-04-30 |
2013-08-20 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase implants
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
US8425929B2
(en)
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US20050244500A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US7803366B2
(en)
*
|
2004-05-07 |
2010-09-28 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
US20060185357A1
(en)
*
|
2004-05-07 |
2006-08-24 |
Kovacevich Ian D |
Independently drawing and tensioning lines with bi-directional rotary device having two spools
|
WO2005113596A2
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
WO2005115384A2
(en)
*
|
2004-05-25 |
2005-12-08 |
Metabolex, Inc. |
Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
|
CN1997633A
(zh)
*
|
2004-05-25 |
2007-07-11 |
麦它波莱克斯股份有限公司 |
作为ppar调节剂的取代的三唑及其制备方法
|
EP1755388B1
(en)
|
2004-05-28 |
2010-10-06 |
Transform Pharmaceuticals, Inc. |
Mixed co-crystals and pharmaceutical compositions comprising the same
|
US20060009425A1
(en)
*
|
2004-05-28 |
2006-01-12 |
Leticia Delgado-Herrera |
Oral formulations of paricalcitol
|
US20050267555A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Marnfeldt Goran N |
Engagement tool for implantable medical devices
|
ES2623362T3
(es)
*
|
2004-05-28 |
2017-07-11 |
Human Biomolecular Research Institute |
Analgésicos metabólicamente estables y medicaciones para el dolor
|
WO2005120584A2
(en)
*
|
2004-06-03 |
2005-12-22 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled arylsulfonyl compounds and uses thereof
|
WO2005121070A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Xenoport, Inc. |
Levodopa prodrugs, and compositions and uses thereof
|
ZA200610042B
(en)
*
|
2004-06-04 |
2008-06-25 |
Xenoport Inc |
Levodopa prodrugs, and compositions and uses thereof
|
EP1604667A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
HUE037643T2
(hu)
|
2004-06-12 |
2018-09-28 |
Collegium Pharmaceutical Inc |
Visszaélésre nem alkalmas gyógyszerkészítmények
|
US20050276848A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Nilobon Podhipleux |
Sustained release neutralized divalproex sodium
|
US7713550B2
(en)
*
|
2004-06-15 |
2010-05-11 |
Andrx Corporation |
Controlled release sodium valproate formulation
|
JP5017103B2
(ja)
*
|
2004-06-17 |
2012-09-05 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
薬剤共結晶組成物および関連した使用方法
|
WO2006025920A2
(en)
*
|
2004-06-19 |
2006-03-09 |
Human Biomolecular Research Institute |
Modulators of central nervous system neurotransmitters
|
US20050287185A1
(en)
*
|
2004-06-23 |
2005-12-29 |
David Wong |
Extended release oxybutynin formulation
|
WO2006007351A2
(en)
*
|
2004-06-28 |
2006-01-19 |
Alza Corporation |
Squeeze controlled oral dosage form
|
US20050287213A1
(en)
*
|
2004-06-28 |
2005-12-29 |
Wong Patrick S |
Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
|
US20050287212A1
(en)
*
|
2004-06-28 |
2005-12-29 |
Liang-Chang Dong |
Oral delivery system comprising a drug/polymer complex
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US20080027513A1
(en)
*
|
2004-07-09 |
2008-01-31 |
Advanced Bionics Corporation |
Systems And Methods For Using A Butterfly Coil To Communicate With Or Transfer Power To An Implantable Medical Device
|
US7241807B2
(en)
*
|
2004-07-12 |
2007-07-10 |
Xenoport, Inc. |
Prodrugs of propofol, compositions and uses thereof
|
WO2006017352A1
(en)
*
|
2004-07-12 |
2006-02-16 |
Xenoport, Inc. |
Amino acid derived prodrugs of propofol, compositions and uses thereof
|
US20060128676A1
(en)
*
|
2004-07-13 |
2006-06-15 |
Pharmacofore, Inc. |
Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
|
WO2006012536A2
(en)
|
2004-07-22 |
2006-02-02 |
Ritter Andrew J |
Methods and compositions for treating lactose intolerance
|
GB0417401D0
(en)
|
2004-08-05 |
2004-09-08 |
Controlled Therapeutics Sct |
Stabilised prostaglandin composition
|
MX2007001558A
(es)
*
|
2004-08-06 |
2008-03-13 |
Transform Pharmaceuticals Inc |
Formulaciones novedosas de fenofibrato y metodos de tratamiento relacionados.
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
EP1786414A4
(en)
*
|
2004-08-06 |
2008-04-09 |
Transform Pharmaceuticals Inc |
NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
|
SG164375A1
(en)
*
|
2004-08-13 |
2010-09-29 |
Boehringer Ingelheim Int |
Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
|
EA201001083A1
(ru)
*
|
2004-08-13 |
2011-08-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
|
US8452407B2
(en)
*
|
2004-08-16 |
2013-05-28 |
Boston Scientific Neuromodulation Corporation |
Methods for treating gastrointestinal disorders
|
JP2008510000A
(ja)
*
|
2004-08-19 |
2008-04-03 |
アルザ・コーポレーシヨン |
制御放出性ナノ粒子有効薬剤配合物投与剤型品および方法
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
WO2006025882A2
(en)
|
2004-08-25 |
2006-03-09 |
The Uab Research Foundation |
Absorption enhancers for drug administration
|
US8268791B2
(en)
|
2004-08-25 |
2012-09-18 |
Aegis Therapeutics, Llc. |
Alkylglycoside compositions for drug administration
|
WO2006026555A2
(en)
*
|
2004-08-30 |
2006-03-09 |
Seo Hong Yoo |
Neuroprotective effect of solubilized udca in focal ischemic model
|
JP5132310B2
(ja)
*
|
2004-09-08 |
2013-01-30 |
スパイナル・モデュレーション・インコーポレイテッド |
神経刺激の方法及びシステム
|
US9205261B2
(en)
|
2004-09-08 |
2015-12-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neurostimulation methods and systems
|
US20120277839A1
(en)
|
2004-09-08 |
2012-11-01 |
Kramer Jeffery M |
Selective stimulation to modulate the sympathetic nervous system
|
NZ588431A
(en)
|
2004-09-17 |
2012-02-24 |
Whitehead Biomedical Inst |
Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
|
CN101083985A
(zh)
*
|
2004-09-21 |
2007-12-05 |
幸讬制药公司 |
用于炎症及免疫相关用途的化合物
|
US8541026B2
(en)
*
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
CN101039677A
(zh)
|
2004-10-15 |
2007-09-19 |
Cv医药有限公司 |
利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
|
JP2008516977A
(ja)
|
2004-10-15 |
2008-05-22 |
セオ ホン ユー |
薬剤学的化合物の毒性を減少させるための方法及び組成物
|
CA2583185A1
(en)
*
|
2004-10-20 |
2006-04-27 |
Cv Therapeutics, Inc. |
Use of a2a adenosine receptor agonists
|
US20090170790A1
(en)
*
|
2004-10-25 |
2009-07-02 |
Biswajit Das |
Ketolide derivatives as antibacterial agents
|
BRPI0518062A
(pt)
*
|
2004-10-28 |
2008-10-28 |
Celgene Corp |
uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica
|
ATE491456T1
(de)
*
|
2004-11-01 |
2011-01-15 |
Seo Hong Yoo |
Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
|
MX2007005289A
(es)
|
2004-11-02 |
2007-07-19 |
Banyu Pharma Co Ltd |
Derivados de bencimidazol ariloxi-sustituido.
|
US7494985B2
(en)
*
|
2004-11-03 |
2009-02-24 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
|
US7566738B2
(en)
*
|
2004-11-03 |
2009-07-28 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
|
CN101068538A
(zh)
*
|
2004-11-04 |
2007-11-07 |
什诺波特有限公司 |
加巴喷丁前体药物持续释放口服剂型
|
US9358393B1
(en)
|
2004-11-09 |
2016-06-07 |
Andres M. Lozano |
Stimulation methods and systems for treating an auditory dysfunction
|
WO2006053184A2
(en)
*
|
2004-11-10 |
2006-05-18 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating or preventing a vascular disease
|
EP1817295B1
(en)
|
2004-11-18 |
2012-11-07 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
EP1828174A1
(en)
*
|
2004-11-19 |
2007-09-05 |
Ranbaxy Laboratories Limited |
Azabicyclic muscarinic receptor antagonists
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
US7483746B2
(en)
*
|
2004-12-06 |
2009-01-27 |
Boston Scientific Neuromodulation Corp. |
Stimulation of the stomach in response to sensed parameters to treat obesity
|
WO2006065793A2
(en)
|
2004-12-13 |
2006-06-22 |
Indevus Pharmaceuticals, Inc. |
TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
|
US20060128738A1
(en)
*
|
2004-12-13 |
2006-06-15 |
Indevus Pharmaceuticals, Inc. |
Treatment of interstitial cystitis using cannabinoid analogs
|
ES2401285T3
(es)
|
2004-12-16 |
2013-04-18 |
The Regents Of The University Of California |
Fármacos con el pulmón como diana
|
SI2561872T1
(sl)
|
2004-12-17 |
2015-02-27 |
Anadys Pharmaceuticals, Inc. |
3,5-disubstituirane in 3,5,7-trisubstituiran-3H-oksazolo in 3H-tiazolo(4,5-d)pirimidin-2-onske spojine in njihova predzdravila
|
US9327069B2
(en)
|
2004-12-21 |
2016-05-03 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating a medical condition by promoting neural remodeling within the brain
|
US20060161217A1
(en)
*
|
2004-12-21 |
2006-07-20 |
Jaax Kristen N |
Methods and systems for treating obesity
|
US9095713B2
(en)
*
|
2004-12-21 |
2015-08-04 |
Allison M. Foster |
Methods and systems for treating autism by decreasing neural activity within the brain
|
US20070038264A1
(en)
*
|
2004-12-21 |
2007-02-15 |
Jaax Kristen N |
Methods and systems for treating autism
|
US9352145B2
(en)
*
|
2004-12-22 |
2016-05-31 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating a psychotic disorder
|
US8515541B1
(en)
|
2004-12-22 |
2013-08-20 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating post-stroke disorders
|
WO2006071995A1
(en)
*
|
2004-12-23 |
2006-07-06 |
Xenoport, Inc. |
Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
|
EP2096107A1
(en)
|
2004-12-23 |
2009-09-02 |
GPC Biotech AG |
Derivatives of squaric acid with anti-proliferative activity
|
WO2006073779A1
(en)
*
|
2004-12-30 |
2006-07-13 |
Transform Phamaceuticals, Inc. |
Novel omeprazole forms and related methods
|
MX2007008290A
(es)
*
|
2005-01-07 |
2008-02-15 |
Synta Pharmaceuticals Corp |
Compuestos para inflamacion y usos inmuno-relacionados.
|
ES2567853T3
(es)
|
2005-01-25 |
2016-04-26 |
Synta Pharmaceuticals Corporation |
Compuestos contra la inflamación y utilizaciones relacionadas con el sistema inmunitario
|
US20060165798A1
(en)
*
|
2005-01-27 |
2006-07-27 |
Edgren David E |
Oral osmotic dosage form having a high flux membrane
|
EP3228308A1
(en)
*
|
2005-01-28 |
2017-10-11 |
Euro-Celtique S.A. |
Alcohol resistant dosage forms
|
EP1690540A1
(en)
*
|
2005-02-15 |
2006-08-16 |
Neuro3D |
Composition comprising ocaperidone
|
JP2006224318A
(ja)
*
|
2005-02-15 |
2006-08-31 |
Brother Ind Ltd |
インクジェット記録装置
|
US20060185665A1
(en)
*
|
2005-02-22 |
2006-08-24 |
Bachinski Thomas J |
Sauna fireplace
|
US20060194724A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Whitehurst Todd K |
Methods and systems for nerve regeneration
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
US7312217B2
(en)
|
2005-03-11 |
2007-12-25 |
Syntrix Biosystems, Inc. |
Aminopterin dosage forms and methods for inflammatory disorders
|
US7920915B2
(en)
*
|
2005-11-16 |
2011-04-05 |
Boston Scientific Neuromodulation Corporation |
Implantable stimulator
|
US7848803B1
(en)
|
2005-03-14 |
2010-12-07 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for facilitating stimulation of one or more stimulation sites
|
US8423155B1
(en)
|
2005-03-14 |
2013-04-16 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for facilitating stimulation of one or more stimulation sites
|
US7853321B2
(en)
|
2005-03-14 |
2010-12-14 |
Boston Scientific Neuromodulation Corporation |
Stimulation of a stimulation site within the neck or head
|
US20060206165A1
(en)
*
|
2005-03-14 |
2006-09-14 |
Jaax Kristen N |
Occipital nerve stimulation to treat headaches and other conditions
|
US8288438B2
(en)
|
2005-03-21 |
2012-10-16 |
Metabolex, Inc. |
Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
EP1866319B1
(en)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
EP1868587A2
(en)
|
2005-04-08 |
2007-12-26 |
Abbott Laboratories |
Pharmaceutical formulations comprising fenofibric acid and/or its salts
|
US20080152714A1
(en)
*
|
2005-04-08 |
2008-06-26 |
Yi Gao |
Pharmaceutical Formulations
|
AR053710A1
(es)
*
|
2005-04-11 |
2007-05-16 |
Xenon Pharmaceuticals Inc |
Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
|
MY158766A
(en)
*
|
2005-04-11 |
2016-11-15 |
Xenon Pharmaceuticals Inc |
Spiro-oxindole compounds and their uses as therapeutic agents
|
US20060229261A1
(en)
*
|
2005-04-12 |
2006-10-12 |
John Devane |
Acarbose methods and formulations for treating chronic constipation
|
WO2006109156A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Ranbaxy Laboratories Limited |
Oxazolidinone derivatives as antimicrobials
|
US20060233882A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Sowden Harry S |
Osmotic dosage form
|
JP2008536928A
(ja)
*
|
2005-04-19 |
2008-09-11 |
アルザ・コーポレーシヨン |
トラマドール及び、ガバペンチンを含んでなる物質、の組み合わせ物
|
AR053713A1
(es)
*
|
2005-04-20 |
2007-05-16 |
Xenon Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos como agentes terapeuticos
|
AU2006242154B2
(en)
|
2005-05-02 |
2011-11-03 |
Cold Spring Harbor Laboratory |
Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
|
WO2006119510A2
(en)
*
|
2005-05-04 |
2006-11-09 |
Receptor Biologix, Inc. |
Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
|
US20070041944A1
(en)
*
|
2005-05-05 |
2007-02-22 |
The Trustees Of Columbia University In The City Of New York |
Treating tumors by ENH dislocation of ID proteins
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
RU2415858C2
(ru)
*
|
2005-06-16 |
2011-04-10 |
Си Ви Терапьютикс, Инк. |
Пролекарства антагонистов a2b рецептора аденозина
|
EP1919859B1
(en)
*
|
2005-06-20 |
2010-06-02 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of tranexamic acid and use
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
US20070054868A1
(en)
*
|
2005-06-20 |
2007-03-08 |
The Trustees Of Columbia University In The City Of New York |
Synergistic polyphenol compounds, compositions thereof, and uses thereof
|
WO2007002597A2
(en)
|
2005-06-27 |
2007-01-04 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
WO2007002867A1
(en)
|
2005-06-28 |
2007-01-04 |
Cv Therapeutics, Inc. |
Abca1 elevating compounds
|
JP2009500339A
(ja)
*
|
2005-06-29 |
2009-01-08 |
アルザ・コーポレーシヨン |
浸透性剤形のための低下された乾燥時間を提供する半透過性組成物
|
US8348930B2
(en)
*
|
2005-07-01 |
2013-01-08 |
Microlin, Llc |
Fluid delivery device with a diffusion membrane and electrochemical pump
|
EP1904046A4
(en)
*
|
2005-07-06 |
2008-10-01 |
Sepracor Inc |
COMBINATIONS OF ESZOPICLON AND O-DESMETHYLVENLAFAXINE AND METHOD FOR THE TREATMENT OF MENOPAUSE AND HUMOR FLUCTUATIONS; ANXIETY AND COGNITIVE INTERFERENCE
|
US20070009573A1
(en)
*
|
2005-07-07 |
2007-01-11 |
L N K International |
Method of forming immediate release dosage form
|
TWI279234B
(en)
*
|
2005-07-12 |
2007-04-21 |
Anchen Pharmaceuticals Taiwan |
Method for controlling lag time of in-situ passageway formation in osmotic delivery system
|
US20070021734A1
(en)
*
|
2005-07-15 |
2007-01-25 |
Sai Bhavaraju |
Bioelectro-osmotic engine fluid delivery device
|
US20070025869A1
(en)
*
|
2005-07-15 |
2007-02-01 |
Gordon John H |
Fluid Delivery Device
|
US20070023291A1
(en)
*
|
2005-07-15 |
2007-02-01 |
Sai Bhavaraju |
Metal Trap
|
WO2007013929A1
(en)
|
2005-07-22 |
2007-02-01 |
Amgen Inc. |
Aniline sulfonamide derivatives and their uses
|
US20070031496A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Edgren David E |
Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
|
US20070135380A1
(en)
|
2005-08-12 |
2007-06-14 |
Radiorx, Inc. |
O-nitro compounds, pharmaceutical compositions thereof and uses thereof
|
US7507842B2
(en)
|
2005-08-12 |
2009-03-24 |
Radiorx, Inc. |
Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
|
US20070049626A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Tran Pierre V |
Treating premature ejaculation using gabapentin and pregabalin prodrugs
|
EP1959923A4
(en)
*
|
2005-08-30 |
2012-05-02 |
Piramal Life Sciences Ltd |
PHARMACEUTICAL METFORMIN COMPOSITION WITH EXTENDED RELEASE AND METHOD OF PREPARATION THEREOF
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
KR20080042158A
(ko)
|
2005-08-31 |
2008-05-14 |
셀진 코포레이션 |
이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
|
BRPI0615691A8
(pt)
|
2005-08-31 |
2017-08-15 |
Aryx Therapeutics Inc |
Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
WO2008051197A2
(en)
*
|
2005-09-20 |
2008-05-02 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
US7684858B2
(en)
*
|
2005-09-21 |
2010-03-23 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for placing an implanted stimulator for stimulating tissue
|
US20070072838A1
(en)
*
|
2005-09-26 |
2007-03-29 |
Pharmacyclics, Inc. |
High-purity texaphyrin metal complexes
|
US20070078119A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Pharmacyclics, Inc. |
Storage system for texaphyrin pharmaceutical formulations
|
US7799820B2
(en)
*
|
2005-09-30 |
2010-09-21 |
Banyu Pharmaceutical Co., Ltd. |
2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
|
US20070190137A1
(en)
*
|
2005-10-07 |
2007-08-16 |
Reyes Iran |
Osmotic dosage form with controlled release and fast release aspects
|
JP2009511593A
(ja)
*
|
2005-10-13 |
2009-03-19 |
シーブイ・セラピューティクス・インコーポレイテッド |
A1アデノシンレセプターアゴニスト
|
US20070092585A1
(en)
*
|
2005-10-14 |
2007-04-26 |
Skinner Michael K |
Cancer chemotherapy compositions comprising PI3K pathways modulators and triptolide
|
PL116330U1
(en)
*
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
US8629147B2
(en)
|
2005-11-03 |
2014-01-14 |
Chembridge Corporation |
Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
WO2007132293A2
(en)
|
2005-11-10 |
2007-11-22 |
Circ Pharma Research And Development Limited |
Once-daily administration of central nervous system drugs
|
CA2628928A1
(en)
*
|
2005-11-10 |
2007-05-24 |
Receptor Biologix, Inc. |
Hepatocyte growth factor intron fusion proteins
|
WO2007059010A2
(en)
|
2005-11-14 |
2007-05-24 |
Enterprise Partners Venture Capital |
Stem cell factor therapy for tissue injury
|
CN101312964A
(zh)
|
2005-11-21 |
2008-11-26 |
普渡制药公司 |
4-噁二唑基哌啶化合物及其用途
|
US7729758B2
(en)
|
2005-11-30 |
2010-06-01 |
Boston Scientific Neuromodulation Corporation |
Magnetically coupled microstimulators
|
WO2007067495A2
(en)
*
|
2005-12-05 |
2007-06-14 |
Xenoport, Inc. |
Levodopa prodrug mesylate, compositions thereof, and uses thereof
|
US7982066B2
(en)
|
2005-12-09 |
2011-07-19 |
Novalife, Inc. |
High protein supplement
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
US20090176882A1
(en)
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
EP3363455A1
(en)
|
2005-12-30 |
2018-08-22 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for improved cardiac function
|
US7610100B2
(en)
*
|
2005-12-30 |
2009-10-27 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating osteoarthritis
|
US7835803B1
(en)
|
2006-01-17 |
2010-11-16 |
Boston Scientific Neuromodulation Corporation |
Lead assemblies with one or more switching networks
|
WO2007087442A2
(en)
|
2006-01-25 |
2007-08-02 |
Synta Pharmaceuticals Corp. |
Substituted biaryl compounds for inflammation and immune-related uses
|
TW200806292A
(en)
|
2006-01-25 |
2008-02-01 |
Synta Pharmaceuticals Corp |
Vinyl-phenyl derivatives for inflammation and immune-related uses
|
US8455658B2
(en)
*
|
2006-01-25 |
2013-06-04 |
Synta Pharmaceuticals Corp. |
Thiazole and thiadiazole compounds for inflammation and immune-related uses
|
EP1813276A1
(en)
*
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Tamper resistant dosage forms
|
US20070254926A1
(en)
*
|
2006-01-31 |
2007-11-01 |
Jun Jiang |
Pyridylphenyl compounds for inflammation and immune-related uses
|
KR20080090491A
(ko)
|
2006-02-03 |
2008-10-08 |
씨브이 쎄러퓨틱스, 인코포레이티드 |
A2a-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
|
EP1986639A4
(en)
*
|
2006-02-03 |
2010-04-28 |
Avanir Pharmaceuticals |
PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
|
US20090041844A1
(en)
*
|
2006-02-10 |
2009-02-12 |
Boehringer Ingelheim International Gmbh |
Modified Release Formulation
|
WO2007090883A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Boehringer Ingelheim International Gmbh |
Extended release formulation
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
US20070196487A1
(en)
*
|
2006-02-16 |
2007-08-23 |
Geerke Johan H |
Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
|
US7518017B2
(en)
|
2006-02-17 |
2009-04-14 |
Idexx Laboratories |
Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
|
US20070201024A1
(en)
*
|
2006-02-28 |
2007-08-30 |
Geerke Johan H |
Method and apparatus for semi-permeable membrane detection on osmotic tablets incorating near-infrared spectroscopy
|
AU2007225273A1
(en)
|
2006-03-10 |
2007-09-20 |
Neurogen Corporation |
Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
|
JP2009530280A
(ja)
*
|
2006-03-13 |
2009-08-27 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
シタクスセンタンナトリウムの配合物
|
JP2009530284A
(ja)
*
|
2006-03-13 |
2009-08-27 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
拡張期心不全を治療するための方法と組成物
|
PL2383271T3
(pl)
*
|
2006-03-13 |
2013-12-31 |
Kyorin Seiyaku Kk |
Aminochinolony jako inhibitory GSK-3
|
US8175710B2
(en)
*
|
2006-03-14 |
2012-05-08 |
Boston Scientific Neuromodulation Corporation |
Stimulator system with electrode array and the method of making the same
|
US20070219174A1
(en)
*
|
2006-03-15 |
2007-09-20 |
Pharmacyclics, Inc. |
Methods of treating cancer using hypofractionated radiation and texaphyrins
|
US20100273776A1
(en)
*
|
2006-03-29 |
2010-10-28 |
FOLDRx PHARMACEUTICALS, INC |
Inhibition of alpha-synuclein toxicity
|
US20190083399A9
(en)
*
|
2006-04-03 |
2019-03-21 |
Isa Odidi |
Drug delivery composition
|
EP2007360B1
(en)
|
2006-04-03 |
2014-11-26 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
JP2009535552A
(ja)
*
|
2006-04-28 |
2009-10-01 |
コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ |
少なくとも1つの帯電可能な材料を有する浸透圧ポンプ
|
US9011930B2
(en)
*
|
2006-05-01 |
2015-04-21 |
Zycal Bioceuticals Healthcare Company, Inc. |
Nutritional supplement and use thereof
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
CA2651732C
(en)
|
2006-05-18 |
2014-10-14 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
US8058260B2
(en)
*
|
2006-05-22 |
2011-11-15 |
Xenoport, Inc. |
2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
|
DK2046393T3
(da)
|
2006-05-26 |
2014-05-12 |
Signature Therapeutics Inc |
Kontrolleret frigivelse af phenol-opioider
|
TW200808695A
(en)
*
|
2006-06-08 |
2008-02-16 |
Amgen Inc |
Benzamide derivatives and uses related thereto
|
US7659287B2
(en)
*
|
2006-06-08 |
2010-02-09 |
Amgen Inc. |
Benzamide derivatives and uses related thereto
|
NZ574093A
(en)
*
|
2006-06-12 |
2011-03-31 |
Symphogen As |
Pan-cell surface receptor- specific therapeutics
|
CA2655835C
(en)
|
2006-06-19 |
2015-07-21 |
Alpharma, Inc. |
Abuse-resistant pharmaceutical compositions of opioid agonists
|
ATE496924T1
(de)
|
2006-06-22 |
2011-02-15 |
Anadys Pharmaceuticals Inc |
Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
|
JP5306194B2
(ja)
|
2006-06-22 |
2013-10-02 |
アナディス ファーマシューティカルズ インク |
ピロ[1,2−b]ピリダジノン化合物
|
EP2068850A1
(en)
*
|
2006-06-22 |
2009-06-17 |
Cv Therapeutics, Inc. |
Use of a2a adenosine receptor agonists in the treatment of ischemia
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
WO2007149929A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Aryx Therapeutics, Inc. |
Piperidine derivatives for the treatment of gastrointestinal and cns disorders
|
US8401654B1
(en)
|
2006-06-30 |
2013-03-19 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating one or more effects of deafferentation
|
US8504163B1
(en)
|
2006-06-30 |
2013-08-06 |
Boston Scientific Neuromodulation Corporation |
Cranially mounted stimulation systems and methods
|
GB0613333D0
(en)
|
2006-07-05 |
2006-08-16 |
Controlled Therapeutics Sct |
Hydrophilic polyurethane compositions
|
SG175602A1
(en)
|
2006-07-05 |
2011-11-28 |
Catalyst Biosciences Inc |
Protease screening methods and proteases identified thereby
|
GB0613638D0
(en)
|
2006-07-08 |
2006-08-16 |
Controlled Therapeutics Sct |
Polyurethane elastomers
|
EP2043603A4
(en)
|
2006-07-11 |
2010-10-27 |
Arubor Corp |
PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
|
WO2008011406A2
(en)
|
2006-07-18 |
2008-01-24 |
Anadys Pharmaceuticals, Inc. |
Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
|
CA2671197A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophobic abuse deterrent delivery system
|
CA2653056A1
(en)
|
2006-07-27 |
2008-01-31 |
Cv Therapeutics, Inc. |
Aldh-2 inhibitors in the treatment of addiction
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
AU2007293107A1
(en)
*
|
2006-08-04 |
2008-03-13 |
Agi Therapeutics Research Limited |
Methods for treating at least one condition having MT1 receptor, 5HT2GB receptor, and L-type calcium channel activity
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
US9114133B2
(en)
|
2006-08-25 |
2015-08-25 |
U.S. Dept. Of Veterans Affairs |
Method of improving diastolic dysfunction
|
MX2009001989A
(es)
|
2006-08-30 |
2009-03-09 |
Celgene Corp |
Compuestos de isoindolina 5-substituidos.
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
JP2010502649A
(ja)
*
|
2006-09-01 |
2010-01-28 |
シーブイ・セラピューティクス・インコーポレイテッド |
心筋層画像化法中の患者の耐性を増加させるための方法および組成物
|
US20090081120A1
(en)
*
|
2006-09-01 |
2009-03-26 |
Cv Therapeutics, Inc. |
Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
|
US8604244B2
(en)
|
2010-07-02 |
2013-12-10 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
|
BRPI0716952A2
(pt)
*
|
2006-09-15 |
2013-10-29 |
Reviva Pharmaceuticals Inc |
Composto, métodos para tratar e/ou prevenir obesidade ou indicação co-mórbida relacionada à obesidade, e para sintetizar derivado de cicloalquilmetilamina
|
WO2008033572A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
|
EP2066662B1
(en)
|
2006-09-21 |
2012-12-05 |
Kyorin Pharmaceutical Co., Ltd. |
Serine hydrolase inhibitors
|
US8779154B2
(en)
|
2006-09-26 |
2014-07-15 |
Qinglin Che |
Fused ring compounds for inflammation and immune-related uses
|
PL2420498T3
(pl)
|
2006-09-26 |
2017-10-31 |
Celgene Corp |
5-podstawione pochodne chinazolinonu jako środki przeciwnowotworowe
|
CA2663361A1
(en)
*
|
2006-09-29 |
2008-04-10 |
Cv Therapeutics, Inc. |
Methods for myocardial imaging in patients having a history of pulmonary disease
|
US7445528B1
(en)
|
2006-09-29 |
2008-11-04 |
Boston Scientific Neuromodulation Corporation |
Connector assemblies
|
MX2009003658A
(es)
*
|
2006-10-05 |
2009-04-22 |
Cv Therapeutics Inc |
Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
|
US7893066B2
(en)
*
|
2006-10-05 |
2011-02-22 |
Gilead Palo Alto, Inc. |
Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
|
AR063028A1
(es)
|
2006-10-06 |
2008-12-23 |
Banyu Pharma Co Ltd |
Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
|
EP2124556B1
(en)
|
2006-10-09 |
2014-09-03 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
CA2666143A1
(en)
*
|
2006-10-12 |
2008-04-17 |
Xenon Pharmaceuticals Inc. |
Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
|
WO2008060789A2
(en)
*
|
2006-10-12 |
2008-05-22 |
Xenon Pharmaceuticals Inc. |
Use of spiro-oxindole compounds as therapeutic agents
|
EP2076518A1
(en)
*
|
2006-10-12 |
2009-07-08 |
Xenon Pharmaceuticals Inc. |
Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
GB0620685D0
(en)
|
2006-10-18 |
2006-11-29 |
Controlled Therapeutics Sct |
Bioresorbable polymers
|
JP5550906B2
(ja)
|
2006-10-19 |
2014-07-16 |
ゲンズイメ コーポレーション |
嚢胞性疾患の治療のためのプリン誘導体
|
AU2007310949A1
(en)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
US7347746B1
(en)
|
2006-10-27 |
2008-03-25 |
Boston Scientific Neuromodulation Corporation |
Receptacle connector assembly
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
WO2008063504A2
(en)
|
2006-11-13 |
2008-05-29 |
Synta Pharmaceuticals Corp. |
Cyclohexenyl-aryl compounds for inflammation and immune-related uses
|
EP2096923B1
(en)
|
2006-11-27 |
2014-01-22 |
H. Lundbeck A/S |
Heteroaryl amide derivatives
|
WO2008066131A1
(fr)
|
2006-12-01 |
2008-06-05 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau dérivé de phényl-isoxazol-3-ol
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
EP2121705A2
(en)
|
2006-12-01 |
2009-11-25 |
Cv Therapeutics, Inc. |
A2a adenosine receptor antagonists
|
CA2671286C
(en)
|
2006-12-06 |
2017-09-19 |
Spinal Modulation, Inc. |
Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
|
WO2008070809A2
(en)
|
2006-12-06 |
2008-06-12 |
Spinal Modulation, Inc. |
Implantable flexible circuit leads and methods of use
|
US9427570B2
(en)
*
|
2006-12-06 |
2016-08-30 |
St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) |
Expandable stimulation leads and methods of use
|
AU2007329252A1
(en)
|
2006-12-06 |
2008-06-12 |
Spinal Modulation, Inc. |
Hard tissue anchors and delivery devices
|
MX2009006080A
(es)
*
|
2006-12-08 |
2009-07-14 |
Xenoport Inc |
Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
|
WO2008073452A1
(en)
*
|
2006-12-11 |
2008-06-19 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
|
JP2010512414A
(ja)
|
2006-12-12 |
2010-04-22 |
ギリード・コロラド・インコーポレーテッド |
肺高血圧を処置するための組成物
|
GB0624880D0
(en)
*
|
2006-12-14 |
2007-01-24 |
Johnson Matthey Plc |
Improved method for making analgesics
|
US20080147186A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Joshi Ashok V |
Electrochemical Implant For Delivering Beneficial Agents
|
US7829592B2
(en)
*
|
2006-12-21 |
2010-11-09 |
Xenoport, Inc. |
Catechol protected levodopa diester prodrugs, compositions, and methods of use
|
WO2008076458A1
(en)
*
|
2006-12-21 |
2008-06-26 |
Xenoport, Inc. |
Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
|
KR20090086115A
(ko)
*
|
2006-12-22 |
2009-08-10 |
엔싸이시브 파마슈티칼즈 인코퍼레이티드 |
C3a 수용체의 조정제 및 이의 사용 방법
|
US7932421B2
(en)
*
|
2006-12-26 |
2011-04-26 |
Amgen Inc. |
N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
|
EP2119442A4
(en)
|
2006-12-28 |
2010-12-15 |
Astellas Pharma Inc |
PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
EP2099360A2
(en)
*
|
2007-01-03 |
2009-09-16 |
CV Therapeutics Inc. |
Myocardial perfusion imaging
|
PT2076506E
(pt)
|
2007-01-16 |
2010-12-10 |
Purdue Pharma Lp |
Compostos de piperidina substituídos nos grupos heterocíclicos como ligandos orl-1
|
US20080176955A1
(en)
*
|
2007-01-16 |
2008-07-24 |
Victory Pharma, Inc. |
Combined administration of benzonatate and guaifenesin
|
CN101678203A
(zh)
*
|
2007-01-29 |
2010-03-24 |
脊髓调制公司 |
无缝合线引线保持构造
|
US7999107B2
(en)
|
2007-01-31 |
2011-08-16 |
Merck Sharp & Dohme Corp. |
Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
|
KR20200123866A
(ko)
|
2007-02-09 |
2020-10-30 |
메타베이시스 테라퓨틱스, 인크. |
글루카곤 수용체의 길항제
|
US8524749B2
(en)
*
|
2007-02-09 |
2013-09-03 |
Alza Corporation |
Controlled release compositions of tizanidine
|
TWI446903B
(zh)
|
2007-02-21 |
2014-08-01 |
Sepracor Inc |
含(-)-o-去甲基泛拉弗辛(venlafaxine)之固體形式及其用途
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
CL2008000666A1
(es)
*
|
2007-03-07 |
2008-06-13 |
Xenon Pharmaceuticals Inc |
Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
|
WO2008112495A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Wyeth |
Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
|
TW200909417A
(en)
*
|
2007-03-12 |
2009-03-01 |
Biolipox Ab |
Piperidinones useful in the treatment of inflammation
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
TW200846305A
(en)
|
2007-03-15 |
2008-12-01 |
Auspex Pharmaceuticals Inc |
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
CA2683409A1
(en)
|
2007-04-04 |
2008-10-16 |
Sigmoid Pharma Limited |
A pharmaceutical composition of tacrolimus
|
CA2681560A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Cv Therapeutics, Inc. |
Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
|
US20090105283A1
(en)
*
|
2007-04-11 |
2009-04-23 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
US20080255161A1
(en)
*
|
2007-04-11 |
2008-10-16 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
ES2963291T3
(es)
|
2007-04-26 |
2024-03-26 |
Sublimity Therapeutics Ltd |
Fabricación de múltiples minicápsulas
|
EP2142529B1
(en)
|
2007-04-27 |
2013-12-25 |
Purdue Pharma LP |
Trpv1 antagonists and uses thereof
|
NZ579820A
(en)
|
2007-04-27 |
2011-01-28 |
Purdue Pharma Lp |
Therapeutic agents useful for treating pain
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
EP2162135A4
(en)
*
|
2007-05-21 |
2012-02-22 |
Reviva Pharmaceuticals Inc |
COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
|
EP2019101A1
(en)
*
|
2007-07-26 |
2009-01-28 |
GPC Biotech AG |
Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
|
NZ580429A
(en)
|
2007-05-31 |
2012-04-27 |
Sepracor Inc |
Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
|
CN101820757A
(zh)
|
2007-06-01 |
2010-09-01 |
普林斯顿大学托管委员会 |
通过调节宿主细胞代谢途径治疗病毒感染
|
US20100240713A1
(en)
*
|
2007-06-05 |
2010-09-23 |
Xenon Pharmaceuticals Inc. |
Aromatic and heteroaromatic compounds useful in treating iron disorders
|
WO2009011988A2
(en)
*
|
2007-06-05 |
2009-01-22 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
|
US8633186B2
(en)
|
2007-06-08 |
2014-01-21 |
Senomyx Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
US20080306076A1
(en)
*
|
2007-06-08 |
2008-12-11 |
Senomyx, Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
ES2601856T3
(es)
|
2007-06-08 |
2017-02-16 |
Mannkind Corporation |
Inhibidores de la IRE-1A
|
US9603848B2
(en)
*
|
2007-06-08 |
2017-03-28 |
Senomyx, Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
US7928111B2
(en)
*
|
2007-06-08 |
2011-04-19 |
Senomyx, Inc. |
Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
|
US20090012103A1
(en)
*
|
2007-07-05 |
2009-01-08 |
Matthew Abelman |
Substituted heterocyclic compounds
|
US20090042987A1
(en)
*
|
2007-07-06 |
2009-02-12 |
Michael Lionel Selley |
Treatment of neuropathic pain
|
CN101801188A
(zh)
*
|
2007-07-12 |
2010-08-11 |
特拉加拉医药品公司 |
治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
|
WO2009012263A2
(en)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
CN101754962B
(zh)
*
|
2007-07-19 |
2013-12-25 |
赛马拜制药公司 |
作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
|
TWI444186B
(zh)
|
2007-08-01 |
2014-07-11 |
Synta Pharmaceuticals Corp |
用於發炎與免疫相關用途之雜環-芳基化合物
|
US8349841B2
(en)
|
2007-08-01 |
2013-01-08 |
Synta Pharmaceuticals Corp. |
Vinyl-aryl derivatives for inflammation and immune-related uses
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
LT2194783T
(lt)
|
2007-08-10 |
2017-10-25 |
Vm Discovery, Inc. |
Apoptozės moduliatorių kompozicijos ir būdai
|
WO2009023718A2
(en)
|
2007-08-13 |
2009-02-19 |
Metabasis Therapeutics, Inc. |
Novel activators of glucokinase
|
US20090062242A1
(en)
*
|
2007-08-28 |
2009-03-05 |
Agi Therapeutics Plc |
Methods and compositions for treating gastrointestinal conditions
|
ES2593706T3
(es)
|
2007-08-31 |
2016-12-12 |
Purdue Pharma Lp |
Compuestos de piperidina, de tipo quinoxalina sustituida, y usos de los mismos
|
US20090082315A1
(en)
*
|
2007-09-05 |
2009-03-26 |
Raif Tawakol |
Compositions and Methods for Controlling Cholesterol Levels
|
MX2010002667A
(es)
*
|
2007-09-11 |
2010-04-01 |
Activx Biosciences Inc |
Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
|
BRPI0816814B1
(pt)
|
2007-09-12 |
2021-08-31 |
Kyorin Pharmaceutical Co. Ltd |
Composto, composição farmacêutica e uso de um composto
|
CZ300468B6
(cs)
*
|
2007-09-20 |
2009-05-27 |
Zentiva, A. S |
Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy
|
CN101952272B
(zh)
|
2007-09-26 |
2014-08-27 |
细胞基因公司 |
6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
|
US20090087484A1
(en)
*
|
2007-09-28 |
2009-04-02 |
Alza Corporation |
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
|
AR068540A1
(es)
*
|
2007-09-28 |
2009-11-18 |
Merck & Co Inc |
Metodos de produccion de un derivado de pirazol-3-il-benzamida.
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
KR20100082775A
(ko)
*
|
2007-10-16 |
2010-07-19 |
심포젠 에이/에스 |
최적화된 her1 및 her3 멀티머를 포함하는 조성물 및 그것의 사용 방법
|
WO2009052454A2
(en)
|
2007-10-19 |
2009-04-23 |
University Of California |
Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
|
CA2705370C
(en)
|
2007-11-12 |
2015-10-13 |
Banyu Pharmaceutical Co., Ltd. |
Heteroaryloxy quinazoline derivatives
|
DK2596784T3
(en)
|
2007-11-23 |
2017-03-06 |
Gruenenthal Gmbh |
Tapentadol compositions
|
CA2706931C
(en)
|
2007-12-06 |
2015-05-12 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20090162417A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Cook Incorporated |
Drug eluting ocular conformer
|
US20100261699A1
(en)
|
2007-12-25 |
2010-10-14 |
Banyu Pharmaceutical Co., Ltd. |
N-pyrazole-2-pyridine carboxamide derivative
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
EP2240022B1
(en)
|
2008-01-09 |
2016-12-28 |
Charleston Laboratories, Inc. |
Bilayered tablets comprising oxycodone and promethazine
|
US9226907B2
(en)
|
2008-02-01 |
2016-01-05 |
Abbvie Inc. |
Extended release hydrocodone acetaminophen and related methods and uses thereof
|
WO2009100326A1
(en)
*
|
2008-02-07 |
2009-08-13 |
Cv Therapeutics, Inc. |
Abca-1 elevating compounds and the use thereof
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
US20090214665A1
(en)
*
|
2008-02-26 |
2009-08-27 |
Lai Felix S |
Controlled Release Muscarinic Receptor Antagonist Formulation
|
WO2009111611A2
(en)
*
|
2008-03-05 |
2009-09-11 |
Proteotech Inc. |
Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
US8618289B2
(en)
|
2008-03-17 |
2013-12-31 |
Ambit Biosciences Corporation |
RAF kinase modulator compounds and methods of use thereof
|
MX2010010272A
(es)
|
2008-03-19 |
2011-05-25 |
Chembridge Corp |
Nuevos inhibidores de tirosina quinasa.
|
US8822500B2
(en)
|
2008-03-19 |
2014-09-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
US9249147B2
(en)
|
2008-03-19 |
2016-02-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
EP2687213B1
(en)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
KR20150038547A
(ko)
|
2008-03-27 |
2015-04-08 |
셀진 코포레이션 |
(+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온을 포함하는 고체 형태, 이의 조성물, 및 이의 용도
|
US20090270404A1
(en)
*
|
2008-03-31 |
2009-10-29 |
Metabolex, Inc. |
Oxymethylene aryl compounds and uses thereof
|
SG189714A1
(en)
|
2008-04-01 |
2013-05-31 |
Antipodean Pharmaceuticals Inc |
Compositions and methods for skin care
|
CA2719288A1
(en)
*
|
2008-04-04 |
2009-11-12 |
Gilead Sciences, Inc. |
Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
|
CN103381267A
(zh)
|
2008-04-14 |
2013-11-06 |
哈洛齐梅公司 |
修饰的透明质酸酶及其在治疗透明质酸相关疾病和病症中的应用
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
BRPI0912842A8
(pt)
*
|
2008-05-20 |
2019-01-29 |
Cerenis Therapeutics Holding |
composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
|
US8207163B2
(en)
*
|
2008-05-27 |
2012-06-26 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using piperazine based antipsychotic agents
|
EP2298750A4
(en)
|
2008-06-02 |
2012-04-25 |
Msd Kk |
NOVEL ISOXAZOLE DERIVATIVE
|
US8894602B2
(en)
|
2010-09-17 |
2014-11-25 |
Johnson & Johnson Vision Care, Inc. |
Punctal plugs with directional release
|
PL2318035T3
(pl)
|
2008-07-01 |
2019-10-31 |
Curemark Llc |
Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
|
ES2458358T3
(es)
|
2008-07-02 |
2014-05-05 |
Idenix Pharmaceuticals, Inc. |
Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
|
AR072578A1
(es)
|
2008-07-21 |
2010-09-08 |
Purdue Pharma Lp |
Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos
|
NZ588311A
(en)
*
|
2008-07-24 |
2012-08-31 |
Handa Pharmaceuticals Llc |
Stabilized atypical antipsychotic formulation to treat psychiatric conditions
|
WO2010014229A1
(en)
|
2008-07-30 |
2010-02-04 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
RU2511315C2
(ru)
|
2008-07-31 |
2014-04-10 |
Синомикс, Инк. |
Композиции, содержащие усилители сладкого вкуса, и способы их получения
|
WO2010014666A2
(en)
|
2008-07-31 |
2010-02-04 |
Senomyx, Inc. |
Processes and intermediates for making sweet taste enhancers
|
EP2326618B1
(en)
|
2008-08-13 |
2014-10-15 |
Metabasis Therapeutics, Inc. |
Glucagon antagonists
|
EP2348863A4
(en)
|
2008-09-04 |
2012-03-07 |
Anacor Pharmaceuticals Inc |
BORN SMALL MOLECULES
|
US20100190752A1
(en)
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
AU2009296235A1
(en)
*
|
2008-09-29 |
2010-04-01 |
Gilead Sciences, Inc. |
Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
|
CA2739322A1
(en)
*
|
2008-10-01 |
2010-04-08 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
EP3025727A1
(en)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Methods of treating liver disease
|
AU2009302241B2
(en)
|
2008-10-08 |
2015-10-29 |
Xgene Pharmaceutical Inc. |
GABA conjugates and methods of use thereof
|
WO2010042834A1
(en)
|
2008-10-09 |
2010-04-15 |
Anadys Pharmaceuticals, Inc. |
A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
|
EP3135672B9
(en)
|
2008-10-10 |
2020-05-20 |
VM Discovery, Inc. |
Compositions and methods for treating alcohol use disorders, pain and other diseases
|
US20100267752A1
(en)
*
|
2008-10-15 |
2010-10-21 |
Gilead Palo Alto, Inc. |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
EP2350091B1
(en)
|
2008-10-17 |
2015-06-03 |
Xenon Pharmaceuticals Inc. |
Spiro-oxindole compounds and their use as therapeutic agents
|
US8263606B2
(en)
|
2008-10-17 |
2012-09-11 |
Xenon Pharmaceuticals Inc. |
Spiro-oxindole compounds and their use as therapeutic agents
|
US8399513B2
(en)
*
|
2008-10-20 |
2013-03-19 |
Xenoport, Inc. |
Levodopa prodrug mesylate hydrate
|
CN102186804A
(zh)
*
|
2008-10-20 |
2011-09-14 |
克塞诺波特公司 |
合成左旋多巴酯前药的方法
|
JP2012506386A
(ja)
*
|
2008-10-21 |
2012-03-15 |
メタボレックス, インコーポレイテッド |
アリールgpr120受容体アゴニストおよびその使用
|
AU2009307884B2
(en)
|
2008-10-22 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US8703962B2
(en)
*
|
2008-10-24 |
2014-04-22 |
Purdue Pharma L.P. |
Monocyclic compounds and their use as TRPV1 ligands
|
US8546388B2
(en)
*
|
2008-10-24 |
2013-10-01 |
Purdue Pharma L.P. |
Heterocyclic TRPV1 receptor ligands
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
WO2010062622A2
(en)
|
2008-10-27 |
2010-06-03 |
Spinal Modulation, Inc. |
Selective stimulation systems and signal parameters for medical conditions
|
SI2358697T1
(sl)
|
2008-10-29 |
2016-02-29 |
Celgene Corporation |
Spojine izoindolina za uporabo pri zdravljenju raka
|
WO2010074807A1
(en)
|
2008-10-30 |
2010-07-01 |
Gilead Palo Alto, Inc. |
3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
|
CN104257600A
(zh)
|
2008-10-30 |
2015-01-07 |
格吕伦塔尔有限公司 |
新型有效的他喷他多剂型
|
WO2010056527A2
(en)
|
2008-10-30 |
2010-05-20 |
Gilead Palo Alto, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
BRPI0921625A2
(pt)
|
2008-11-04 |
2016-01-05 |
Univ Kentucky Res Foundation Inc |
composicoes baseadas em d-tagatose e metodos para previnir e tratar aterosclerose, sindrome metabolica, e sintomas dos mesmos
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
BRPI0922224A2
(pt)
|
2008-12-08 |
2016-08-02 |
Vm Pharma Llc |
composições de inibidores de proteína tirosina quiinase receptora.
|
ES2724588T3
(es)
|
2008-12-09 |
2019-09-12 |
Halozyme Inc |
Polipéptidos de PH20 soluble extendida y usos de los mismos
|
AU2009330355B2
(en)
|
2008-12-16 |
2016-06-30 |
Sunovion Pharmaceuticals Inc. |
Triple reuptake inhibitors and methods of their use
|
EP2376633A1
(en)
|
2008-12-17 |
2011-10-19 |
AVI BioPharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
AR074760A1
(es)
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
AU2009330192A1
(en)
|
2008-12-22 |
2011-07-14 |
Sloan-Kettering Institute For Cancer Research |
Methods for treating or preventing cancer and neurodegenerative diseases
|
US20110306605A1
(en)
|
2008-12-22 |
2011-12-15 |
Sloan-Kettering Institute For Cancer Research |
Coumarin-based compounds for the treatment of alzheimer's disease and cancer
|
US20110269788A1
(en)
|
2008-12-29 |
2011-11-03 |
Xenon Pharmaceuticals Inc. |
Spiro-oxindole-derivatives as sodium channel blockers
|
US8536114B2
(en)
|
2008-12-31 |
2013-09-17 |
Scynexis, Inc. |
Macrocycles
|
WO2010080835A1
(en)
|
2009-01-06 |
2010-07-15 |
Curemark Llc |
Compositions and methods for the treatment or the prevention oral infections by e. coli
|
KR20170005192A
(ko)
|
2009-01-06 |
2017-01-11 |
큐어론 엘엘씨 |
스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
CN102341105B
(zh)
|
2009-02-03 |
2014-09-17 |
微生物公司 |
用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇
|
CN102340992B
(zh)
|
2009-02-09 |
2014-11-05 |
桑诺维恩药品公司 |
吡咯烷三重再摄取抑制剂
|
CA2750123A1
(en)
|
2009-02-10 |
2010-08-19 |
Celgene Corporation |
Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
|
CN102388043A
(zh)
|
2009-02-11 |
2012-03-21 |
桑诺维恩药品公司 |
组胺h3反相激动剂和拮抗剂及其使用方法
|
WO2010093434A1
(en)
|
2009-02-11 |
2010-08-19 |
Celgene Corporation |
Isotopologues of lenalidomide
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
WO2010093873A2
(en)
|
2009-02-12 |
2010-08-19 |
Incept, Llc |
Drug delivery through hydrogel plugs
|
US20110275647A1
(en)
|
2009-02-23 |
2011-11-10 |
Msd K.K. |
Pyrimidin-4-(3h)-one derivatives
|
BRPI1008280A2
(pt)
|
2009-02-24 |
2015-08-25 |
Ritter Pharmaceuticals Inc |
Formulações prebióticas e métodos mde uso
|
EP2448406B1
(en)
|
2009-02-26 |
2016-04-20 |
Relmada Therapeutics, Inc. |
Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
|
KR101705727B1
(ko)
|
2009-02-26 |
2017-02-10 |
레비바 파마슈티칼스, 아이엔씨. |
아릴피페라진 유도체의 조성물, 합성, 및 사용 방법
|
CN102395576A
(zh)
*
|
2009-02-27 |
2012-03-28 |
埃姆比特生物科学公司 |
调控jak激酶的喹唑啉衍生物和其使用方法
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
CA2754461A1
(en)
*
|
2009-03-06 |
2010-09-10 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloprotease 1 and uses thereof
|
UY32487A
(es)
|
2009-03-10 |
2010-06-30 |
Euro Celtique Sa |
Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
|
MX2011009413A
(es)
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
AU2010221990B2
(en)
*
|
2009-03-11 |
2015-06-04 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as GSK-3 inhibitors
|
EP2406248B1
(en)
|
2009-03-11 |
2013-12-25 |
Msd K.K. |
Novel isoindolin-1-one derivative
|
CN102448458B
(zh)
|
2009-03-18 |
2015-07-22 |
小利兰·斯坦福大学理事会 |
治疗黄病毒科病毒感染的方法和组合物
|
JP2012521801A
(ja)
|
2009-03-24 |
2012-09-20 |
スパイナル・モデュレーション・インコーポレイテッド |
錯感覚に対する閾値以下の刺激を伴う疼痛の管理
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
SG174527A1
(en)
|
2009-03-27 |
2011-11-28 |
Pathway Therapeutics Inc |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
CN102481276A
(zh)
|
2009-04-20 |
2012-05-30 |
埃尔舍利克斯治疗公司 |
基于化学感受受体配体的治疗法
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
CN102459210B
(zh)
|
2009-04-22 |
2015-09-02 |
埃克希金医药品有限公司 |
芳基磺酰胺ccr3拮抗剂
|
BRPI1014669A2
(pt)
|
2009-04-22 |
2017-07-18 |
Axikin Pharmaceuticals Inc |
antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída
|
NZ595797A
(en)
|
2009-04-22 |
2014-03-28 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
WO2010127452A1
(en)
|
2009-05-04 |
2010-11-11 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
5-oxo-ete receptor antagonist compounds
|
US20100292217A1
(en)
*
|
2009-05-14 |
2010-11-18 |
Gilead Palo Alto, Inc. |
Ranolazine for the treatment of cns disorders
|
AU2010248802B2
(en)
|
2009-05-15 |
2017-02-02 |
Spinal Modulation, Inc. |
Methods, systems and devices for neuromodulating spinal anatomy
|
EP2432455B1
(en)
|
2009-05-18 |
2014-11-12 |
Sigmoid Pharma Limited |
Composition comprising oil drops
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
US8956654B2
(en)
|
2009-06-02 |
2015-02-17 |
Dow Global Technologies Llc |
Sustained release dosage form
|
JP2012529529A
(ja)
|
2009-06-10 |
2012-11-22 |
スノビオン プハルマセウトイカルス インコーポレイテッド |
ヒスタミンh3インバースアゴニスト及びアンタゴニスト、並びにその使用方法
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
AU2010260208B2
(en)
|
2009-06-16 |
2014-11-13 |
Bristol-Myers Squibb Holdings Ireland Unlimited Company |
Dosage forms of apixaban
|
AR077252A1
(es)
|
2009-06-29 |
2011-08-10 |
Xenon Pharmaceuticals Inc |
Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
EP3072890B1
(en)
|
2009-07-07 |
2018-10-17 |
MEI Pharma, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
EP3311667A1
(en)
|
2009-07-08 |
2018-04-25 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
HUE035519T2
(en)
|
2009-07-08 |
2018-05-02 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical composition
|
TWI625121B
(zh)
|
2009-07-13 |
2018-06-01 |
基利科學股份有限公司 |
調節細胞凋亡信號之激酶的抑制劑
|
EP2467144A1
(en)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
PL2464645T3
(pl)
|
2009-07-27 |
2017-12-29 |
Gilead Sciences, Inc. |
Skondensowane heterocykliczne związki jako modulatory kanałów jonowych
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
WO2011014775A1
(en)
|
2009-07-31 |
2011-02-03 |
The Brigham And Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
CA2770570A1
(en)
|
2009-08-12 |
2011-02-17 |
Sigmoid Pharma Limited |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
US20110039799A1
(en)
|
2009-08-14 |
2011-02-17 |
Gilead Palo Alto, Inc. |
A1 adenosine receptor agonist polymorphs
|
CA2770454A1
(en)
|
2009-08-19 |
2011-02-24 |
Ambit Biosciences Corporation |
Biaryl compounds and methods of use thereof
|
US20120190743A1
(en)
|
2009-09-04 |
2012-07-26 |
United Paragon Associates Inc. |
Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
|
WO2011028234A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Xenoport, Inc. |
Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
|
MX2012002898A
(es)
|
2009-09-11 |
2012-04-02 |
Sunovion Pharmaceuticals Inc |
Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
|
CN102666553B
(zh)
*
|
2009-10-01 |
2015-05-06 |
赛马拜制药公司 |
取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
|
US20110136751A1
(en)
|
2009-10-06 |
2011-06-09 |
Green Molecular |
Use of Polyphenols in the Treatment of Cancer
|
US20110082198A1
(en)
*
|
2009-10-07 |
2011-04-07 |
Jiangsu Dehe Bio-Tech Co., Ltd. |
Theaflavin compositions, production, and methods to control physiological disorders in mammals
|
US8282970B2
(en)
*
|
2009-10-07 |
2012-10-09 |
Jiahgsu Dehe Bio-Tech Co., Ltd |
Theaflavin compositions, related processes and methods of use
|
US20110086899A1
(en)
*
|
2009-10-14 |
2011-04-14 |
Xenon Pharmaceuticals Inc. |
Pharmaceutical compositions for oral administration
|
RU2015103694A
(ru)
|
2009-10-14 |
2015-06-27 |
Ксенон Фармасьютикалз Инк. |
Способы синтеза спиро-оксиндольных соединений
|
KR20120093970A
(ko)
|
2009-10-19 |
2012-08-23 |
신타 파마슈티칼스 코프. |
에이취에스피90 억제 화합물을 이용한 조합 항암 요법
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
WO2011056985A2
(en)
|
2009-11-04 |
2011-05-12 |
Gilead Sciences, Inc. |
Substituted heterocyclic compounds
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
ES2565644T3
(es)
|
2009-11-09 |
2016-04-06 |
Xenoport, Inc. |
Composiciones farmacéuticas y formas de dosificación oral de un pre medicamento de levodopa y los métodos de utilización
|
KR101769637B1
(ko)
|
2009-11-09 |
2017-08-18 |
알러간, 인코포레이티드 |
모발 성장을 촉진하기 위한 조성물 및 방법
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
WO2011063102A1
(en)
|
2009-11-19 |
2011-05-26 |
Celgene Corporation |
Apremilast for the treatment of sarcoidosis
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
SG181498A1
(en)
|
2009-12-04 |
2012-07-30 |
Sunovion Pharmaceuticals Inc |
Multicyclic compounds and methods of use thereof
|
KR101755743B1
(ko)
|
2009-12-04 |
2017-07-07 |
선오비온 파마슈티컬스 인코포레이티드 |
트랜스노르세르트랄린의 제형, 염 및 다형체, 및 이들의 용도
|
CN102869367A
(zh)
|
2009-12-09 |
2013-01-09 |
西尼克斯公司 |
新颖的环肽
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
CA2784748A1
(en)
|
2009-12-18 |
2011-06-23 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
TWI508726B
(zh)
|
2009-12-21 |
2015-11-21 |
Gilead Sciences Inc |
治療心房纖維性顫動之方法
|
CA2783616A1
(en)
|
2009-12-22 |
2011-06-30 |
Celgene Corporation |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
IN2012DN04858A
(hr)
*
|
2009-12-23 |
2015-09-25 |
Map Pharmaceuticals Inc |
|
US20120010131A1
(en)
|
2009-12-30 |
2012-01-12 |
Scynexis, Inc. |
Novel cyclosporin analogues
|
JP5916622B2
(ja)
|
2010-01-04 |
2016-05-11 |
マピ ファーマ リミテッド |
グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
CA2786266A1
(en)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
|
WO2011089166A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
|
WO2011091164A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Xenoport, Inc. |
Oral dosage forms having a high loading of a tranexamic acid prodrug
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
WO2011097525A1
(en)
|
2010-02-05 |
2011-08-11 |
Tragara Pharmaceuticals, Inc. |
Solid state forms of macrocyclic kinase inhibitors
|
US8471041B2
(en)
*
|
2010-02-09 |
2013-06-25 |
Alliant Techsystems Inc. |
Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
|
EP4289838A3
(en)
|
2010-02-11 |
2024-03-13 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
WO2011106273A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
MX343215B
(es)
|
2010-02-26 |
2016-10-27 |
Xenon Pharmaceuticals Inc |
Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
|
HUE025699T2
(en)
|
2010-03-02 |
2016-04-28 |
Axikin Pharmaceuticals Inc |
Isotopically enriched arylsulfonamide derivatives as CCR3 antagonists
|
AU2011226689B2
(en)
|
2010-03-11 |
2016-09-01 |
Kronos Bio, Inc. |
Imidazopyridines Syk inhibitors
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
JP2013522236A
(ja)
|
2010-03-12 |
2013-06-13 |
セルジーン コーポレイション |
レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー
|
MX336559B
(es)
|
2010-03-17 |
2016-01-25 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida.
|
JP5849947B2
(ja)
|
2010-03-29 |
2016-02-03 |
アステラス製薬株式会社 |
放出制御医薬組成物
|
JP2013525281A
(ja)
|
2010-04-05 |
2013-06-20 |
マンカインド コーポレ−ション |
IRE−1αインヒビター
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
CN102884072A
(zh)
|
2010-04-08 |
2013-01-16 |
爱默蕾大学 |
被取代的雄甾-4-烯二酮
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
US20130156755A1
(en)
|
2010-04-19 |
2013-06-20 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
EP2563372A4
(en)
|
2010-04-28 |
2013-10-02 |
Ritter Pharmaceuticals Inc |
PREBIOTIC FORMULATIONS AND METHODS OF USE
|
WO2011140360A1
(en)
|
2010-05-05 |
2011-11-10 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled compounds and uses thereof
|
CA2798961A1
(en)
|
2010-05-10 |
2011-11-17 |
Spinal Modulation, Inc. |
Methods, systems and devices for reducing migration
|
WO2011146803A1
(en)
|
2010-05-20 |
2011-11-24 |
Synta Pharmaceuticals Corp. |
Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
|
WO2011149824A1
(en)
|
2010-05-24 |
2011-12-01 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
|
MX351368B
(es)
|
2010-05-26 |
2017-10-12 |
Sunovion Pharmaceuticals Inc |
Compuestos heteroarilo y metodos para utilizarlos.
|
US9296722B2
(en)
|
2010-05-27 |
2016-03-29 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
EP2576520A1
(en)
|
2010-05-28 |
2013-04-10 |
GE Healthcare UK Limited |
Radiolabeled compounds and methods thereof
|
WO2011153199A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
|
CA2801001A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
|
CA2801778C
(en)
|
2010-06-07 |
2018-06-05 |
Novomedix, Llc |
Furanyl compounds and the use thereof
|
ES2526124T3
(es)
|
2010-06-16 |
2015-01-07 |
Cymabay Therapeutics, Inc. |
Agonistas del receptor GPR120 y sus usos
|
US8299117B2
(en)
|
2010-06-16 |
2012-10-30 |
Metabolex Inc. |
GPR120 receptor agonists and uses thereof
|
TW201215392A
(en)
|
2010-06-16 |
2012-04-16 |
Gilead Sciences Inc |
Use of ranolazine for treating pulmonary hypertension
|
BR112012032248A2
(pt)
|
2010-06-23 |
2016-09-13 |
Metabolex Inc |
composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
|
CA2802891A1
(en)
|
2010-06-30 |
2012-01-05 |
Gilead Sciences, Inc. |
Use of a2b adenosine receptor antagonists for treating pulmonary hypertension
|
MX2012015105A
(es)
|
2010-07-02 |
2013-05-28 |
Gilead Sciences Inc |
Inhibidores de cinasa de regulacion mediante señal de apoptosis.
|
CN103096977B
(zh)
|
2010-07-02 |
2017-02-15 |
吉利德科学公司 |
作为离子通道调节剂的稠杂环化合物
|
AR082189A1
(es)
|
2010-07-06 |
2012-11-21 |
Gruenenthal Gmbh |
Formas de dosificacion gastrorretentivas, procedimiento
|
US20120015031A1
(en)
|
2010-07-14 |
2012-01-19 |
Grunenthal Gmbh |
Novel gastro-retentive dosage forms
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
US8906943B2
(en)
|
2010-08-05 |
2014-12-09 |
John R. Cashman |
Synthetic compounds and methods to decrease nicotine self-administration
|
BR112013003332B1
(pt)
|
2010-08-12 |
2018-11-13 |
Senomyx, Inc. |
método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado
|
DK2608782T3
(en)
|
2010-08-24 |
2016-09-05 |
Algiax Pharmaceuticals Gmbh |
New use of leflunomide malononitrilamider
|
WO2012030668A1
(en)
|
2010-08-30 |
2012-03-08 |
SinuSys Corporation |
Device and kit for inserting a sinus dilator
|
EP2611502A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
US8633207B2
(en)
|
2010-09-01 |
2014-01-21 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
EP2611794A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
WO2012030944A2
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline compounds and methods of use thereof
|
JP5932794B2
(ja)
|
2010-09-01 |
2016-06-08 |
アムビト ビオスシエンセス コルポラチオン |
光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
|
US20130303533A1
(en)
|
2010-09-01 |
2013-11-14 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
WO2012030910A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
CA2809983A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
EP2611812A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
EP2611448A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
US8821457B2
(en)
|
2010-09-08 |
2014-09-02 |
Johnson & Johnson Vision Care, Inc. |
Punctal plug containing drug formulation
|
AU2011302344B2
(en)
|
2010-09-13 |
2015-01-15 |
Synta Pharmaceuticals Corp. |
HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
|
WO2012050922A2
(en)
|
2010-09-28 |
2012-04-19 |
Depomed, Inc. |
Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
|
WO2012050907A2
(en)
|
2010-09-28 |
2012-04-19 |
The Regents Of The University Of California |
Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
WO2012051090A1
(en)
|
2010-10-11 |
2012-04-19 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
BR112013008983A2
(pt)
|
2010-10-15 |
2016-07-05 |
Gilead Sciences Inc |
composições e métodos de tratamento da hipertensão pulmonar
|
WO2012051567A2
(en)
|
2010-10-15 |
2012-04-19 |
The Trustees Of Columbia University In The City Of New York |
Obesity-related genes and their proteins and uses thereof
|
MX337179B
(es)
|
2010-10-18 |
2016-02-15 |
Cerenis Therapeutics Holding Sa |
Compuestos, composiciones y metodos utiles para la movilizacion de colesterol.
|
CN104220875A
(zh)
|
2010-10-19 |
2014-12-17 |
埃尔舍利克斯治疗公司 |
基于化学感应受体配体的治疗
|
ES2655084T3
(es)
|
2010-10-29 |
2018-02-16 |
Algiax Pharmaceuticals Gmbh |
Empleo de malononitrilamidas en dolor neuropático
|
EP2638032A1
(en)
|
2010-11-09 |
2013-09-18 |
Synta Pharmaceuticals Corp. |
Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
|
AU2011326427B2
(en)
|
2010-11-10 |
2016-01-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
RU2013127625A
(ru)
|
2010-11-18 |
2014-12-27 |
Зе Дженерал Хоспитал Корпорейшен |
Новые композиции и применения антигипертензивных средств для терапии рака
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
EP2648676A4
(en)
|
2010-12-06 |
2016-05-04 |
Follica Inc |
METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
US20140005145A1
(en)
|
2010-12-08 |
2014-01-02 |
Synta Pharmaceuticals Corp. |
Combination breast cancer therapy with hsp90 inhibitory compounds
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US20120157938A1
(en)
|
2010-12-16 |
2012-06-21 |
Tokarski Jason M |
Punctal plug with drug core retention features
|
MX354210B
(es)
|
2010-12-16 |
2018-02-16 |
Celgene Corp |
Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
|
DK2826467T3
(en)
|
2010-12-22 |
2017-10-16 |
Purdue Pharma Lp |
INCLUDED, MANIPULATION-PROPOSED SLOW-DELIVERY DOSAGE FORMS
|
AU2011346749A1
(en)
|
2010-12-22 |
2013-05-02 |
Purdue Pharma L.P. |
Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
|
CN107412173A
(zh)
|
2010-12-23 |
2017-12-01 |
普渡制药公司 |
抗篡改固体口服剂型
|
MX2013007884A
(es)
|
2011-01-07 |
2013-09-13 |
Elcelyx Therapeutics Inc |
Terapias a base de ligando del receptor quimiosensorial.
|
US8853175B2
(en)
|
2011-01-10 |
2014-10-07 |
Celgene Corporation |
Phenethylsulfone isoindoline derivatives and their use
|
MX2013007959A
(es)
|
2011-01-10 |
2013-12-06 |
Celgene Corp |
Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
|
BR112013017670B1
(pt)
|
2011-01-10 |
2022-07-19 |
Infinity Pharmaceuticals, Inc |
Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
|
WO2012096919A1
(en)
|
2011-01-11 |
2012-07-19 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
|
CN103619841B
(zh)
|
2011-01-11 |
2017-03-29 |
桑诺维恩药品公司 |
杂芳基化合物及其使用方法
|
WO2012097116A2
(en)
|
2011-01-14 |
2012-07-19 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
HUE026715T2
(en)
|
2011-01-20 |
2016-07-28 |
Bionevia Pharmaceuticals Inc |
Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use
|
CN103338753A
(zh)
|
2011-01-31 |
2013-10-02 |
细胞基因公司 |
胞苷类似物的药物组合物及其使用方法
|
WO2012106281A2
(en)
|
2011-01-31 |
2012-08-09 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
CA2825763A1
(en)
|
2011-02-02 |
2012-08-09 |
Spinal Modulation, Inc. |
Devices, systems and methods for the targeted treatment of movement disorders
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
|
WO2012116061A1
(en)
|
2011-02-23 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with radiotherapy
|
JP2014507443A
(ja)
|
2011-02-24 |
2014-03-27 |
シンタ ファーマシューティカルズ コーポレーション |
Hsp90阻害化合物での前立腺癌治療
|
WO2012116247A1
(en)
|
2011-02-25 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
|
US8796258B2
(en)
|
2011-02-25 |
2014-08-05 |
Merck Sharp & Dohme Corp. |
Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
US9795792B2
(en)
|
2011-02-25 |
2017-10-24 |
Medtronic, Inc. |
Emergency mode switching for non-pacing modes
|
EP2683376B1
(en)
|
2011-03-07 |
2018-11-28 |
Celgene Corporation |
Methods for treating diseases using isoindoline compounds
|
PE20140983A1
(es)
|
2011-03-11 |
2014-08-25 |
Celgene Corp |
Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
|
HUE027481T2
(en)
|
2011-03-11 |
2016-09-28 |
Celgene Corp |
Methods of treating cancer with 3- (5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl) -piperidine-2,6-dione
|
US20140057978A1
(en)
|
2011-03-17 |
2014-02-27 |
Algiax Pharmaceuticals Gmbh |
Novel use of benzofuranylsulfonates
|
WO2012123406A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of imidazotriazinones
|
US9585930B2
(en)
|
2011-03-20 |
2017-03-07 |
Trustees Of Boston University |
Therapeutic agent for emphysema and COPD
|
US20140088103A1
(en)
|
2011-03-28 |
2014-03-27 |
Mei Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
TWI572599B
(zh)
|
2011-03-28 |
2017-03-01 |
Mei製藥公司 |
(α-經取代之芳烷胺基及雜芳烷胺基)嘧啶基及1,3,5-三基苯并咪唑,其醫藥組合物及其在治療增生性疾病之用途
|
AU2012236722A1
(en)
|
2011-03-28 |
2013-10-17 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
US9090585B2
(en)
|
2011-03-28 |
2015-07-28 |
Deuterx, Llc |
2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
EP2691409B1
(en)
|
2011-03-31 |
2018-02-21 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2012158271A1
(en)
|
2011-04-06 |
2012-11-22 |
Anadys Pharmaceuticals, Inc. |
Bridged polycyclic compounds as antiviral agents
|
AR085942A1
(es)
|
2011-04-07 |
2013-11-06 |
Gilead Sciences Inc |
Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
|
ES2601892T3
(es)
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
BR112013027034A8
(pt)
|
2011-04-21 |
2018-01-02 |
Curemark Llc |
"compostos para o tratamento de transtornos neuropsiquiátricos."
|
CN103635188B
(zh)
|
2011-04-28 |
2017-03-22 |
细胞基因公司 |
使用pde4抑制剂用于治疗和控制自身免疫性疾病和炎性疾病的方法和组合物
|
KR20140024914A
(ko)
|
2011-04-29 |
2014-03-03 |
셀진 코포레이션 |
예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
|
US9604978B2
(en)
|
2011-05-03 |
2017-03-28 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
US9480696B2
(en)
|
2011-05-04 |
2016-11-01 |
Trustees Of Boston University |
Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
|
US9301874B2
(en)
|
2011-05-06 |
2016-04-05 |
Johnson & Johnson Vision Care, Inc. |
Punctal plugs for controlled release of therapeutic agents
|
MX361350B
(es)
|
2011-05-10 |
2018-12-04 |
Gilead Sciences Inc |
Compuestos heterocíclicos fusionados como moduladores del canal de sodio.
|
US20140315943A1
(en)
|
2011-05-24 |
2014-10-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
|
SG195288A1
(en)
|
2011-06-07 |
2013-12-30 |
Anadys Pharmaceuticals Inc |
[1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
|
RU2011122942A
(ru)
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
US20140221427A1
(en)
|
2011-06-22 |
2014-08-07 |
Celgene Corporation |
Isotopologues of pomalidomide
|
RU2621708C2
(ru)
|
2011-06-22 |
2017-06-07 |
ПУРДЬЮ ФАРМА Эл. Пи. |
Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
|
MX2013015373A
(es)
|
2011-06-23 |
2014-02-11 |
Map Pharmaceuticals Inc |
Nuevos analogos de fluoroergolina.
|
WO2012175698A1
(en)
|
2011-06-23 |
2012-12-27 |
Université Libre de Bruxelles |
Therapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
NO3175985T3
(hr)
|
2011-07-01 |
2018-04-28 |
|
|
TWI567061B
(zh)
|
2011-07-01 |
2017-01-21 |
吉李德科學股份有限公司 |
用於治療成癮之化合物
|
TW201837023A
(zh)
|
2011-07-01 |
2018-10-16 |
美商基利科學股份有限公司 |
作為離子通道調節劑之稠合雜環化合物
|
DE102011051653A1
(de)
*
|
2011-07-07 |
2013-01-10 |
Lts Lohmann Therapie-Systeme Ag |
Quellfähige Manteltablette
|
EP2729144A2
(en)
|
2011-07-07 |
2014-05-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
US10702485B2
(en)
|
2011-07-09 |
2020-07-07 |
Syntrix Biosystems Inc. |
Compositions and methods for overcoming resistance to tramadol
|
WO2013012915A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
AR088218A1
(es)
|
2011-07-19 |
2014-05-21 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos utiles como inhibidores de pi3k
|
GB201112987D0
(en)
|
2011-07-28 |
2011-09-14 |
Ge Healthcare Ltd |
Novel compound
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
WO2013021276A1
(en)
|
2011-08-10 |
2013-02-14 |
Purdue Pharma L.P. |
Trpv1 antagonists including dihydroxy substituent and uses thereof
|
EP2741760A2
(en)
|
2011-08-12 |
2014-06-18 |
B.S.R.C. "Alexander Fleming" |
Tnf superfamily trimerization inhibitors
|
WO2013028505A1
(en)
|
2011-08-19 |
2013-02-28 |
Synta Pharmaceuticals Corp. |
Combination cancer therapy of hsp90 inhibitor with antimetabolite
|
ES2544845T3
(es)
|
2011-08-23 |
2015-09-04 |
Cornerstone Therapeutics Inc. |
Uso de zileutón en el tratamiento de pólipos nasales en pacientes con fibrosis quística
|
US8664247B2
(en)
|
2011-08-26 |
2014-03-04 |
Radiorx, Inc. |
Acyclic organonitro compounds for use in treating cancer
|
CA2846431A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
TWI468403B
(zh)
|
2011-08-30 |
2015-01-11 |
Gilead Sciences Inc |
用於治療成癮之aldh-2抑制劑
|
WO2013033636A2
(en)
|
2011-09-01 |
2013-03-07 |
University Of Southern California |
Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
|
TW201329096A
(zh)
|
2011-09-12 |
2013-07-16 |
Idenix Pharmaceuticals Inc |
經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
|
AU2012308900A1
(en)
|
2011-09-12 |
2013-05-09 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013040501A1
(en)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
|
CA2849505A1
(en)
|
2011-09-21 |
2013-03-28 |
Gilead Sciences, Inc. |
Sodium channel blockers reduce glucagon secretion
|
CN104114182A
(zh)
|
2011-09-23 |
2014-10-22 |
细胞基因公司 |
罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用
|
KR20140069271A
(ko)
|
2011-09-26 |
2014-06-09 |
셀진 코포레이션 |
화학요법 내성 암에 대한 병용 요법
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
EP2764406B1
(en)
|
2011-10-07 |
2018-03-14 |
Cedars-Sinai Medical Center |
Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
|
WO2013052803A2
(en)
|
2011-10-07 |
2013-04-11 |
Radiorx, Inc. |
Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
|
WO2013052164A1
(en)
|
2011-10-07 |
2013-04-11 |
Radiorx, Inc. |
Organonitro thioether compounds and medical uses thereof
|
EP2766041B1
(en)
|
2011-10-12 |
2018-12-05 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
JP6162130B2
(ja)
|
2011-10-14 |
2017-07-12 |
アムビト ビオスシエンセス コルポラチオン |
Iii型受容体チロシンキナーゼの調節因子としての複素環式化合物及びその使用
|
TW201331221A
(zh)
|
2011-10-14 |
2013-08-01 |
Idenix Pharmaceuticals Inc |
嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
|
ES2586213T3
(es)
|
2011-10-31 |
2016-10-13 |
Xenon Pharmaceuticals Inc. |
Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
|
CN104168884A
(zh)
|
2011-11-01 |
2014-11-26 |
细胞基因公司 |
使用胞苷类似物的口服制剂治疗癌症的方法
|
TWI615155B
(zh)
|
2011-11-01 |
2018-02-21 |
拜耳股份有限公司 |
滲透活性的陰道遞送系統
|
US9439899B2
(en)
|
2011-11-02 |
2016-09-13 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
|
JP2014534228A
(ja)
|
2011-11-02 |
2014-12-18 |
シンタ ファーマシューティカルズ コーポレーション |
白金含有剤とhsp90阻害剤の組合せ療法
|
US9243037B2
(en)
|
2011-11-10 |
2016-01-26 |
Trustees Of Boston College |
Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
|
WO2013074594A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
AU2012324015A1
(en)
|
2011-12-01 |
2013-06-20 |
Purdue Pharma L.P. |
Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
MX349036B
(es)
|
2011-12-06 |
2017-07-07 |
Univ Leland Stanford Junior |
Metodos y composiciones para tratar enfermedades virales.
|
JP5946921B2
(ja)
|
2011-12-08 |
2016-07-06 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
四級化ブプレノルフィン類似体
|
CA2859173A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
US8946420B2
(en)
|
2011-12-21 |
2015-02-03 |
Map Pharmaceuticals, Inc. |
Neuromodulatory compounds
|
EP2809656A2
(en)
|
2011-12-28 |
2014-12-10 |
Allergan, Inc. |
Benzimidazole derivatives as selective blockers of persistent sodium current
|
ES2851602T3
(es)
|
2011-12-28 |
2021-09-08 |
Allergan Inc |
Derivados de 3-fenil-5-ureidoisotiazol-4-carboxamida como inhibidores de cinasa
|
WO2013101926A1
(en)
|
2011-12-28 |
2013-07-04 |
Allergan, Inc. |
Benzimidazole derivatives as selective blockers of persistent sodium current
|
DK2797622T3
(en)
|
2011-12-30 |
2017-01-16 |
Halozyme Inc |
PH20 polypeptide variants, formulations and uses thereof
|
EP2797870B1
(en)
|
2011-12-30 |
2019-02-20 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using 1-[1-phenyl-cyclobutyl]isobutylamine derivatives
|
MX351313B
(es)
|
2012-01-05 |
2017-10-10 |
Boston Medical Ct Corp |
Señalización de slit-robo para diagnosis y tratamiento de enfermedad del riñón.
|
CN110693867A
(zh)
|
2012-01-06 |
2020-01-17 |
埃尔舍利克斯治疗公司 |
用于治疗代谢性病症的组合物和方法
|
AU2012363873B2
(en)
|
2012-01-06 |
2017-11-23 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
AU2013203252B2
(en)
|
2012-01-27 |
2015-08-20 |
Gilead Sciences, Inc. |
Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
|
AU2013216935C1
(en)
|
2012-02-08 |
2017-12-14 |
John Emmerson Campbell |
Heteroaryl compounds and methods of use thereof
|
EP2817300B1
(en)
|
2012-02-21 |
2018-04-25 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
TWI635855B
(zh)
|
2012-02-29 |
2018-09-21 |
壯生和壯生視覺關懷公司 |
具有激能圍阻陣列之淚管塞
|
WO2013130468A1
(en)
|
2012-02-29 |
2013-09-06 |
SinuSys Corporation |
Devices and methods for dilating a paranasal sinus opening and for treating sinusitis
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
WO2013133708A1
(en)
|
2012-03-07 |
2013-09-12 |
Stichting Vu-Vumc |
Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
|
SG10201507714XA
(en)
|
2012-03-16 |
2015-10-29 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
CA2901394A1
(en)
|
2012-03-19 |
2013-09-26 |
The Brigham And Women's Hosptial, Inc. |
Growth differentiation factor (gdf) for treatment of diastolic heart failure
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
EP2830616A1
(en)
|
2012-03-27 |
2015-02-04 |
Incuron LLC |
Curaxins for use in treating breast cancer and method for identifying patients likely to respond
|
WO2013148857A1
(en)
|
2012-03-28 |
2013-10-03 |
Synta Pharmaceuticals Corp. |
Triazole derivatives as hsp90 inhibitors
|
JP2015515477A
(ja)
|
2012-04-04 |
2015-05-28 |
シンタ ファーマシューティカルズ コーポレーション |
Hsp90活性を調節する新規トリアゾール化合物
|
RS57449B1
(sr)
|
2012-04-04 |
2018-09-28 |
Halozyme Inc |
Kombinovana terapija sa hijaluronidazom i taksanom koji ciljno deluje na tumor
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
EP3485880A1
(en)
|
2012-04-17 |
2019-05-22 |
Purdue Pharma LP |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
ES2656292T3
(es)
|
2012-05-01 |
2018-02-26 |
Translatum Medicus Inc. |
Métodos de tratamiento y diagnóstico de enfermedades oculares que causan ceguera
|
WO2013170159A1
(en)
|
2012-05-10 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
TW201408645A
(zh)
|
2012-05-11 |
2014-03-01 |
Purdue Pharma Lp |
苯並嗎凡類似物及其用途
|
US9074972B2
(en)
|
2012-05-16 |
2015-07-07 |
Dionex Corporation |
Surrogate addition device and a method of analyte concentration
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
EP2852603B1
(en)
|
2012-05-22 |
2021-05-12 |
Idenix Pharmaceuticals LLC |
D-amino acid compounds for liver disease
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
WO2013187965A1
(en)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
癌を処置するための組成物および該組成物を製造するための方法
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
ES2872967T3
(es)
|
2012-06-29 |
2021-11-03 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
EP2872127A1
(en)
|
2012-07-11 |
2015-05-20 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
WO2014014427A1
(en)
|
2012-07-16 |
2014-01-23 |
Mahmut Bilgic |
Modified release pharmaceutical tablet formulations
|
BR112015000867A2
(pt)
|
2012-07-16 |
2019-10-15 |
Rhodes Tech |
processo para síntese melhorada de opioide.
|
EP2872516B1
(en)
|
2012-07-16 |
2017-08-30 |
Rhodes Technologies |
Process for improved opioid synthesis
|
US9085561B2
(en)
|
2012-07-30 |
2015-07-21 |
Purdue Pharma L.P. |
Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
|
US10513540B2
(en)
|
2012-07-31 |
2019-12-24 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
RU2666534C2
(ru)
|
2012-08-06 |
2018-09-11 |
Сеномикс, Инк. |
Модификатор сладкого вкуса и аромата
|
AU2013299631B2
(en)
|
2012-08-09 |
2017-09-28 |
Celgene Corporation |
Salts and solid forms of (S)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
|
PL2882442T3
(pl)
|
2012-08-09 |
2021-12-13 |
Celgene Corporation |
Sposoby leczenia nowotworów z wykorzystaniem 3-(4-((4-(morfolinometylo)benzylo)oksy)-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu
|
PL2882441T3
(pl)
|
2012-08-09 |
2020-09-21 |
Celgene Corporation |
Leczenie chorób immunologicznych i zapalnych
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
US8841340B2
(en)
|
2012-08-17 |
2014-09-23 |
Gilead Sciences, Inc. |
Solid forms of an antiviral compound
|
US10624859B2
(en)
|
2012-08-20 |
2020-04-21 |
Rhodes Technologies |
Systems and methods for increasing stability of dronabinol compositions
|
WO2014031465A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives
|
US9315514B2
(en)
|
2012-08-27 |
2016-04-19 |
Rhodes Technologies |
1,3-dioxanomorphides and 1,3-dioxanocodides
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
CN104781240A
(zh)
|
2012-09-07 |
2015-07-15 |
埃克希金医药品有限公司 |
同位素富集的芳基磺酰胺ccr3拮抗剂
|
EA201590535A1
(ru)
|
2012-09-10 |
2015-07-30 |
Селджин Корпорейшн |
Способы лечения локально прогрессирующего запущенного рака молочной железы
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
CN111848711A
(zh)
|
2012-10-08 |
2020-10-30 |
埃迪尼克斯医药有限责任公司 |
用于hcv感染的2′-氯核苷类似物
|
BR112015008118A2
(pt)
|
2012-10-12 |
2017-12-05 |
Brigham & Womens Hospital Inc |
reforço da resposta imune
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
TR201812261T4
(tr)
|
2012-11-01 |
2018-11-21 |
Infinity Pharmaceuticals Inc |
Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
|
EP2916830A2
(en)
|
2012-11-08 |
2015-09-16 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
CA2890655A1
(en)
|
2012-11-09 |
2014-05-15 |
Purdue Pharma L.P. |
Benzomorphan analogs and the use thereof
|
US20150290171A1
(en)
|
2012-11-09 |
2015-10-15 |
Celgene Corporation |
Methods for the treatment of bone loss
|
US20160151321A1
(en)
|
2012-11-13 |
2016-06-02 |
Dinesh C. Patel |
Methods for the treatment of sialorrhea
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
US9670230B2
(en)
|
2012-11-29 |
2017-06-06 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
MX370519B
(es)
|
2012-11-30 |
2019-12-17 |
Novomedix Llc |
Sulfonamidas con sustitucion biarilo y su uso.
|
US9175000B2
(en)
|
2012-12-07 |
2015-11-03 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
WO2014091298A2
(en)
|
2012-12-14 |
2014-06-19 |
Purdue Pharma L.P. |
Nitrogen containing morphinan derivatives and the use thereof
|
EP2931724B1
(en)
|
2012-12-14 |
2017-01-25 |
Purdue Pharma LP |
Pyridonemorphinan analogs and biological activity on opioid receptors
|
ES2621305T3
(es)
|
2012-12-14 |
2017-07-03 |
Purdue Pharma Lp |
Morfinanos espirocíclicos y su uso
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
UY35212A
(es)
|
2012-12-21 |
2014-06-30 |
Gilead Sciences Inc |
Inhibidores de la quinasa que regula la señal de la apoptosis
|
US8895743B2
(en)
|
2012-12-21 |
2014-11-25 |
Map Pharmaceuticals, Inc. |
Methysergide derivatives
|
BR112015014585A2
(pt)
|
2012-12-21 |
2017-07-11 |
Gilead Calistoga Llc |
composto, composição farmacêutica, e, método de tratamento de um ser humano
|
US9029384B2
(en)
|
2012-12-21 |
2015-05-12 |
Gilead Calistoga, LLC. |
Phosphatidylinositol 3-kinase inhibitors
|
WO2014102589A1
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
|
US9040533B2
(en)
|
2012-12-27 |
2015-05-26 |
Purdue Pharma L.P. |
Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
|
WO2014102590A1
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Substituted piperidin-4-amino-type compounds and uses thereof
|
US9090618B2
(en)
|
2012-12-27 |
2015-07-28 |
Purdue Pharma L.P. |
Substituted benzimidazole-type piperidine compounds and uses thereof
|
US9963458B2
(en)
|
2012-12-27 |
2018-05-08 |
Purdue Pharma L.P. |
Indole and indoline-type piperidine compounds and uses thereof
|
WO2014102593A1
(en)
|
2012-12-28 |
2014-07-03 |
Purdue Pharma L.P. |
Substituted morphinans and the use thereof
|
TW201441198A
(zh)
|
2012-12-28 |
2014-11-01 |
Purdue Pharma Lp |
7,8-環嗎啡喃類似物
|
CA2896871A1
(en)
|
2012-12-31 |
2014-07-03 |
Kerry L. Spear |
Heterocyclic compounds and methods of use thereof
|
MX2015008625A
(es)
|
2013-01-05 |
2015-09-23 |
Elcelyx Therapeutics Inc |
Composicion de liberacion demorada que comprende biguanida.
|
WO2014107745A1
(en)
|
2013-01-07 |
2014-07-10 |
Halozyme, Inc. |
Metal sensitive mutants of matrix metalloproteases and uses thereof
|
WO2014110127A1
(en)
|
2013-01-08 |
2014-07-17 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
US9617607B2
(en)
|
2013-01-08 |
2017-04-11 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
PE20151431A1
(es)
|
2013-01-09 |
2015-09-23 |
Edgemont Pharmaceuticals Llc |
Formulaciones de lorazepam de liberacion controlada
|
US8999393B1
(en)
|
2013-01-09 |
2015-04-07 |
Edgemont Pharmaceuticals Llc |
Sustained release formulations of lorazepam
|
WO2014110305A1
(en)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamins c and k for treating polycystic diseases
|
WO2014110558A1
(en)
|
2013-01-14 |
2014-07-17 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
US9695145B2
(en)
|
2013-01-22 |
2017-07-04 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
US20150342946A1
(en)
|
2013-01-30 |
2015-12-03 |
Pharmorx Therapeutics, Inc. |
Treatments For Depression And Other Diseases With A Low Dose Agent
|
EP2951160B1
(en)
|
2013-01-31 |
2019-04-24 |
Purdue Pharma LP |
Benzomorphan analogs and the use thereof
|
AU2014215478B2
(en)
|
2013-02-05 |
2018-09-13 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
KR20150119254A
(ko)
|
2013-02-15 |
2015-10-23 |
알러간, 인코포레이티드 |
지속된 약물 전달 임플란트
|
JO3155B1
(ar)
|
2013-02-19 |
2017-09-20 |
Senomyx Inc |
معدِّل نكهة حلوة
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
WO2014134419A1
(en)
|
2013-03-01 |
2014-09-04 |
Gilead Sciences, Inc. |
Use of ikach blockers for the treatment of cardiac diseases
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
NZ628320A
(en)
|
2013-03-14 |
2017-04-28 |
Celgene Corp |
Treatment of psoriatic arthritis using apremilast
|
US8969358B2
(en)
|
2013-03-15 |
2015-03-03 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
ES2687958T3
(es)
|
2013-03-15 |
2018-10-30 |
The Regents Of The University Of California |
Fosfonato diésteres de nucleósido acíclico
|
AU2014233453A1
(en)
|
2013-03-15 |
2015-10-01 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
JP2016514459A
(ja)
|
2013-03-15 |
2016-05-23 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
線維素溶解についての二重反応性の強力なクニッツ阻害剤
|
JP6041823B2
(ja)
|
2013-03-16 |
2016-12-14 |
ファイザー・インク |
トファシチニブの経口持続放出剤形
|
TWI530499B
(zh)
*
|
2013-03-28 |
2016-04-21 |
吉李德科學股份有限公司 |
作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
MX2015013912A
(es)
|
2013-04-02 |
2016-08-12 |
Celgene Corp |
Metodos y composiciones que utilizan 4-amino-2-(2,6-dioxo-piperidi n-3-il)-isoindolin-1,3-diona para tratamiento y manejo de canceres en el sistema nervioso central.
|
WO2014168973A2
(en)
|
2013-04-08 |
2014-10-16 |
President And Fellows Of Harvard College |
Methods and compositions for rejuvenating skeletal muscle stem cells
|
KR20160003128A
(ko)
|
2013-04-30 |
2016-01-08 |
애브비 인코포레이티드 |
아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
US9687263B2
(en)
|
2013-05-30 |
2017-06-27 |
SinuSys Corporation |
Devices and methods for inserting a sinus dilator
|
SG11201509842SA
(en)
|
2013-05-30 |
2015-12-30 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
CA2914365C
(en)
|
2013-06-05 |
2022-03-15 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
EP3004396B1
(en)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Compositions for the treatment of cancer
|
WO2014201143A1
(en)
|
2013-06-11 |
2014-12-18 |
President And Fellows Of Harvard College |
Methods and compositions for increasing neurogenesis and angiogenesis
|
AU2014278011B2
(en)
|
2013-06-14 |
2020-03-19 |
Alyssum Therapeutics, Inc. |
Lipid-based platinum compounds and nanoparticles
|
EA028319B1
(ru)
|
2013-06-14 |
2017-11-30 |
Джилид Калистога Ллс |
Ингибиторы фосфатидилинозитол-3-киназы
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
ES2703623T3
(es)
|
2013-06-28 |
2019-03-11 |
Purdue Pharma Lp |
Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
US9333208B2
(en)
|
2013-07-16 |
2016-05-10 |
Movses H. Karakossian |
HCN inhibitors affecting ganglion cell function and visual function
|
UA116567C2
(uk)
|
2013-07-23 |
2018-04-10 |
Євро-Селтік С.А. |
Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
|
MX2016001427A
(es)
|
2013-07-31 |
2016-08-03 |
Gilead Sciences Inc |
Inhibidores de syk.
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
CA2919602C
(en)
|
2013-08-02 |
2018-03-13 |
Johnson Matthey Public Limited Company |
Process for the preparation of oxymorphone
|
EP3036226B1
(en)
|
2013-08-22 |
2020-01-08 |
The General Hospital Corporation |
Inhibitors of human 12/15-lipoxygenase
|
EP3038625A4
(en)
|
2013-08-29 |
2017-08-23 |
Trustees of Boston University |
Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
|
CN105683182A
(zh)
|
2013-08-30 |
2016-06-15 |
埃姆比特生物科学公司 |
联芳基乙酰胺化合物及其使用方法
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
US20160213659A1
(en)
|
2013-09-24 |
2016-07-28 |
George Sylvestre |
Treatment of burn pain by trpv1 modulators
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
MY175778A
(en)
|
2013-10-04 |
2020-07-08 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061091A1
(en)
|
2013-10-21 |
2015-04-30 |
The General Hospital Corporation |
Methods relating to circulating tumor cell clusters and the treatment of cancer
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015065876A1
(en)
|
2013-10-29 |
2015-05-07 |
Thomas Jefferson University |
Methods of prevention or treatment for pathologic thrombosis or inflammation
|
EP3063165A1
(en)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
GB201319792D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
ES2909014T3
(es)
|
2013-11-26 |
2022-05-04 |
Brigham & Womens Hospital Inc |
Composiciones y métodos para modular una respuesta inmunitaria
|
EP3074389B1
(en)
|
2013-11-26 |
2019-08-14 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
JP2017504572A
(ja)
|
2013-11-27 |
2017-02-09 |
アイデニクス・ファーマシューティカルズ・エルエルシー |
肝臓癌治療のためのヌクレオチド類
|
MX2016007311A
(es)
|
2013-12-04 |
2016-09-07 |
Gilead Sciences Inc |
Metodos para tratar canceres.
|
WO2015089321A2
(en)
|
2013-12-11 |
2015-06-18 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
ES2691541T3
(es)
|
2013-12-19 |
2018-11-27 |
Gilead Sciences, Inc. |
Compuestos heterocíclicos condensados como moduladores de canales iónicos
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
EP3082840B1
(en)
|
2013-12-20 |
2021-03-24 |
The General Hospital Corporation |
Methods and assays relating to circulating tumor cells
|
TWI662037B
(zh)
|
2013-12-23 |
2019-06-11 |
美商基利科學股份有限公司 |
脾酪胺酸激酶抑制劑
|
WO2015097548A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
7-beta-alkyl analogs of orvinols
|
EP3087079B1
(en)
|
2013-12-26 |
2019-04-03 |
Purdue Pharma LP |
Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
|
US9994571B2
(en)
|
2013-12-26 |
2018-06-12 |
Purdue Pharma L.P. |
10-substituted morphinan hydantoins
|
WO2015097546A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Propellane-based compounds and their use as opioid receptor modulators
|
WO2015099863A1
(en)
|
2013-12-27 |
2015-07-02 |
Purdue Pharma L.P. |
6-substituted and 7-substituted morphinan analogs and the use thereof
|
US9902726B2
(en)
|
2013-12-30 |
2018-02-27 |
Purdue Pharma L.P. |
Pyridone-sulfone morphinan analogs as opioid receptor ligands
|
KR101868723B1
(ko)
|
2014-01-15 |
2018-06-18 |
로드스 테크놀로지즈 |
개선된 옥시코돈 합성을 위한 방법
|
EP3094328B1
(en)
|
2014-01-15 |
2020-08-19 |
Poxel SA |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
MX2016009125A
(es)
|
2014-01-15 |
2017-02-02 |
Rhodes Tech |
Proceso para la sintesis mejorada de oximorfona.
|
ES2733552T3
(es)
|
2014-01-24 |
2019-11-29 |
Celgene Corp |
Procedimientos para el tratamiento de la obesidad mediante apremilast
|
CN106029614B
(zh)
|
2014-02-05 |
2019-05-31 |
Vm肿瘤药物有限责任公司 |
化合物的组合物及其用途
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
WO2015138420A1
(en)
|
2014-03-10 |
2015-09-17 |
Kadmon Corporation, Llc |
Treatment of brain and central nervous system tumors
|
EP3119744B1
(en)
|
2014-03-18 |
2019-03-06 |
Algiax Pharmaceuticals GmbH |
2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
|
CN106456628A
(zh)
|
2014-03-19 |
2017-02-22 |
无限药品股份有限公司 |
用于治疗PI3K‑γ介导的障碍的杂环化合物
|
US11369588B2
(en)
|
2014-03-20 |
2022-06-28 |
The Trustees Of Princeton University |
NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
|
PT3119762T
(pt)
|
2014-03-20 |
2021-08-31 |
Capella Therapeutics Inc |
Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
|
WO2015143161A1
(en)
|
2014-03-20 |
2015-09-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
US20170107300A1
(en)
|
2014-03-21 |
2017-04-20 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
US9062063B1
(en)
|
2014-03-21 |
2015-06-23 |
Johnson Matthey Public Limited Company |
Forms of oxymorphone hydrochloride
|
US20150283149A1
(en)
|
2014-04-02 |
2015-10-08 |
Gilead Sciences, Inc. |
Methods of treating patients having implantable cardiac devices
|
JP2017513931A
(ja)
|
2014-04-03 |
2017-06-01 |
インビクタス オンコロジー ピーヴィティー.リミテッド |
超分子コンビナトリアル治療薬
|
EP3125905A4
(en)
|
2014-04-04 |
2017-11-08 |
Ritter Pharmaceuticals, Inc. |
Methods and compositions for microbiome alteration
|
US10106549B2
(en)
|
2014-04-09 |
2018-10-23 |
Siteone Therapeutics, Inc. |
10′,11′-modified saxitoxins useful for the treatment of pain
|
WO2015155307A1
(en)
|
2014-04-11 |
2015-10-15 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
|
EP2933002A1
(en)
|
2014-04-11 |
2015-10-21 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Pharmaceutical combinations of dabigatran and proton pump inhibitors
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
KR20160147912A
(ko)
|
2014-04-25 |
2016-12-23 |
존슨 앤드 존슨 비젼 케어, 인코포레이티드 |
활성제 방출 시스템에 대한 방법 및 활성제 방출 시스템을 갖는 안과용 디바이스
|
EP3134733B1
(en)
|
2014-04-25 |
2020-10-14 |
The Brigham and Women's Hospital, Inc. |
Assay and method for treating subjects with immune-mediated diseases
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
KR20170015312A
(ko)
|
2014-05-12 |
2017-02-08 |
코나터스 파마슈티칼스, 인크. |
카스파제 억제제를 사용한 만성 간질환의 합병증의 치료
|
ES2751773T3
(es)
|
2014-05-15 |
2020-04-01 |
Amgen Europe Gmbh |
Uso de inhibidores pde4 y combinaciones de los mismos para el tratamiento de la fibrosis quística
|
EP3142663A1
(en)
|
2014-05-16 |
2017-03-22 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
US11021435B2
(en)
|
2014-05-19 |
2021-06-01 |
Northeastern University |
Serotonin receptor-targeting compounds and methods
|
EP3145500A1
(en)
|
2014-05-23 |
2017-03-29 |
Sigmoid Pharma Limited |
Celecoxib formulations useful for treating colorectal cancer
|
CA2947939A1
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
WO2015187541A1
(en)
|
2014-06-02 |
2015-12-10 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
EP3154956A4
(en)
|
2014-06-12 |
2018-01-17 |
Ligand Pharmaceuticals, Inc. |
Glucagon antagonists
|
SG11201609877XA
(en)
|
2014-06-13 |
2016-12-29 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
CA2952044C
(en)
|
2014-06-13 |
2019-01-29 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
WO2015195634A1
(en)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
AU2015277786B2
(en)
|
2014-06-19 |
2019-04-18 |
Takeda Pharmaceutical Company Limited |
Heteroaryl compounds for kinase inhibition
|
ES2749433T3
(es)
|
2014-06-23 |
2020-03-20 |
Celgene Corp |
Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
NZ726365A
(en)
|
2014-07-14 |
2018-06-29 |
Gilead Sciences Inc |
Combinations for treating cancers
|
CA2910865C
(en)
|
2014-07-15 |
2016-11-29 |
Isa Odidi |
Compositions and methods for reducing overdose
|
CA2956256A1
(en)
|
2014-08-01 |
2016-02-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions relating to treatment of pulmonary arterial hypertension
|
US10092541B2
(en)
|
2014-08-15 |
2018-10-09 |
Celgene Corporation |
Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
|
RS64038B1
(sr)
|
2014-08-22 |
2023-04-28 |
Celgene Corp |
Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima
|
PL3186281T3
(pl)
|
2014-08-28 |
2019-10-31 |
Halozyme Inc |
Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
|
EP3185910A4
(en)
|
2014-08-29 |
2018-01-10 |
Children's Medical Center Corporation |
Methods and compositions for the treatment of cancer
|
US20170319548A1
(en)
|
2014-09-12 |
2017-11-09 |
Tobira Therapeutics, Inc. |
Cenicriviroc combination therapy for the treatment of fibrosis
|
EP3193872A4
(en)
|
2014-09-14 |
2018-02-28 |
Avanir Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
|
SG11201701957XA
(en)
|
2014-09-15 |
2017-04-27 |
Univ California |
Nucleotide analogs
|
WO2016044707A1
(en)
|
2014-09-18 |
2016-03-24 |
Cedars-Sinai Medical Center |
Compositions and methods for treating fibrosis
|
ES2727376T3
(es)
|
2014-09-26 |
2019-10-15 |
Gilead Sciences Inc |
Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9353093B2
(en)
|
2014-10-07 |
2016-05-31 |
Allergan, Inc. |
Indole-1-carboxamides as kinase inhibitors
|
US9403803B2
(en)
|
2014-10-08 |
2016-08-02 |
Allergan, Inc. |
Indole-3-carboxamides as kinase inhibitors
|
US9359336B2
(en)
|
2014-10-09 |
2016-06-07 |
Allergan, Inc. |
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
|
US9296747B1
(en)
|
2014-10-10 |
2016-03-29 |
Allergan, Inc. |
Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
|
NZ730563A
(en)
|
2014-10-14 |
2019-05-31 |
Halozyme Inc |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
EP3206708B1
(en)
|
2014-10-16 |
2022-11-02 |
Cleveland Biolabs, Inc. |
Methods and compositions for the treatment of radiation-related disorders
|
CA2965169C
(en)
|
2014-10-21 |
2021-11-16 |
Ariad Pharmaceuticals, Inc. |
Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
CA2936741C
(en)
|
2014-10-31 |
2018-11-06 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
PL3215127T3
(pl)
|
2014-11-07 |
2021-05-17 |
Sublimity Therapeutics Limited |
Kompozycje zawierające cyklosporynę
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
SG11201704791WA
(en)
|
2014-12-16 |
2017-07-28 |
Celgene Corp |
Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
CN107250116B
(zh)
|
2014-12-23 |
2020-10-27 |
艾士盟医疗公司 |
3,5-二氨基吡唑激酶抑制剂
|
MA41252A
(fr)
|
2014-12-23 |
2017-10-31 |
Gilead Sciences Inc |
Formes solides d'un inhibiteur d'ask 1
|
JP2018502157A
(ja)
|
2015-01-12 |
2018-01-25 |
レビバ ファーマシューティカルズ,インコーポレイティド |
アルツハイマー病の治療方法
|
EP3244896B1
(en)
|
2015-01-12 |
2024-06-12 |
Reviva Pharmaceuticals, Inc. |
Methods for treating pulmonary hypertension
|
AU2016206682B2
(en)
|
2015-01-14 |
2021-11-11 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer with anti-LAP monoclonal antibodies
|
AU2016209490B2
(en)
|
2015-01-20 |
2020-09-03 |
Xoc Pharmaceuticals, Inc. |
Isoergoline compounds and uses thereof
|
EP3253753A4
(en)
|
2015-01-20 |
2018-06-27 |
Xoc Pharmaceuticals, Inc |
Ergoline compounds and uses thereof
|
US9918979B2
(en)
|
2015-01-29 |
2018-03-20 |
Johnson Matthey Public Limited Company |
Process of preparing low ABUK oxymorphone hydrochloride
|
TW201636017A
(zh)
|
2015-02-05 |
2016-10-16 |
梯瓦製藥國際有限責任公司 |
以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
|
US11497733B2
(en)
|
2015-02-09 |
2022-11-15 |
Synta Pharmaceuticals Corp. |
Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancer
|
WO2016132217A1
(en)
|
2015-02-20 |
2016-08-25 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Method of improving gaba-b receptor agonist therapy
|
CN107660207B
(zh)
|
2015-03-10 |
2020-09-29 |
罗德科技公司 |
丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
WO2016172479A1
(en)
|
2015-04-22 |
2016-10-27 |
Cedars-Sinai Medical Center |
Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
|
US10010502B2
(en)
|
2015-05-19 |
2018-07-03 |
Amorphex Therapeutics Llc |
Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
|
CN108368147A
(zh)
|
2015-05-27 |
2018-08-03 |
南方研究院 |
用于治疗癌症的核苷酸
|
WO2016196664A1
(en)
|
2015-06-01 |
2016-12-08 |
Cedars-Sinai Medical Center |
Methods and use of compounds that bind to rela of nf-kb
|
WO2016202721A1
(en)
|
2015-06-16 |
2016-12-22 |
F. Hoffmann-La Roche Ag |
Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
|
US20190015396A1
(en)
|
2015-06-23 |
2019-01-17 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
KR20180023968A
(ko)
|
2015-07-02 |
2018-03-07 |
셀진 코포레이션 |
혈액암 및 충실성 종양의 치료를 위한 병용 요법
|
PT3456717T
(pt)
|
2015-07-06 |
2021-05-26 |
Gilead Sciences Inc |
Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias
|
MX2018001075A
(es)
|
2015-07-28 |
2019-04-15 |
Vyome Therapeutics Ltd |
Agentes terapeuticos y profilacticos antibacterianos.
|
AU2016303688B2
(en)
|
2015-07-31 |
2023-06-15 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
PT3640345T
(pt)
|
2015-08-17 |
2021-12-29 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
KR20180050679A
(ko)
|
2015-08-27 |
2018-05-15 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
통증 치료용 조성물 및 방법
|
EP3347486A4
(en)
|
2015-09-09 |
2019-06-19 |
The Trustees of Columbia University in the City of New York |
REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
|
US10172842B2
(en)
|
2015-09-11 |
2019-01-08 |
PharmaDax Inc. |
Sustained release oral dosage form containing dalfampridine
|
US10457627B2
(en)
|
2015-09-23 |
2019-10-29 |
Xw Laboratories Inc. |
Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
|
WO2017058828A1
(en)
|
2015-09-28 |
2017-04-06 |
Children's Hospital Los Angeles |
Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
|
AU2016329201A1
(en)
|
2015-09-30 |
2018-04-26 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
UA126549C2
(uk)
|
2015-10-01 |
2022-11-02 |
Хіт Байолоджикс, Інк. |
Композиція і спосіб для з'єднання позаклітинних доменів типу і та типу іі як гетерологічного химерного білка
|
US10335406B2
(en)
|
2015-10-01 |
2019-07-02 |
Elysium Therapeutics, Inc. |
Opioid compositions resistant to overdose and abuse
|
US9808452B2
(en)
|
2015-10-01 |
2017-11-07 |
Elysium Therapeutics, Inc. |
Polysubunit opioid prodrugs resistant to overdose and abuse
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP3365027B1
(en)
|
2015-10-14 |
2022-03-30 |
Research Institute at Nationwide Children's Hospital |
Hu specific antibodies and their use in inhibiting biofilm
|
WO2017064657A1
(en)
|
2015-10-16 |
2017-04-20 |
Invictus Oncology Pvt. Ltd. |
Fluorescent anticancer platinum drugs
|
US10342778B1
(en)
|
2015-10-20 |
2019-07-09 |
Epicentrx, Inc. |
Treatment of brain metastases using organonitro compound combination therapy
|
US9987270B1
(en)
|
2015-10-29 |
2018-06-05 |
Epicentrix, Inc. |
Treatment of gliomas using organonitro compound combination therapy
|
HUE065406T2
(hu)
|
2015-10-30 |
2024-05-28 |
Neurocrine Biosciences Inc |
Valbenazin-dihidroklorid sók és polimorfjaik
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
CA3003969A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
EP3373916A1
(en)
|
2015-11-11 |
2018-09-19 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
MX2018007421A
(es)
|
2015-12-17 |
2018-08-15 |
Gilead Sciences Inc |
Compuestos inhibidores de quinasa de union a tank.
|
DK3394057T3
(da)
|
2015-12-23 |
2022-04-11 |
Neurocrine Biosciences Inc |
Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
WO2017117478A1
(en)
|
2015-12-31 |
2017-07-06 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
MX367669B
(es)
|
2016-01-08 |
2019-08-30 |
Celgene Corp |
Compuestos antiproliferativos y sus composiciones farmacéuticas y usos.
|
TWI733734B
(zh)
|
2016-01-08 |
2021-07-21 |
美商西建公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧六氫吡啶-3-基)-1-氧基異吲哚啉-5-基)甲基)-2,2-二氟乙醯胺之固體型式,及其醫藥組合物及用途
|
US10648983B2
(en)
|
2016-01-08 |
2020-05-12 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
DK3402480T3
(da)
|
2016-01-11 |
2021-06-28 |
Epicentrx Inc |
Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon
|
EP3411407B1
(en)
|
2016-02-05 |
2024-04-03 |
Orionis Biosciences BV |
Bispecific signaling agents and uses thereof
|
EP3848373A1
(en)
|
2016-02-19 |
2021-07-14 |
Phoenix Molecular Designs |
N-(1-((heterocyclyl)methyl)-1h-pyrazol-4-yl)-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
|
US20190119236A1
(en)
|
2016-02-23 |
2019-04-25 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
WO2017152062A1
(en)
|
2016-03-04 |
2017-09-08 |
Gilead Sciences, Inc. |
Compositions and combinations of autotaxin inhibitors
|
CA3055170A1
(en)
|
2016-03-04 |
2017-09-08 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
JP2019507762A
(ja)
|
2016-03-07 |
2019-03-22 |
ブイアイビー ブイゼットダブリュー |
Cd20結合単一ドメイン抗体
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017168174A1
(en)
|
2016-04-02 |
2017-10-05 |
N4 Pharma Uk Limited |
New pharmaceutical forms of sildenafil
|
CA3020681A1
(en)
|
2016-04-11 |
2017-10-19 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
EP3448851B8
(en)
|
2016-04-29 |
2022-04-27 |
FGH BioTech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
EP3452473A1
(en)
|
2016-05-04 |
2019-03-13 |
Purdue Pharma L.P. |
Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
US11753463B2
(en)
|
2016-05-13 |
2023-09-12 |
Orionis Biosciences BV |
Therapeutic targeting of non-cellular structures
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
MX2018013985A
(es)
|
2016-05-20 |
2019-08-22 |
Xenon Pharmaceuticals Inc |
Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos.
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
CA3029457A1
(en)
|
2016-06-30 |
2018-01-04 |
Gilead Sciences, Inc. |
4,6-diaminoquinazolines as cot modulators and methods of use thereof
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
RU2744615C2
(ru)
|
2016-07-18 |
2021-03-11 |
Фармена С.А. |
Использование 1-метилникотинамида для лечения заболеваний, связанных с c-реактивным белком
|
JOP20190008A1
(ar)
|
2016-07-26 |
2019-01-24 |
Purdue Pharma Lp |
علاج ومنع اضطرابات النوم
|
EP3490607A4
(en)
|
2016-07-29 |
2020-04-08 |
Sunovion Pharmaceuticals Inc. |
COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
|
WO2018023072A2
(en)
|
2016-07-29 |
2018-02-01 |
Sunovion Pharmaceuticals, Inc. |
Compounds and compositions and uses thereof
|
US10292983B2
(en)
|
2016-08-03 |
2019-05-21 |
Cymabay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
CA3036195A1
(en)
|
2016-09-07 |
2018-03-15 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
US10736905B1
(en)
|
2016-09-09 |
2020-08-11 |
Shahin Fatholahi |
Nefopam dosage forms and methods of treatment
|
WO2018053190A1
(en)
|
2016-09-14 |
2018-03-22 |
Gilead Sciences, Inc. |
Syk inhibitors
|
TW201822764A
(zh)
|
2016-09-14 |
2018-07-01 |
美商基利科學股份有限公司 |
Syk抑制劑
|
KR20190058550A
(ko)
|
2016-09-19 |
2019-05-29 |
메이 파마, 아이엔씨. |
병용 요법
|
WO2018057808A1
(en)
|
2016-09-23 |
2018-03-29 |
Gilead Sciences, Inc. |
Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2018069312A1
(en)
|
2016-10-11 |
2018-04-19 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) |
Treatment of synucleinopathies
|
SG11201903312VA
(en)
|
2016-10-14 |
2019-05-30 |
Epicentrix Inc |
Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
|
WO2018071814A1
(en)
|
2016-10-14 |
2018-04-19 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
EP3528805B1
(en)
|
2016-10-21 |
2023-12-06 |
Cedars-Sinai Medical Center |
Simvastatin and chemotherapeutic conjugates comprising a heptamethine carbocyanine dye for resensitising human tumors to hormonal antagonists and chemotherapy
|
US11084859B2
(en)
|
2016-10-24 |
2021-08-10 |
Orionis Biosciences BV |
Targeted mutant interferon-gamma and uses thereof
|
DK3534885T3
(da)
|
2016-11-03 |
2021-04-12 |
Kura Oncology Inc |
Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft
|
TW201828932A
(zh)
|
2016-11-09 |
2018-08-16 |
美商諾沃麥迪斯有限責任公司 |
1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
BR112019010880A2
(pt)
|
2016-11-28 |
2019-10-01 |
Praxis Prec Medicines Inc |
compostos e seus métodos de uso
|
US11261188B2
(en)
|
2016-11-28 |
2022-03-01 |
Praxis Precision Medicines, Inc. |
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
|
AR110252A1
(es)
|
2016-11-30 |
2019-03-13 |
Gilead Sciences Inc |
Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
|
CN110191705A
(zh)
|
2016-12-01 |
2019-08-30 |
亚尼塔公司 |
治疗癌症的方法
|
WO2018102673A1
(en)
|
2016-12-02 |
2018-06-07 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
MA48583A
(fr)
|
2016-12-09 |
2021-04-21 |
Xenon Pharmaceuticals Inc |
Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
|
WO2018115888A1
(en)
|
2016-12-21 |
2018-06-28 |
N4 Pharma Uk Limited |
Novel formulations of aprepitant
|
US10784877B2
(en)
|
2016-12-21 |
2020-09-22 |
Johnson & Johnson Vision Care, Inc. |
Extended period timer circuits for ophthalmic devices
|
US11564982B2
(en)
|
2017-01-04 |
2023-01-31 |
Research Institute At Nationwide Children's Hospital |
DNABII vaccines and antibodies with enhanced activity
|
EP3565834A1
(en)
|
2017-01-04 |
2019-11-13 |
The Research Institute at Nationwide Children's Hospital |
Antibody fragments for the treatment of biofilm-related disorders
|
KR20230038601A
(ko)
|
2017-01-27 |
2023-03-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
JP7062010B2
(ja)
|
2017-01-27 |
2022-05-02 |
セルジーン コーポレイション |
3-(1-オキソ-4-((4-((3-オキソモルホリノ)メチル)ベンジル)オキシ)イソインドリン-2-イル)ピペリジン-2,6-ジオン及びそのアイソトポログ
|
EP3576765A4
(en)
|
2017-02-06 |
2020-12-02 |
Orionis Biosciences, Inc. |
TARGETED ENGINEERING INTERFERON AND USES OF IT
|
JOP20180009A1
(ar)
|
2017-02-06 |
2019-01-30 |
Gilead Sciences Inc |
مركبات مثبط فيروس hiv
|
JP7476467B2
(ja)
|
2017-02-06 |
2024-05-01 |
オリオンズ バイオサイエンス ビーブイ |
標的化キメラタンパク質及びその使用
|
CA3049690C
(en)
|
2017-02-06 |
2023-03-21 |
Spero Therapeutics, Inc. |
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
|
CA3050601A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzm |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
WO2018148745A1
(en)
|
2017-02-13 |
2018-08-16 |
Praxis Precision Medicines , Inc. |
Compounds and their methods of use
|
EP3582815A1
(en)
|
2017-02-16 |
2019-12-25 |
Sunovion Pharmaceuticals Inc. |
Methods of treating schizophrenia
|
EP3432883B1
(en)
|
2017-02-21 |
2021-07-28 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US11192933B2
(en)
|
2017-02-27 |
2021-12-07 |
Shattuck Labs, Inc. |
VSIG8-based chimeric proteins
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
WO2018165142A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
CA3056239C
(en)
|
2017-03-17 |
2023-09-12 |
Elysium Therapeutics, Inc. |
Polysubunit opioid prodrugs resistant to overdose and abuse
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
MX2019010174A
(es)
|
2017-03-26 |
2019-10-15 |
Mapi Pharma Ltd |
Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
|
CN110799192A
(zh)
|
2017-03-27 |
2020-02-14 |
加利福尼亚大学董事会 |
治疗癌症的组合物和方法
|
EP3601291A1
(en)
|
2017-03-29 |
2020-02-05 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
JP2020515611A
(ja)
|
2017-03-29 |
2020-05-28 |
サイトワン セラピューティクス, インコーポレイテッド |
疼痛の処置のための11,13−修飾サキシトキシン
|
US11731966B2
(en)
|
2017-04-04 |
2023-08-22 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
WO2018195471A1
(en)
|
2017-04-21 |
2018-10-25 |
Gilead Sciences, Inc. |
Syk inhibitors in combination with hypomethylating agents
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
CN111093658B
(zh)
|
2017-05-19 |
2022-10-14 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
|
US11161845B2
(en)
|
2017-05-19 |
2021-11-02 |
Nflection Therapeutics, Inc. |
Pyrrolopyridine-aniline compounds for treatment of dermal disorders
|
US20200155526A1
(en)
|
2017-05-31 |
2020-05-21 |
The Children's Medical Center Corporation |
Targeting lysine demethylases (kdms) as a therapeutic strategy for diffuse large b-cell lymphoma
|
JP2020522504A
(ja)
|
2017-06-01 |
2020-07-30 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc |
多環式化合物およびそれらの用途
|
US11400136B2
(en)
|
2017-06-19 |
2022-08-02 |
President And Fellows Of Harvard College |
Methods and compositions for treating a microbial infection
|
WO2019005874A1
(en)
|
2017-06-26 |
2019-01-03 |
The Trustees Of Columbia University In The City Of New York |
CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
|
BR112020000196A2
(pt)
|
2017-07-07 |
2020-07-07 |
Epicentrx, Inc. |
composições para administração parenteral de agentes terapêuticos
|
US11168326B2
(en)
|
2017-07-11 |
2021-11-09 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
JP7191085B2
(ja)
|
2017-08-02 |
2022-12-16 |
サノビオン ファーマシューティカルズ インク |
イソクロマン化合物およびその使用
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
MY200746A
(en)
|
2017-08-07 |
2024-01-13 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2019035951A1
(en)
|
2017-08-15 |
2019-02-21 |
Praxis Precision Medicines, Inc. |
COMPOUNDS AND THEIR METHODS OF USE
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
AR112413A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas sólidas de un inhibidor de la cápside del vih
|
JP6934562B2
(ja)
|
2017-08-22 |
2021-09-15 |
ギリアード サイエンシーズ, インコーポレイテッド |
治療用複素環式化合物
|
US11446311B2
(en)
|
2017-09-08 |
2022-09-20 |
Shahin Fatholahi |
Methods for treating pain associated with sickle cell disease
|
US10736874B1
(en)
|
2017-09-08 |
2020-08-11 |
Shahin Fatholahi |
Methods for treating pain associated with sickle cell disease
|
CA3076000A1
(en)
|
2017-09-21 |
2019-03-28 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
EP3691658A4
(en)
|
2017-10-04 |
2021-06-23 |
The Regents of The University of California |
IMMUNOMODULATOR OLIGOSACCHARIDES
|
US20200230127A1
(en)
|
2017-10-10 |
2020-07-23 |
Neurocrine Biosciences, Inc. |
Methods for the Administration of Certain VMAT2 Inhibitors
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
US20200340060A1
(en)
|
2017-11-13 |
2020-10-29 |
Gilead Sciences, Inc. |
Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
|
EP3713916A1
(en)
|
2017-11-20 |
2020-09-30 |
Kiakos, Konstantinos |
3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
CA3088630A1
(en)
|
2017-12-15 |
2019-06-20 |
Solarea Bio, Inc. |
Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
|
WO2019126136A2
(en)
|
2017-12-18 |
2019-06-27 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
WO2019133901A1
(en)
|
2017-12-28 |
2019-07-04 |
Reviva Pharmaceuticals, Inc. |
Methods for treating pulmonary fibrosis
|
US11510901B2
(en)
|
2018-01-08 |
2022-11-29 |
Epicentrx, Inc. |
Methods and compositions utilizing RRx-001 combination therapy for radioprotection
|
TWI823890B
(zh)
|
2018-01-10 |
2023-12-01 |
美商克拉治療有限責任公司 |
包含苯基磺醯胺之醫藥組合物及其治療應用
|
US20210052529A1
(en)
|
2018-01-10 |
2021-02-25 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
AU2019212435B2
(en)
|
2018-01-24 |
2022-03-10 |
Purdue Pharma L. P. |
Sleep disorder treatment and prevention
|
AU2019215440A1
(en)
|
2018-02-05 |
2020-08-27 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
EP3752532A1
(en)
|
2018-02-12 |
2020-12-23 |
Diabetes-Free, Inc. |
Improved antagonistic anti-human cd40 monoclonal antibodies
|
AU2019221568B2
(en)
|
2018-02-15 |
2021-04-22 |
Gilead Sciences, Inc. |
Pyridine derivatives and their use for treating HIV infection
|
WO2019161307A1
(en)
|
2018-02-16 |
2019-08-22 |
Esperion Therapeutics, Inc. |
Sustained release formulations of bempedoic acid
|
US20210008030A1
(en)
|
2018-02-16 |
2021-01-14 |
Sunovion Pharmaceuticals Inc. |
Methods of treating social function disorders
|
PL3752496T3
(pl)
|
2018-02-16 |
2023-11-27 |
Gilead Sciences, Inc. |
Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae
|
JP7354123B2
(ja)
|
2018-02-21 |
2023-10-02 |
エイアイ・セラピューティクス・インコーポレーテッド |
アピリモドとグルタミン酸作動薬を用いた併用療法
|
US11759417B2
(en)
|
2018-02-28 |
2023-09-19 |
Shanghai Wd Pharmaceutical Co., Ltd |
Pharmaceutical composition and preparation method therefor and use thereof
|
MX2020008972A
(es)
|
2018-03-02 |
2020-10-05 |
Univ Oregon Health & Science |
Profármacos de amidas de moduladores de receptores nucleares de moléculas pequeñas.
|
JP7384815B2
(ja)
|
2018-03-22 |
2023-11-21 |
ザ チルドレンズ メディカル センター コーポレーション |
肺の修復に関する方法および組成物
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
US11911513B2
(en)
|
2018-05-23 |
2024-02-27 |
Shanghai Wd Pharmaceutical Co., Ltd |
Controlled-release system of active pharmaceutical ingredient and preparation method therefor
|
CN112118886B
(zh)
|
2018-05-23 |
2022-08-23 |
上海汉都医药科技有限公司 |
活性药物成分的控释系统及其制备方法
|
EP3801535A4
(en)
|
2018-05-30 |
2022-03-02 |
Praxis Precision Medicines, Inc. |
ION CHANNEL MODULATORS
|
CN112262142B
(zh)
|
2018-06-13 |
2023-11-14 |
泽农医药公司 |
苯磺酰胺化合物及其作为治疗剂的用途
|
KR20210021006A
(ko)
|
2018-06-14 |
2021-02-24 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
Vmat2 억제제 화합물, 조성물 및 그와 관련된 방법
|
CA3105352A1
(en)
|
2018-06-29 |
2020-01-02 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
AU2019297362B2
(en)
|
2018-07-06 |
2022-05-26 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
JP7199502B2
(ja)
|
2018-07-06 |
2023-01-05 |
ギリアード サイエンシーズ, インコーポレイテッド |
治療用複素環式化合物
|
KR20210030973A
(ko)
|
2018-07-11 |
2021-03-18 |
액팀 테라퓨틱스, 인코퍼레이티드 |
조작된 면역자극성 박테리아 균주 및 이의 용도
|
AU2019307500B2
(en)
|
2018-07-16 |
2022-09-29 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of HIV
|
PE20211065A1
(es)
|
2018-07-27 |
2021-06-09 |
Xenon Pharmaceuticals Inc |
Metodo para tratar la epilepsia
|
TWI829205B
(zh)
|
2018-07-30 |
2024-01-11 |
美商基利科學股份有限公司 |
抗hiv化合物
|
US11945813B2
(en)
|
2018-08-07 |
2024-04-02 |
Firmenich Incorporated |
5-substituted 4-amino-1H-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
|
EP3836926A4
(en)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences, Inc. |
METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
|
CN112912141A
(zh)
|
2018-08-27 |
2021-06-04 |
斯皮诺吉尼克斯公司 |
用于树突棘生成的肌成束蛋白结合化合物
|
US12030858B2
(en)
|
2018-08-27 |
2024-07-09 |
Oregon Health & Science University |
PARP inhibitors for treating cancer and asthma
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
CA3109354A1
(en)
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Combination therapies comprising pd-1-based chimeric proteins
|
EP3844158A1
(en)
|
2018-08-31 |
2021-07-07 |
Xenon Pharmaceuticals Inc. |
Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
|
JP7450606B2
(ja)
|
2018-08-31 |
2024-03-15 |
ゼノン・ファーマシューティカルズ・インコーポレイテッド |
ヘテロアリール置換スルホンアミド化合物および治療剤としてのそれらの使用
|
CA3111795A1
(en)
|
2018-09-05 |
2020-03-12 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases
|
US11980647B2
(en)
|
2018-09-05 |
2024-05-14 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
EP3860975B1
(en)
|
2018-10-01 |
2023-10-18 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin for the treatment of sickle cell disease
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
EP3860714B1
(en)
|
2018-10-03 |
2023-09-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
CN113227089B
(zh)
|
2018-10-31 |
2024-07-05 |
吉利德科学公司 |
作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
|
CA3117968A1
(en)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10570127B1
(en)
|
2018-11-05 |
2020-02-25 |
Renexxion, Llc |
Material and methods for the treatment of gastro-intestinal disorders
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
RS62970B1
(sr)
|
2018-11-19 |
2022-03-31 |
Global Blood Therapeutics Inc |
2-formil-3-hidroksifeniloksimetil jedinjenja sposobna da moduliraju hemoglobin
|
JP7393808B2
(ja)
|
2018-11-20 |
2023-12-07 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのナフチリジノン-アニリン化合物
|
JP7406264B2
(ja)
|
2018-11-20 |
2023-12-27 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのシアノアリール-アニリン化合物
|
JP2022511127A
(ja)
|
2018-11-20 |
2022-01-28 |
エヌフレクション セラピューティクス インコーポレイテッド |
あざの処置のためのアリールアニリンおよびヘテロアリールアニリン化合物
|
EP4233865A3
(en)
|
2018-11-20 |
2023-09-27 |
NFlection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
JP2022513159A
(ja)
|
2018-11-29 |
2022-02-07 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
Rnaを調節する方法
|
JP2022513449A
(ja)
|
2018-12-12 |
2022-02-08 |
オートバーン セラピューティクス,インク. |
新規な甲状腺模倣物
|
ES2934492T3
(es)
|
2018-12-13 |
2023-02-22 |
Global Blood Therapeutics Inc |
Inhibidores de ferroportina y métodos de uso
|
JP7407461B2
(ja)
|
2018-12-19 |
2024-01-04 |
シャイ・セラピューティクス・エルエルシー |
がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
|
CA3124616A1
(en)
|
2018-12-21 |
2020-06-25 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
US20220133894A1
(en)
|
2019-02-06 |
2022-05-05 |
Oregon Health & Science University |
Bisphosphonate-linked compounds
|
WO2020163554A1
(en)
|
2019-02-06 |
2020-08-13 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
CN113677681A
(zh)
|
2019-02-11 |
2021-11-19 |
凤凰分子设计公司 |
Rsk抑制剂的结晶形式
|
CA3130848A1
(en)
|
2019-02-22 |
2020-08-27 |
Kronos Bio, Inc. |
Solid forms of condensed pyrazines as syk inhibitors
|
JP2022521431A
(ja)
|
2019-02-25 |
2022-04-07 |
シーエイチディーアイ ファウンデーション,インコーポレーテッド |
変異型ハンチンチンタンパク質を標的とするための化合物及びその使用
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
KR20220004959A
(ko)
|
2019-02-27 |
2022-01-12 |
액팀 테라퓨틱스, 인코퍼레이티드 |
종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3931180A1
(en)
|
2019-03-01 |
2022-01-05 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
US11597703B2
(en)
|
2019-03-07 |
2023-03-07 |
Histogen, Inc. |
Caspase inhibitors and methods of use thereof
|
MX2021010880A
(es)
|
2019-03-14 |
2022-01-18 |
Sunovion Pharmaceuticals Inc |
Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
EP3941900A1
(en)
|
2019-03-22 |
2022-01-26 |
Deutsches Krebsforschungszentrum |
Novel inhibitors of histone deacetylase 10
|
EP3712127A1
(en)
|
2019-03-22 |
2020-09-23 |
Deutsches Krebsforschungszentrum |
Novel inhibitors of histone deacetylase 10
|
US11000488B2
(en)
|
2019-03-22 |
2021-05-11 |
Syntrix Biosystems Inc. |
Treating pain using desmetramadol
|
CN113795253A
(zh)
|
2019-03-29 |
2021-12-14 |
库拉肿瘤学公司 |
用法呢基转移酶抑制剂治疗鳞状细胞癌的方法
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
JP2022527825A
(ja)
|
2019-04-03 |
2022-06-06 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
薬物送達のためのイオン液体
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
KR20220016086A
(ko)
|
2019-05-03 |
2022-02-08 |
프락시스 프리시젼 메디신즈, 인크. |
Kcnt1 억제제 및 사용 방법
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
US11773099B2
(en)
|
2019-05-28 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
US11279700B2
(en)
|
2019-05-31 |
2022-03-22 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
US11505554B2
(en)
|
2019-05-31 |
2022-11-22 |
Praxis Precision Medicines, Inc. |
Substituted pyridines as ion channel modulators
|
CN113874375A
(zh)
|
2019-06-03 |
2021-12-31 |
株式会社大分大学先端医学研究所 |
用于治疗狂犬病的环状酰胺化合物及其方法
|
TW202235416A
(zh)
|
2019-06-14 |
2022-09-16 |
美商基利科學股份有限公司 |
Cot 調節劑及其使用方法
|
EP3986163A2
(en)
|
2019-06-19 |
2022-04-27 |
Solarea Bio, Inc. |
Microbial compositions and methods for producing upgraded probiotic assemblages
|
US20220275064A1
(en)
|
2019-07-08 |
2022-09-01 |
Research Institute At Nationwide Children's Hospital |
Antibody compositions for disrupting biofilms
|
AU2020310190A1
(en)
|
2019-07-11 |
2022-02-24 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
JP2022540253A
(ja)
|
2019-07-11 |
2022-09-14 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
T型カルシウムチャネル調節因子の製剤およびその使用方法
|
EP3997068A1
(en)
|
2019-07-11 |
2022-05-18 |
Cura Therapeutics, LLC |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
EP4003314B1
(en)
|
2019-07-26 |
2024-07-10 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
|
US10792262B1
(en)
|
2019-07-29 |
2020-10-06 |
Saol International Limited |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US11654124B2
(en)
|
2019-07-29 |
2023-05-23 |
Amneal Pharmaceuticals Llc |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
EP4021479A2
(en)
|
2019-08-27 |
2022-07-06 |
Tonix Pharma Limited |
Modified tff2 polypeptides
|
KR20220101075A
(ko)
|
2019-09-16 |
2022-07-19 |
다이스 알파, 인크. |
Il-17a 조절인자 및 이의 용도
|
JP2022551422A
(ja)
|
2019-09-26 |
2022-12-09 |
エグゼリクシス, インコーポレイテッド |
ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
|
US20230008367A1
(en)
|
2019-09-26 |
2023-01-12 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
TW202126631A
(zh)
|
2019-10-01 |
2021-07-16 |
美商分子皮膚療法公司 |
作為klk5/7雙重抑制劑之苯并酮化合物
|
TW202128627A
(zh)
|
2019-10-10 |
2021-08-01 |
加拿大商再諾製藥公司 |
選擇性鉀通道調節劑之固態晶型
|
CN114929676A
(zh)
|
2019-11-01 |
2022-08-19 |
紫丁香疗法有限公司 |
作为乙醇酸氧化酶抑制剂的杂环羧酸酯化合物
|
KR20220113943A
(ko)
|
2019-11-12 |
2022-08-17 |
액팀 테라퓨틱스, 인코퍼레이티드 |
면역자극성 박테리아 전달 플랫폼 및 치료 제품의 전달을 위한 이의 용도
|
KR20220101099A
(ko)
|
2019-11-13 |
2022-07-19 |
랩트 테라퓨틱스, 인크. |
C-c 케모카인 수용체 유형 4 길항제의 결정 형태 및 이의 용도
|
AU2020388387A1
(en)
|
2019-11-22 |
2022-06-02 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
AU2020391466B2
(en)
|
2019-11-26 |
2024-05-23 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of HIV
|
KR20220121238A
(ko)
|
2019-11-27 |
2022-08-31 |
프락시스 프리시젼 메디신즈, 인크. |
이온 채널 조절제의 제형 및 이온 채널 조절제의 제조 및 사용 방법
|
KR20220110243A
(ko)
|
2019-12-02 |
2022-08-05 |
셀진 코포레이션 |
암의 치료를 위한 요법
|
JP7453399B2
(ja)
|
2020-02-24 |
2024-03-19 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hiv感染症を治療するための四環式化合物及びその使用
|
CA3171473A1
(en)
|
2020-02-24 |
2021-09-02 |
Exelixis, Inc. |
Compounds and methods of use
|
US20230093147A1
(en)
|
2020-03-09 |
2023-03-23 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
CA3175541A1
(en)
|
2020-03-30 |
2021-10-07 |
Gilead Sciences, Inc. |
Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
|
CA3176429A1
(en)
|
2020-03-31 |
2021-10-07 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin
|
WO2021202796A1
(en)
|
2020-04-01 |
2021-10-07 |
Global Blood Therapeutics, Inc. |
Pyrrolidine-pyrazoles as pyruvate kinase activators
|
KR20220160645A
(ko)
|
2020-04-02 |
2022-12-06 |
길리애드 사이언시즈, 인코포레이티드 |
Cot 저해제 화합물의 제조 방법
|
CA3180661A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Cycloalkyl pyrimidines as ferroportin inhibitors
|
WO2021222359A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Thieno pyrimidines as ferroportin inhibitors
|
CA3181583A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
CN115996751A
(zh)
|
2020-04-28 |
2023-04-21 |
哈佛大学校长及研究员协会 |
与离子液体佐剂有关的方法和组合物
|
WO2021226033A1
(en)
|
2020-05-07 |
2021-11-11 |
President And Fellows Of Harvard College |
Hyaluronic acid drug conjugates
|
US20230173095A1
(en)
|
2020-05-29 |
2023-06-08 |
President And Fellows Of Harvard College |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
PL4153136T3
(pl)
|
2020-06-10 |
2024-06-24 |
Auspex Pharmaceuticals, Inc. |
Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowania
|
WO2021257828A1
(en)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
US20230102840A1
(en)
|
2020-06-23 |
2023-03-30 |
President And Fellows Of Harvard College |
Compositions and methods relating to combinatorial hyaluronic acid conjugates
|
AU2021296607B2
(en)
|
2020-06-25 |
2024-07-25 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of HIV
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
WO2022006228A1
(en)
|
2020-06-30 |
2022-01-06 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
WO2022008976A1
(en)
|
2020-07-10 |
2022-01-13 |
Institut Pasteur |
Use of gdf11 to diagnose and treat anxiety and depression
|
EP4188542A1
(en)
|
2020-08-03 |
2023-06-07 |
Global Blood Therapeutics, Inc. |
Urea derivatives as pyruvate kinase activators
|
EP4196139A2
(en)
|
2020-08-12 |
2023-06-21 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
AU2021326546A1
(en)
|
2020-08-14 |
2023-04-13 |
Siteone Therapeutics, Inc. |
Non-hydrated ketone inhibitors of NaV1.7 for the treatment of pain
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
TW202222798A
(zh)
|
2020-09-30 |
2022-06-16 |
美商基利科學股份有限公司 |
橋接三環胺甲醯基吡啶酮化合物及其用途
|
WO2022069701A1
(en)
|
2020-10-01 |
2022-04-07 |
Nogra Pharma Limited |
Methods of treating pulmonary fibrosis
|
US20220133669A1
(en)
|
2020-10-30 |
2022-05-05 |
Ds Biopharma Limited |
Pharmaceutical compositions comprising 15-hetre and methods of use thereof
|
US11773088B2
(en)
|
2020-11-02 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
KCNT1 inhibitors and methods of use
|
EP4267559A1
(en)
|
2020-12-22 |
2023-11-01 |
Gilead Sciences, Inc. |
Substituted indole compounds
|
TW202241419A
(zh)
|
2020-12-22 |
2022-11-01 |
美商基利科學股份有限公司 |
6-取代之吲哚化合物
|
WO2022155410A1
(en)
|
2021-01-15 |
2022-07-21 |
President And Fellows Of Harvard College |
Methods and compositions relating to anti-mfsd2a antibodies
|
KR20230134529A
(ko)
|
2021-01-19 |
2023-09-21 |
길리애드 사이언시즈, 인코포레이티드 |
치환된 피리도트리아진 화합물 및 이의 용도
|
US20240115607A1
(en)
|
2021-01-26 |
2024-04-11 |
Cytocares (Shanghai) Inc. |
Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
|
WO2022164997A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
TW202245758A
(zh)
|
2021-02-08 |
2022-12-01 |
美商全球血液治療公司 |
作為丙酮酸激酶活化劑之吡咯啶-吡唑
|
JP2024505721A
(ja)
|
2021-02-09 |
2024-02-07 |
ギリアード サイエンシーズ, インコーポレイテッド |
チエノピロール化合物
|
WO2022178205A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
WO2022187573A1
(en)
|
2021-03-05 |
2022-09-09 |
President And Fellows Of Harvard College |
Methods and compositions relating to cell membrane hybridization and camouflaging
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
CR20230472A
(es)
|
2021-03-10 |
2024-03-21 |
Dice Molecules Sv Inc |
Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
|
WO2022198002A1
(en)
|
2021-03-19 |
2022-09-22 |
Tiba Biotech Llc |
Artificial alphavirus-derived rna replicon expression systems
|
TW202302598A
(zh)
|
2021-04-16 |
2023-01-16 |
美商基利科學股份有限公司 |
噻吩并吡咯化合物
|
EP4326721A1
(en)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
EP4337659A1
(en)
|
2021-05-14 |
2024-03-20 |
Global Blood Therapeutics, Inc. |
Solid forms of a modulator of hemoglobin
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
TW202304435A
(zh)
|
2021-06-04 |
2023-02-01 |
美商基利科學股份有限公司 |
治療nash之方法
|
WO2022265880A1
(en)
|
2021-06-16 |
2022-12-22 |
President And Fellows Of Harvard College |
Improved methods and compositions for drug delivery relating to ionic liquids
|
WO2022266370A1
(en)
|
2021-06-17 |
2022-12-22 |
Aria Pharmaceuticals, Inc. |
Sparsentan for treating idiopathic pulmonary fibrosis
|
TW202311256A
(zh)
|
2021-06-18 |
2023-03-16 |
美商基利科學股份有限公司 |
用於治療fxr誘發之搔癢之il-31調節劑
|
WO2022271537A1
(en)
|
2021-06-25 |
2022-12-29 |
President And Fellows Of Harvard College |
Compositions and methods relating to injectable microemulsions
|
WO2023278843A2
(en)
|
2021-07-02 |
2023-01-05 |
Acer Therapeutics, Inc. |
Solid forms of osanetant
|
CN117980309A
(zh)
|
2021-08-05 |
2024-05-03 |
百时美施贵宝公司 |
用作her2抑制剂的三环稠合嘧啶化合物
|
EP4396380A1
(en)
|
2021-09-01 |
2024-07-10 |
Flagship Pioneering Innovations VI, LLC |
In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
|
WO2023034506A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin
|
EP4396331A1
(en)
|
2021-09-01 |
2024-07-10 |
Flagship Pioneering Innovations VI, LLC |
Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
|
EP4396578A1
(en)
|
2021-09-01 |
2024-07-10 |
Flagship Pioneering Innovations VI, LLC |
Methods and compositions for promoting adipocyte beiging
|
WO2023034530A1
(en)
|
2021-09-02 |
2023-03-09 |
Teon Therapeutics, Inc. |
Methods of improving growth and function of immune cells
|
WO2023039162A1
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating enteroendocrine cells
|
WO2023039164A2
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating goblet cells and for muco-obstructive diseases
|
EP4398989A1
(en)
|
2021-09-10 |
2024-07-17 |
Gilead Sciences, Inc. |
Thienopyrrole compounds
|
WO2023043827A2
(en)
|
2021-09-14 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for perturbing monocyte and neutrophil lineages
|
TW202328120A
(zh)
|
2021-09-24 |
2023-07-16 |
加拿大商再諾製藥公司 |
做為鈉通道活化劑之吡啶衍生物及其用途
|
CA3231743A1
(en)
|
2021-09-24 |
2023-03-30 |
Xenon Pharmaceuticals Inc. |
Pyridinylacetamide derivatives as sodium channel activators
|
CN118251389A
(zh)
|
2021-09-24 |
2024-06-25 |
泽农医药公司 |
作为钠通道活化剂的吡啶基衍生物
|
WO2023055457A1
(en)
|
2021-09-29 |
2023-04-06 |
Amneal Pharmaceuticals Llc |
Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
|
WO2023060134A1
(en)
|
2021-10-06 |
2023-04-13 |
Global Blood Therapeutics, Inc. |
Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
|
WO2023059846A1
(en)
|
2021-10-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
EP4162933A1
(en)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Compound for treating non-alcoholic fatty liver disease and related diseases
|
WO2023069770A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
WO2023076404A1
(en)
|
2021-10-27 |
2023-05-04 |
Aria Pharmaceuticals, Inc. |
Methods for treating systemic lupus erythematosus
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
AU2022391767A1
(en)
|
2021-11-22 |
2024-07-04 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
WO2023097233A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097234A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097230A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023102378A1
(en)
|
2021-11-30 |
2023-06-08 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
CN118355020A
(zh)
|
2021-12-03 |
2024-07-16 |
吉利德科学公司 |
Hiv病毒感染的治疗性化合物
|
US20230212148A1
(en)
|
2021-12-03 |
2023-07-06 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
IL312718A
(en)
|
2021-12-03 |
2024-07-01 |
Gilead Sciences Inc |
Therapeutic compounds for HIV infection
|
TW202339732A
(zh)
|
2021-12-10 |
2023-10-16 |
美商全球血液治療公司 |
投予血紅素調節劑的方法
|
US20230190834A1
(en)
|
2021-12-21 |
2023-06-22 |
Solarea Bio, Inc. |
Immunomodulatory compositions comprising microbial entities
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023129576A2
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
WO2023137178A1
(en)
|
2022-01-17 |
2023-07-20 |
Chandrasekhar Satishchandran |
Combinations of vitamin d3, niacinamide and lipoic acid for use in the maintenance of healthy blood glucose levels
|
WO2023147135A1
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Nk receptor antagonists for treatment of prostate cancer
|
WO2023147134A2
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Methods for treating patients having low estrogen with nk3 antagonists
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023178283A1
(en)
|
2022-03-18 |
2023-09-21 |
Epicentrx, Inc. |
Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
|
TW202400593A
(zh)
|
2022-03-28 |
2024-01-01 |
美商艾索司特瑞克斯公司 |
Myst家族離胺酸乙醯轉移酶之抑制劑
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
WO2023192506A1
(en)
|
2022-03-31 |
2023-10-05 |
Rarified Biosciences, Inc. |
Malt1 modulators and uses thereof
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
TW202400172A
(zh)
|
2022-04-06 |
2024-01-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
WO2023201282A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
WO2023215227A1
(en)
|
2022-05-02 |
2023-11-09 |
Epicentrx, Inc. |
Systems and methods to improve exercise tolerance
|
WO2023215220A1
(en)
|
2022-05-02 |
2023-11-09 |
Esperion Therapeutics, Inc. |
Macrocyclic inhibitors of atp citrate lyase
|
WO2023215229A1
(en)
|
2022-05-02 |
2023-11-09 |
Epicentrx, Inc. |
Compositions and methods for treatment of pulmonary hypertension
|
WO2023215781A1
(en)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2023225162A1
(en)
|
2022-05-20 |
2023-11-23 |
Gilead Sciences, Inc. |
Antiviral indolinyl compounds and uses thereof
|
WO2023230524A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of secretory and/or catalytic cells and methods using the same
|
WO2023240186A1
(en)
|
2022-06-08 |
2023-12-14 |
Auspex Pharmaceuticals, Inc. |
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
|
US20240101531A1
(en)
|
2022-06-08 |
2024-03-28 |
Xenon Pharmaceuticals Inc. |
Pyridinamine derivatives and their use as potassium channel modulators
|
TW202408485A
(zh)
|
2022-06-13 |
2024-03-01 |
美商埃皮辛特瑞科斯公司 |
用於減少癌症治療中不良副作用之組合物及方法
|
US20230399299A1
(en)
|
2022-06-14 |
2023-12-14 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
WO2023244584A1
(en)
|
2022-06-14 |
2023-12-21 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
WO2024015827A1
(en)
|
2022-07-12 |
2024-01-18 |
Hotspot Therapeutics, Inc. |
Solid forms of a triazine derivative as cbl-b modulator
|
WO2024015372A1
(en)
|
2022-07-14 |
2024-01-18 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
WO2024015416A1
(en)
|
2022-07-15 |
2024-01-18 |
Celloram Inc. |
Celastrol derivatives
|
WO2024047394A1
(en)
|
2022-08-31 |
2024-03-07 |
Otsuka Pharmaceutical Co., Ltd. |
Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
|
WO2024054832A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
|
US20240131005A1
(en)
|
2022-09-30 |
2024-04-25 |
Boulder Bioscience Llc |
Compositions and methods for treating non-hemorrhagic closed head injury
|
WO2024086246A2
(en)
|
2022-10-18 |
2024-04-25 |
Eluciderm Inc. |
2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
|
WO2024091863A1
(en)
|
2022-10-25 |
2024-05-02 |
Starrock Pharma Llc |
Combinatorial, and rotational combinatorial therapies for obesity and other diseases
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
WO2024092043A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridine compounds
|
US20240174672A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridone Compounds
|
WO2024089668A1
(en)
|
2022-10-28 |
2024-05-02 |
Basecamp Bio Inc. |
Somatostatin receptor 2 agonists and uses thereof
|
US20240165112A1
(en)
|
2022-11-04 |
2024-05-23 |
Bristol-Myers Squibb Company |
Therapy for the treatment of cancer
|
WO2024098009A1
(en)
|
2022-11-04 |
2024-05-10 |
Epicentrx, Inc. |
Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
WO2024124152A1
(en)
|
2022-12-08 |
2024-06-13 |
Epicentrx, Inc. |
Rrx-001 for the treatment of a hemoglobinopathy
|
US11931224B1
(en)
*
|
2022-12-19 |
2024-03-19 |
Robert Parker |
Tooth pod
|
WO2024145662A1
(en)
|
2022-12-30 |
2024-07-04 |
Altay Therapeutics, Inc. |
2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
|